Synthesis of anti-inflamamtory lipid mediators using soybean flour lipoxygenase by Tu, Thi Hoang Anh
 
 
Enzymatic synthesis of anti-inflammatory 





Thi Hoang Anh Tu 
Bachelor of Science in Chemistry 






Submitted in fulfilment of the requirements for the degree of 












I would like to send massive thanks to special people in supporting me through this 
long challenging but rewarding journey especially the final year to complete my 
thesis.  
Firstly, I wish to thank my principal supervisor Dr Jacqui Adcock for your constant 
support and helpful guidance, and for encouraging me to get over challenges. I am 
grateful to you for allowing me to do research independently and being willing to 
help with problem solving. I am thankful for your useful advice and suggestions 
throughout my PhD candidature. Your technical knowledge and experiences in lipid 
research, analytical chemistry and enzyme technology were invaluable. Thank you 
for many meetings throughout the years that I can learn something from. I could not 
have made it without your supervision. Secondly, thank you to my co-supervisor 
Professor Colin Barrow for your great advice and kind support over these years. I 
also would like to thank Dr Tim Nalder for Zetasizer analysis and proof reading 
Chapter 5, and Dr Taiwo Akanbi for helping to start with NMR technique. Dr Celine 
Deffrasnes and Dr Chiara Bortolasci for bioassay testing. Professor Ken Walder for 
training me on SPSS Statistics 25.0 and proof reading Chapter 6. 
Also thanks to other fellow PhD students in my research group and friends (Tej, 
Jessica, San and Mei) for your care and understanding. I wish to thank to Language 
and Learning advisers at Deakin (Ruth, Gail, Dennis and Steven) for helping with my 
writing and presentation skill. Finally, the most important part, I would like to thank 
my family and relatives especially my wonderful mum, and my family friends in 
Australia (Lien, Alice, Charlie, Annie, Johanna, Jenny and Tom) for your 
unconditional love and support. Thank you all for always being there to lift me up 
and remind me that I can do it! 
 
 
List of Abbreviations 
 
SPM   specialised pro-resolving mediator 
Rv   resolvin 
PD   protectin 
LX   lipoxin 
Ma   maresin 
LOX   lipoxygenase 
COX   cyclooxygenase  
P450   cytochrome P450 
sfLOX   soybean flour lipoxygenase 
SBF   soybean flour 
SBM   soybean meal 
LC-PUFA  long chain polyunsaturated fatty acid 
FFA   free fatty acid 
EFA   esterified fatty acid 
FAME   fatty acid methyl ester 
TAG   triacylglycerol 
TL   trilinolein 
DHA TAG  tridocosahexaenoin 
DHA   docosahexaenoic acid 
EPA   eicosapentaenoic acid 
AA/ETE  arachidonic acid/eicosatetraenoic acid 
DPAn-3  omega-3 docosapentaenoic acid 
DPAn-6  omega-6 docosapentaenoic acid 
LA   linoleic acid 
LA ME  linoleic acid methyl ester 
ALA   alpha linolenic acid 
 
 
GLA   gamma linolenic acid 
PL   phospholipid 
PC   phosphatidylcholine 
17-HDHA  17-hydroxy docosahexaenoic acid 
18-HEPE  18-hydroxy eicosapentaenoic acid 
17-H(p)DHA  17-hydro(pero)xy docosahexaenoic acid 
7S,17S-diH(p)DHA 7S,17S-dihydro(pero)xy docosahexaenoic acid 
10S,17S-diH(p)DHA 10S,17S-dihydro(pero)xy docosahexaenoic acid 
13-HLA  13-hydroxy linoleic acid 
MGDG  monogalactosyl diacylglycerol 
IL-1β   interleukin 1 beta 
TNF-α   tumor necrosis factor-alpha 
NP-HPLC  normal phase-high performance liquid chromatography 
RP-HPLC  reversed phase-high performance liquid chromatography 
DAD   diode array detector 
GC-MS  gas chromatography-mass spectrometry 
UV-vis  ultra violet-visible spectrophotometry  













Specialised pro-resolving mediators (SPMs), especially resolvins and protectins, 
have potential to be used as pharmaceuticals and supplements for the treatment and 
prevention of numerous chronic diseases linked to inflammation, as they are found 
naturally in the body and are involved in the active resolution of inflammation. My 
research investigates for the first time, a simple and inexpensive method to produce 
bioactive resolvin and protectin analogues through the direct use of full fat enzyme-
active soybean flour (SBF) as an enzyme source with a variety of long chain 
polyunsaturated fatty acid (LC-PUFA) substrates. This simple method can be used as 
an alternative to expensive commercial lipoxygenases. A range of substrates 
including free LC-PUFAs, triacylglycerols (TAGs) and fish oils (a complex lipid 
mixture of TAGs) were investigated.  
The enzymatic synthesis of resolvin and protectin analogues from omega-3 (n-3) and 
omega-6 (n-6) free fatty acids using SBF lipoxygenase (sfLOX) was studied, using 
docosahexaenoic acid (DHA) as a model compound. The sfLOX-catalysed DHA 
reaction generates bioactive resolvin D5 (RvD5) and protectin DX (PDX). 
Trilinolein (TL) was used as a model triacylglycerol and tuna oil was tested as a 
complex lipid mixture, in reactions catalysed by sfLOX. The reactions were 
optimised to obtain the maximum amount of mono- and di-hydroxylated compounds 
(DHA and tuna oil as substrates) and tri-hydroxylated molecules (TL as a substrate). 
The products formed under optimised conditions were characterised using a variety 
of analytical techniques such as NP-HPLC, RP-HPLC, chiral RP-HPLC, GC-MS, 
UV-visible and NMR spectroscopy.  
The optimised conditions found for the sfLOX-catalysed DHA reaction were applied 
to other n-3 and n-6 LC-PUFAs. A comparison between commercial 15-sLOX-1 and 
 
 
sfLOX-catalysed reactions with DHA for making resolvin and protectin analogues 
was included. sfLOX shows the same efficiency per milligram substrate in 
synthesising anti-inflammatory and/or pro-resolving lipid mediator analogues from 
LC-PUFAs as commercially available 15-sLOX-1. These results have offered a 
potential method for the production of bioactive compounds from the direct use of a 
cheap raw enzyme source.  
The optimised reaction conditions for the sfLOX-catalysed tuna oil reaction were 
also applied to tridocosahexaenoin (DHA TAG) and anchovy oil substrates. It was 
found that sfLOX could act directly on these complex esterified n-3 LC-PUFAs 
substrates (tuna oil, DHA TAG and anchovy oil), without prior hydrolysis 
(enzymatic or chemical), which cannot be achieved using commercial 15-sLOX-1. 
This would be useful for biotechnology applications in separating components of 
complex lipid mixtures after selective oxygenated of PUFAs by sfLOX. TAGs 
containing hydroperoxylated EPA and DHA could be easily separated from the 
remaining mixture of unreacted saturated and mono unsaturated fatty acids based on 
differences in polarity. The hydroperoxylated compounds could then be used for 
pharmaceutical and nutraceutical applications, whilst the remaining saturated and 
monounsaturated fatty acids could be used for the production of biofuel. 
This work is the first time sfLOX was used to catalyse a reaction with biologically 
important C20-22 LC-PUFAs (DHA, EPA, AA, DPAn-3, and DPAn-6) and to 
synthesise di-hydroxylated compounds as SPM analogues. The bioactivity of the 
synthesised compounds was tested in vitro in human monocytic cells (THP-1) and 
mouse brain cells (C8-B4). Most of these compounds have shown potential anti-
inflammatory properties by reducing IL-1β and TNF-α levels in LPS stimulated cells. 
Using SBF as an inexpensive source of lipoxygenase has the potential for application 
 
 
to large-scale SPM production for commercial nutraceuticals and pharmaceuticals. 
SBF has been demonstrated to be more versatile than a commercial enzyme in 
producing the same amount of RvD5 and PDX per milligram of DHA and being able 
to react with esterified fatty acids (pure substrates and natural oils). 
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According to the World Health Organisation, cardiovascular diseases are the leading 
cause of death worldwide with 17.9 million deaths in 2016 [1]. Cardiovascular 
diseases are also the cause of 27% of all deaths in Australia, as reported by the Heart 
Foundation Australia in 2017, with one Australian dying due to cardiovascular 
diseases every 12 minutes [2]. Cardiovascular diseases are a group of diseases related 
to heart and blood vessels. The initiation and development of cardiovascular diseases 
are proved to be strongly linked to inflammation. A number of pro-inflammatory 
cytokines including TNF-α and IL-6 have been found to be associated with an 
increase of cardiovascular disease risk. C-reactive protein can be used as an effective 
downstream inflammatory biomarker to detect cardiovascular diseases [3-5]. Many 
other chronic diseases such as diabetes, Alzheimer’s disease and cancer are also 
known to be associated with inflammation. Resolving inflammation could be the key 
factor in preventing cardiovascular diseases and other inflammatory diseases. Anti-
inflammatory drugs using natural agents with minimal side effects are promising for 
the treatment of inflammatory diseases like cardiovascular diseases. Specialised pro-
resolving mediators (SPMs) are anti-inflammatory and pro-resolving lipid mediators, 
produced endogenously in the body in the active resolution of inflammation [6]. 
Synthesised SPMs could be used as anti-inflammatory drugs and supplements for the 
potential treatment and prevention of a range of chronic diseases linked to 
inflammation. Development of an economical and effective method for the synthesis 
of SPMs will enable the large-scale industrial production of SPMs for 
pharmaceuticals, nutraceuticals, and functional foods to fight inflammation. 
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1. Resolution of inflammation and specialised pro-resolving lipid 
mediators 
Inflammation is a protective response which is controlled primarily by the innate 
immune system of the human body. It is an essential biological process that protects 
the host from attack by harmful stimuli, which may be exogenous or endogenous, 
and ideally results in elimination of the pathogens and healing of the injured tissues 
[7]. As such, inflammation is a necessary process for wound healing. One of the first 
steps in the inflammatory response to microbial invasion and tissue injury is the 
production of pro-inflammatory lipid mediators, known as leukotrienes and 
prostaglandins, along with other chemical mediators such as cytokines and 
chemokines [8]. The release of these mediators results in acute inflammation, with 
specific symptoms including heat, redness, swelling, pain, and loss of tissue function 
[9, 10]. Acute inflammation is followed by other signalling cellular processes that are 
initiated in order to protect the host from damaged tissue and infection [6]. This 
phase should last for a few hours or days [7]. Specifically, white blood cells – mainly 
neutrophils – are recruited to the inflamed tissues to cope with the invaders. They 
release chemical compounds of reactive oxygen species such as hydroxyl radicals 
and hydrogen peroxides to destroy and digest harmful stimuli [11]. After the acute 
inflammatory phase, resolution of inflammation, abscess formation, scar formation, 
and chronic inflammation are all possible outcomes [9, 10, 12]. Resolution of 
inflammation is the ideal outcome of acute inflammation, resulting in a return to a 
non-inflammatory state for host cells, with benefits of tissue recovery and stimulus 
elimination [7, 9, 12]. In contrast, uncontrolled or prolonged acute inflammation 
develops into an unresolved condition called chronic inflammation, an undesirable 
outcome of inflammation, with an increase in pro-inflammatory mediator generation 
[9]. Chronic inflammation is associated with a wide range of diseases [6, 12] such as 
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diabetes, asthma, cardiovascular diseases, inflammatory bowel disease as well as 
neurological disorders (Alzheimer’s disease, etc.) [6] and the progression of cancer 
[7, 13]. Therefore, anti-inflammatory drugs have received tremendous consideration 
in clinical medicine [7]. Research into new anti-inflammatory compounds is needed 
as many current drugs have a range of side-effects and some such as Vioxx have 
even been removed from the market due to serious side effects [14, 15]. 
The current treatment for inflammation with nonsteroidal anti-inflammatory drugs is 
based on blocking pro-inflammatory mediator pathways, but it is not entirely 
effective as many of the enzymes involved triggering inflammation are also involved 
in the resolution of inflammation, and therefore resolving pathways are also 
inhibited. This causes side effects related to inflammation such as increased risk of 
cardiovascular symptoms [7]. Another approach for the treatment of chronic 
inflammation is to target compounds which initiate the resolution pathways [6, 7, 
16]. The resolution of inflammation is not simply a passive process where production 
of pro-inflammatory mediators decreases over time when the harmful stimuli are 
removed. Resolution of inflammation has been demonstrated to involve the active 
biosynthesis of lipid mediators which can switch off the acute inflammatory state. 
These bioactive compounds are anti-inflammatory and/or pro-resolving compounds, 
which can (among other things) stimulate the clearance of neutrophils 
(polymorphonuclear leukocytes) by apoptosis and then recruit monocytes for 
phagocytosis of apoptotic cells and microbes [9, 12]. They are a family of 
compounds termed the specialised pro-resolving mediators (SPMs) and are divided 
into different groups including lipoxins, resolvins, protectins, and maresins. [6, 9, 17-
19]. The active biosynthetic process of resolution is currently studied by 
investigating self-limited inflammatory exudates and tissues enriched with 
docosahexaenoic acid (DHA) [9, 19]. The SPMs derived from the omega-3 long 
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chain polyunsaturated fatty acids (n-3 LC-PUFAs), eicosapentaenoic acid (EPA) and 
DHA, were first discovered in resolving inflammatory exudates and DHA-enriched 
tissues in the early 2000s [20-22]. Since then, a range of new SPMs have been 
continuously discovered. As a result, these SPM compounds have emerged as new 
fascinating drug candidates with therapeutic potential for inflammatory diseases [23, 
24]. 
2. Endogenous metabolism of fatty acids into SPMs 
Linoleic acid (LA) and alpha-linolenic acid (ALA) are the precursors of omega-6 and 
omega-3 LC-PUFAs (n-6 and n-3 LC-PUFAs), respectively, and are essential for 
good health. However, they cannot be synthesised in the body and must be obtained 
from the diet [25]. These fatty acids are synthesised in plants and marine algae 
containing delta 12- and delta 15-desaturase enzymes, which are necessary for the 
synthesis of n-6 and n-3 LC-PUFAs and do not exist in animals [26]. From LA and 
ALA, other n-6 and n-3 LC-PUFAs can be synthesised with more double bonds and 
carbons through desaturation and elongation processes catalysed by desaturase and 
elongase enzymes (Figure 1.1) [25]. Fatty acids can be labelled using a numbering 
system that indicates the number of carbons, the number of double bonds, and the 
unsaturation subclass (eg. omega-3 or omega-6) which is the position of the first 
double bond counted from the methyl end of a fatty acid molecule. For example, 
linoleic acid is labelled as 18:2n-6, indicating that it contains 18 carbons and 2 
double bonds, and is an omega-6 fatty acid (the last double bond is located six 




Figure 1.1: Synthesis of n-6 and n-3 LC-PUFAs from LA and ALA precursors, respectively [25]. 
EPA (20:5n-3) and DHA (22:6n-3), downstream products of ALA bio-metabolism, 
are important to the maintenance of good health for both foetal development and 
healthy aging. EPA and DHA are also beneficial to the prevention of many diseases 
such as Alzheimer’s disease, cardiovascular disease and cancer [27, 28]. Although 
EPA and DHA are beneficial, the mechanism of action is still unclear. The Serhan 
research group was the first to propose that their role as precursors for the 
biosynthesis of potent SPMs was likely explain their benefits in human health [6]. 
In the human body, the conversion of ALA to EPA and DHA is not efficient, 
therefore EPA and DHA need to be obtained from the diet; the best source is oily 
fish [26]. There are various recommendations for omega-3 intake from different 
countries and organisations, ranging from 300 to 4000 mg per day depending on 
health status [29]. For example, it has been recommended that the minimum amount 
of n-3 LC-PUFAs (EPA and DHA) consumption per day should be approximately 
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500 mg in human nutrition in order to prevent clinical symptoms of deficiency [29, 
30]. However, 1 g of DHA and EPA should be consumed by patients with coronary 
disease [29]. Many people do not have an adequate intake of omega-3 PUFAs 
naturally in their diets, so supplementation (typically with fish oils) is required to 
reach the recommended daily intake. Fish oil supplements with up to 90% EPA and 
DHA can be produced from natural fish oils which usually contain approximately 
30% EPA and DHA [31]. Therefore, the global omega-3 market has continued to 
develop, and is now a multi-billion dollar industry, estimated to be valued at USD 
$9.94 billion in 2015. It is predicted to grow at an annual rate of 13.8% from 2015 to 
2020 [32].  
The parent n-6 and n-3 LC-PUFAs compete for the same enzymes (desaturases and 
elongases) to synthesise the downstream fatty acids. Therefore, the synthesis of n-6 
LC-PUFAs depends not only on the consumption of LA but also on ALA, and 
similarly, the synthesis of n-3 LC-PUFAs depends on the consumption of both LA 
and ALA. The downstream products of n-6 LC-PUFAs (mainly from AA) are pro-
inflammatory, whereas n-3 LC-PUFA metabolites, particularly from EPA and DHA, 
shows primarily anti-inflammatory and pro-resolving properties [25]. Appropriate n-
6 and n-3 LC-PUFA consumption could benefit the body by balancing between acute 
inflammation and resolution of inflammation, and preventing the onset of chronic 
inflammation. Therefore, the dietary ratio between omega-6 and omega-3 fatty acids 
is important in maintaining good health. There are many recommendations for this 
ratio from different studies and for various health conditions [29]. It has been 
generally suggested that a ratio of approximately 4:1 n-6 to n-3 LC-PUFAs may be 
ideal for good health, instead of the 10:1 ratio common in modern western societies 
[29, 30].  
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As the biologically produced SPMs are active in vivo at low concentrations, typically 
in the pico to nanomolar range [6], supplementation with very small amounts of 
SPMs could be an alternative to n-3 fish oil supplementation, which requires much 
higher doses due to lower levels of activity. SPMs could be consumed directly for the 
prevention and/or treatment of inflammatory diseases. As these compounds have 
potential pharmaceutical and nutritional utility, effective, simple and inexpensive 
methods to produce these bioactive molecules would be commercially useful. 
3. Lipoxygenase as a biocatalyst for the synthesis of SPM analogues 
Typically, pharmaceuticals are synthesised using complicated and time-consuming 
chemical reactions, often using harmful processes and chemicals [33, 34]. Similarly, 
SPMs have been synthesised in the same way. For example, resolvins D2, D5 and D6 
have been produced by total organic synthesis using lengthy protocols 
(approximately 20 steps), with low total reaction yields (less than 10%), and utilising 
toxic substances such as aluminium lithium hydride, lithium hydroxide, benzene and 
hexane [35-37]. Neuroprotectin D1 analogues were produced by total organic 
synthesis of more than 10 steps with each step requiring 1 – 22 hour reaction times 
[38]. Other resolvins, protectins, and maresins have also been chemically synthesised 
[39-41]. In contrast, using enzymes as biocatalysts has a number of advantages, 
including operating at mild pH, temperature and pressure; high biodegradability; and 
low production of by-products requiring heavy downstream processing [42]. Enzyme 
reactions can also synthesise products with higher purity and higher yields using 
simple techniques compared to organic synthesis, and can often be applied to a wide 
range of substrates without re-optimisation of reaction conditions [43]. Highly 
stereo- and regio-specific molecules can be readily obtained from enzyme-catalysed 
reactions, which is important for producing useful pharmaceuticals where chirality is 
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important for bioactivity [44]. Enzyme technologies have been used in biotechnology 
for pharmaceutical synthesis as an alternative to traditional chemical synthesis [45, 
46]. Enzymes are currently well-established products in biotechnology with the 
global market valued at ~ USD $7 billion in 2017 and expected to increase annually 
by 5.7% from 2018 to 2024 [47].  
Enzymatic synthesis using soybean lipoxygenase as a biocatalyst is a potential 
method to produce various known and novel bioactive lipid mediators in one step for 
pharmaceuticals, nutraceuticals, and functional foods. A commercially purified 
soybean lipoxygenase isoenzyme 1 which oxygenates arachidonic acid at carbon 15 
(15-sLOX-1) has been widely investigated as a biocatalyst to produce hydro(pero)xy 
fatty acids [48-52], and in some studies, SPMs [43, 53, 54]. However, the problem 
with the commercial enzyme 15-sLOX-1 is the high cost of acquiring the enzyme. 
Purified lipoxygenase isoenzymes from soybean have been used as a lipoxygenase 
source but LOX-2 is unstable when purified, and the purification process can be time 
consuming [55, 56]. If the soybean lipoxygenase enzymes can be sourced cheaply 
and simply from natural materials, then low cost methods may be developed for their 
industrial use.  
4. Research questions and project aims 
Soybean flour is a commercial product used as an alternative to wheat flour in a 
variety of products and is available as defatted or full-fat flours [57], which could be 
used directly as a source of lipoxygenase. Soybean flour has been used as an 
alternative to the commercial enzyme in reactions with hydrolysed oils containing 
mainly C18 LC-PUFAs to make hydroperoxides for various purposes, such as 
substrates for green note compound synthesis [58-60]. Soybean flour has been shown 
to contain lipoxygenases able to catalyse reactions with both free fatty acids (such as 
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LA and ALA) and triacylglycerols (such as trilinolein) [56, 61]. However, no work 
has been done on C20-22 LC-PUFAs for the synthesis of resolvin analogues, despite 
the biological relevance of these compounds and their potential high value; and 
complex lipid mixtures, such as fish oils, have not been investigated as esterified 
fatty acid substrates with soybean flour as a biocatalyst, despite their wide 
availability. Soybean flour could be used as a cheap and simple alternative to the 
commercial 15-sLOX-1 for the synthesis of resolvin analogues from a range of 
biologically important LC-PUFAs for pharmaceuticals, nutraceuticals and functional 
foods. 
This project aimed to produce bioactive specialised pro-resolving mediator analogues 
from a range of pure LC-PUFAs and natural oils such as fish oils using soybean flour 
as an inexpensive source of lipoxygenase enzymes. The project addressed the 
following questions: 
• Can soybean flour be used directly as a natural and inexpensive source of 
lipoxygenase enzymes to produce a variety of potentially bioactive resolvin 
and protectin analogues from a range of substrates, including free and 
esterified LC-PUFA?  
• What are the characteristics (product formation efficiency and suitability to 
catalyse a range of substrates) of soybean flour lipoxygenase and is it more 
versatile than the commercially available 15-sLOX-1? 
To answer these questions, the project aims were: 
1) To characterise the reaction catalysed by soybean flour lipoxygenase with 
DHA as a free n-3 LC-PUFA substrate model for the synthesis of resolvin 
and protectin analogues, with full product characterisation. Then, to apply the 
optimised conditions from the soybean flour lipoxygenase-catalysed DHA 
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reaction to a range of biologically important free LC-PUFA substrates (EPA, 
ARA, DPAn-3, and DPAn-6). 
2) To characterise the reaction catalysed by soybean flour lipoxygenase with 
trilinolein as a pure esterified fatty acid model substrate without prior 
hydrolysis, including full product characterisation. 
3) To characterise the reaction catalysed by soybean flour lipoxygenase with 
tuna oil as a complex lipid system, without prior hydrolysis for the synthesis 
of resolvin and protectin analogues. 
4) To identify structure-activity relationships for the bioactivity of the 
synthesised resolvin and protectin analogues, using inflammatory bioassays. 







































Resolvins and protectins are biologically important anti-inflammatory and pro-
resolving lipid mediators for the potential treatment and prevention of a range of 
inflammatory diseases including cardiovascular disease, diabetes and cancer [6, 19]. 
These compounds are naturally found in the resolution of inflammation in the body 
[6, 19]. An up to date summary of specialised pro-resolving mediators, including 
their classification, biosynthesis, and bioactivity is presented and their applications as 
supplements and pharmaceuticals are highlighted. Characteristic properties of 
lipoxygenases in general, and soybean lipoxygenase in particular are summarised in 
relation to oxidation reactions with long chain polyunsaturated fatty acids. Soybean 
flour (SBF) with simple preparation has been investigated in previous studies as an 
inexpensive alternative to commercial lipoxygenases to produce mono-hydroxylated 
compounds from C18 fatty acids for volatile compound synthesis and other purposes. 
The reactivity of different sources of plant lipoxygenases with esterified fatty acids 
are also discussed.  
1. Classification, biosynthesis, and bioactivity of lipid mediators 
Lipid mediators are hydroxylated metabolites of omega-3 and -6 long chain 
polyunsaturated fatty acids (n-3 and n-6 LC-PUFAs). They are endogenously 
synthesised by different types of enzymes – lipoxygenases (LOX), cyclooxygenases 
(COX) in the absence or presence of aspirin, cytochrome P450 (P450), and other 
enzymes. Lipid mediators are classified into two groups: pro-inflammatory lipid 
mediators, and anti-inflammatory and pro-resolving lipid mediators. Each lipid 
mediator within the two groups has distinctive functions in different stages of 
inflammation [6, 62].  
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1.1. Pro-inflammatory lipid mediators 
Pro-inflammatory lipid mediators are divided into two groups of compounds – 
leukotrienes and prostaglandins – each with a variety of derivatives. They are mainly 
biosynthesised from arachidonic acid (AA, C20:4n-6) by 5-LOX and COX-2 
enzymes, although other enzymes may also be involved, and they are also 
synthesised from eicosapentaenoic acid (EPA, C20:5n-3; Figure 2.1). Leukotrienes 
and prostaglandins have specific roles in the initiation of inflammation: leukotrienes 
encourage neutrophil (a type of white blood cells) recruitment to the injured site to 
engulf and destroy the foreigner agents; whilst prostaglandins accelerate the 
inflammatory response. Pro-inflammatory lipid mediators help protect the host from 
attack by outside invaders. However, when acute inflammation is left unchecked 
these lipid mediators can lead to the development of chronic inflammation [6, 18, 
63].  
 
Figure 2.1: Important families of lipid mediators of inflammation and resolution, and their precursor 
fatty acids [43]. 
1.2. Anti-inflammatory and pro-resolving lipid mediators 
Anti-inflammatory and pro-resolving lipid mediators are di- or tri-hydroxylated 
compounds synthesised from n-3 and n-6 LC-PUFAs, and contain a system of 
conjugated double bonds. They are known as specialised pro-resolving mediators 
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(SPMs) and consist of 4 subclasses: lipoxins (lipoxygenase interaction products), 
resolvins (resolution phase interaction products), protectins, and maresins 
(macrophage mediators in resolving inflammation). Lipoxins are derived from AA; 
resolvins can be derived from both EPA and docosahexaenoic acid (DHA, C22:6n-
3); and DHA is the main precursor of protectins and maresins (Figure 2.1) [43]. 
Omega-3 and omega-6 docosapentaenoic acids (DPAn-3, C22:5n-3 and DPAn-6, 
C22:5n-6) have been recently identified as precursors of some resolvins, protectins, 
and maresins [64-67].  
Serhan and his group are the leading research group investigating the endogenous 
biosynthesis and potent actions of SPMs from LC-PUFAs, with numerous studies 
and reviews in the field [6, 9, 16, 18, 19, 62]. They were the first to demonstrate that 
resolution of inflammation involves the production of SPMs and is an active process 
[68]. All of the known SPM compounds are summarised in Table 2.1 and categorised 
into their PUFA precursors and families (subclasses and intermediates). The 
chemical structures (stereospecificity and double bond configurations) are included. 
Key enzymes such as 15-LOX, 12-LOX, 5-LOX, COX-2 and P450 are known to be 
involved in their biosynthesis pathway [6, 17, 64, 66]. These molecules have potent 
actions in resolving acute inflammation and preventing the development of chronic 
inflammation to enable a return to homeostasis [16]. Their anti-inflammatory and 
pro-resolution biological activities have been shown at nano and picomolar 
concentrations both in vitro and in vivo [6]. At a cellular level, they can stop 
neutrophil infiltration (anti-inflammatory property), and accelerate monocyte 
recruitment and activation, followed by enhancing phagocytosis and clearance of 
apoptotic neutrophils by activated macrophages (pro-resolving activity) [6, 9, 18]. 
The biological activities of the compounds are dependent upon the chirality of 
hydroxy groups (S or R), geometry of double bonds (cis or trans), and their 
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conjugation system (conjugated diene, double conjugated dienes, conjugated triene, 
etc.). SPMs and aspirin-triggered SPMs have similar bioactivities, although they are 
synthesised through different biosynthetic pathways and have altered hydroxy group 
chirality. SPMs are synthesised by various LOXs and have S chirality, whereas 
aspirin-triggered SPMs are synthesised by COX-2 in the presence of aspirin or P450 
and have R chirality [6].  
Table 2.1: Classification of SPMs from AA, EPA, DHA, DPAn-3 and DPAn-6 into distinct families 
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Specific potent actions and further information on several well-studied SPMs in each 
group are also described below.  
1.2.1. Lipoxins 
Lipoxins, trihydroxytetraene fatty acids synthesised from AA, were the first 
mediators discovered with dual actions of anti-inflammation and pro-resolution 
confirmed both in vitro and in vivo [17]. For example, lipoxin A4 (LXA4) helps 
reduce organ fibrosis, and has a direct action on both vascular and smooth muscle 
and in reducing pain [17, 63]. 
1.2.2. Resolvins 
There are three types of resolvins termed E-series, D-series, and T-series. E-series 
(RvE) and T-series (RvT) resolvins are derived from EPA and DPAn-3 respectively, 
whereas D-series resolvins are from either DHA or DPAn-3 (Table 2.1). There are 
three resolvins (RvE1, RvE2 and RvE3) in the resolvin E-series. RvE1 (Figure 2.2) 
containing one conjugated diene and one conjugated triene can specifically support 
tissue healing [24]. RvE2 and RvE3 show potent anti-inflammatory actions, by 
blocking or limiting neutrophil infiltration in zymosan-induced peritonitis both in 
vitro and in vivo at nanomolar concentrations, with much lower activity expresses by 
the unnatural stereoisomers [69, 71]. The newest E-series resolvin (RvE3) is anti-
inflammatory but has not been confirmed to be pro-resolving like RvE1 and RvE2 
[68].  
D-series resolvins derived mainly from DHA receive considerable interest because 
DHA is enriched in the brain, synapses, and retina. These compounds can block the 
production of the pro-inflammatory cytokine interleukin 1 beta (IL-1β) as a rapid 
response to neural injury in microglial cells [17], and can also reduce pain and 
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release depression [68]. RvD1 from precursor DHA (RvD1DHA) has a conjugated 
tetraene (Figure 2.2) and especially helps promote tissue repair [24].  
The T-series resolvins synthesised from DPAn-3 were discovered recently [65]. 
Their chemical structures have been proposed without full characterisation [64, 65]. 
These compounds are synthesised by COX-2 and the enzyme is stimulated by 
atorvastatin via S-nitrosylation [64, 66]. They were found to suppress neutrophil 
infiltration and expression of IL-1β, stimulate bacterial phagocytosis and increase 
survival of E. coli-infected mice [64, 66]. 
Figure 2.2: EPA-derived RvE1 and DHA-derived RvD1 [17]. 
1.2.3. Protectins and maresins 
Protectins can be derived from DHA, DPAn-3 or DPAn-6 (Table 2.1). Protectin D1 
(PD1DHA, also known as neuroprotectin D1DHA (NPD1DHA) when found in the brain) 
can protect brain and retina tissues from oxidative stress-induced apoptosis by 
promoting the expression of anti-apoptosis proteins and suppressing pro-apoptosis 
proteins [72]. In Alzheimer’s disease, PD1DHA promotes the survival and function of 
brain cells [73]. PDXDHA is an isomer of PD1DHA, with S stereo-specificity at carbon 
C10 instead of R and double bond geometry between carbons C10 and C17 of E,Z,E 
(PDXDHA) instead of E,E,Z (PD1DHA). PDXDHA was found to be less potent than 
PD1DHA in resolving inflammation, but able to inhibit the aggregation of blood 
platelets [74].  
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Maresins derived from DHA are produced by macrophages in the resolution of 
inflammation and have a direct action on phagocytes in enhancing efferocytosis [24]. 
Maresin R1 (MaR1) has higher bioactivity than MaR2. MaR1 in particular can 
stimulate tissue regeneration and reduce regeneration time [10].  
D-series resolvins, protectins and maresin are also derived partly from DPAn-3 and 
DPAn-6. They are newer members of the SPM super-family. These compounds 
(separately or in mixtures) have also been shown to have anti-inflammatory and/or 
pro-resolving activities in several disease models [66, 67, 75]. For example, a 3:1 
mixture of RvD1 and RvD2 from the DPAn-3 precursor can decrease neutrophil 
infiltration and enhance phagocytosis of zymosan and apoptotic neutrophils in the 
zymosan peritonitis model [66]. PDXDPAn-6 (DPAn-6 precursor) was found to 
suppress leukocyte migration significantly in the inflammatory response induced by 
tumor necrosis factor-alpha (TNF-α) in an air pouch model [67]. 
2. Resolvin analogues as supplements and pharmaceuticals 
2.1. Supplements 
Recently, resolvin analogues have been used in a commercial dietary supplement. 
Metagenics is the first company to commercialise SPMs as a nutraceutical product in 
collaboration with the Serhan group [76]. Metagenics launched OmegaGenics SPM 
Active in October 2015 as a dietary supplement for immune health to protect the 
body from environmental conditions such as unhealthy diet, stress, exercise, irritants, 
and aging. The product is served as softgels with active ingredients listed as: SPM 
compounds (250 – 500 mg) including 17-hydroxy-docosahexaenoic acid (17-HDHA) 
and 18-hydroxy-eicosapentaenoic acid (18-HEPE) fractionated from fish oils 
(anchovy and sardine). Metagenics is holding a patent-pending technology for 
advanced fractionation, termed Active IR to isolate, measure and verify the active 
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SPMs (17-HDHA and 18-HEPE) from fish oils to obtain a standardised material for 
the global healthcare practitioner market [76]. In March 2017, a clinical trial 
(Identifier: NCT03095157), sponsored by Brigham and Women’s Hospital, was 
planned to investigate the role of the supplement in preventing chronic pain 
development up to 3 months after thoracic surgery. The study was estimated to be 
completed in July 2019, but no further updates have been reported since it was first 
posted [77].  
2.2. Potential anti-inflammatory drugs 
Resolvin analogues have been tested in humans for a wide range of inflammatory 
diseases. Resolvins were tested in clinical trials by Resolvyx Pharmaceuticals as a 
new class of medicines for the treatment of inflammatory diseases such as dry eye, 
retinal disease, asthma, inflammatory bowel diseases, rheumatic arthritis, 
cardiovascular diseases and lung inflammation [78]. RvE1 (RX-10001) was found to 
have positive Phase I clinical trial results in asthma, inflammatory bowel diseases, 
rheumatic arthritis and cardiovascular diseases. Phase II results showed that RX-
10001 significantly improved signs and symptoms of corneal inflammation [78, 79].  
RX-10045, a synthetic resolvin analogue of RvE1, successfully completed a Phase II 
study in treating dry eye to improve signs and symptoms and was under a Phase III 
clinical trial [78-80]. RX-10045 is still being improved for continuous Phase III 
testing in dry eye clinical trials due to having non-equivalent efficacy in Phase II 
results compared to that in vivo [81, 82]. This compound was also tested in various 
Phase II clinical trials for ocular conditions (Identifiers: NCT01639846 and 
NCT02329743) [83] but no further results have been released after completion. This 
product is developed by Resolvyx Pharmarceuticals with Celtic Therapeutics as a 
partner [78] and has been given the name navamepent [84]. 
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PD1 (RX-20001) was under pre-clinical testing, for the treatment of multiple 
diseases, including dry eye, macular degeneration, lung inflammation and diabetic 
retinopathy. Other resolvin analogues for multiple indications were also under pre-
clinial trial studies [78]. NPD1/PD1 was also tested in a clinical development 
program of Anida Pharma Inc., licensed by Brigham and Women’s Hospital/Partners 
Health Care for neurodegenerative diseases and hearing loss [10, 18]. LXA4 was 
shown to have positive results on infants with eczema without adverse effects and on 
asthmatic patients [80, 83, 85]. Further results or present status for all these 
compounds have not been released. No SPMs have been made available in the 
pharmaceutical market. 
As SPM compounds in general, and resolvin and protectin analogues in particular, 
have the potential to treat and prevent chronic inflammatory conditions, there is a 
need to develop methods for the large-scale synthesis of these compounds for the 
pharmaceutical, nutraceutical and functional food industries, as these methods are 
currently not well established. A one step lipoxygenase-catalysed reaction using SBF 
as an inexpensive enzyme source is a promising way to approach industrial-scale 
production of these bioactive molecules. 
3. Lipoxygenase enzymes 
LOXs are valuable enzymes that act as biocatalysts in forming hydroperoxy fatty 
acids which are used as precursors for many applications. These hydroperoxy fatty 
acids are substrates for further metabolism in the presence of other enzymes to 
produce diverse signalling molecules such as jasmonic acid and volatile compounds 
in plants [86]. Jasmonic acid and volatile aldehydes contribute to the defence 
response and wound healing in plants [87, 88]. The volatile aldehydes such as 
hexanal and hexenal can be used as fresh green flavours of fruits and vegetables for 
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food products [89]. The enzymes have commercial application in the food industry 
for bleaching activities on wheat flour, noodles and rice by co-oxidation of 
carotenoids and PUFAs [88, 90]. However, these enzymes also result in some 
negative effects such as degradation of pigments, off-flavour, odour production and 
fatty acid oxidation which leads to the deterioration of food quality [88].   
LOXs are also involved in the biosynthetic pathways of a variety of lipid mediators 
in animals (eicosanoids and docosanoids), which are anti-inflammatory and pro-
resolving compounds [91]. These compounds are emerging as a new class of anti-
inflammatory drugs because they may have insignificant side effects as previously 
shown no adverse effect for several compounds in clinical trials [78, 85]. In contrast, 
a range of side effects were reported with the current anti-inflammatory drugs [14, 
15]. Therefore, synthesis of these bioactive compounds for further clinical research 
and potential pharmaceuticals has received considerable interest [23, 41, 67]. 
LOXs, an enzyme family containing a non-heme iron active site, catalyse the single 
and double dioxygenation reaction of PUFAs containing one or more cis,cis-1,4-
pentadiene sites (Figure 2.3A) by adding one or more oxygen molecules to create 
highly regio and stereo specific hydroperoxides with one or more conjugated 
cis,trans double bonds (Figure 2.3B) [86, 90, 91]. The regio and stereo specificity of 
products depend on the specific substrate, LOX isomer and reaction conditions. 
 
Figure 2.3: LOX catalysis of A) cis,cis-1,4-pentadiene unit into B) cis,tran-1,3-pentadienyl 





LOXs are found in a variety of organisms including animals (mammals and fishes), 
plants and microorganisms [56, 87]. Soybean, peas, potato, cucumber, and rice have 
been identified as containing a diversity of LOX isoenzymes [92]. Grain legume 
seeds such as beans and peas, and potato tubers contain a large amount of LOX [88]. 
There are many ways of classifying LOX isozymes including pH optimum, 
positional specificity of substrate fatty acid oxygenation on linoleic acid (LA, 
C18:2n-6) or AA and product specificity [87, 88]. Type-1 LOX have pH optimum in 
an alkaline environment, whereas type-2 LOX isoforms have optimum activity at 
neutral pH [90]. In plants, linoleic acid is used commonly as a substrate, and 9-LOX 
and 13-LOX introduce molecular oxygen onto carbon atom 9 and 13 of LA substrate 
molecules, respectively [93] (Figure 2.4).  
 
Figure 2.4: Comparison of the reaction mechanism of 13- and 9-LOX on LA (left and right, 
respectively) to produce 13S- and 9S-hydroperoxy products. Reproduced from [87] with modification. 
In mammals, LOXs are labelled based on the specific position of oxygen insertion on 
the common substrate AA, such as C-5 (5-LOX), and there are six types of LOXs 
commonly found: 5-LOX, 8-LOX, 9-LOX, 11-LOX, 12-LOX and 15-LOX [94]. 
Soybean LOX, although technically classified as a 13-LOX (introduces molecular 
oxygen onto carbon 13 of LA), is often referred to as a 15-LOX, because it will also 
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accept AA as a substrate to form 15-hydroxylated AA. Soybean LOX has been used 
as a model LOX enzyme to study both plant and animal systems, and the naming of 
the enzyme reflects this. In both plants and animals, LOXs can be additionally 
classified by the stereo-specificity of the product (S/R) along with the positional 
specificity, such as 13S-LOX or 12R-LOX [87]. 
3.2. Mechanism 
The mechanism of LOX catalysis on PUFAs to make hydroperoxides proceeds in 
four main steps within the catalytic pocket of the enzyme: 1) hydrogen abstraction; 
2) radical rearrangement; 3) oxygen insertion; and 4) re-activation of the enzyme and 
proton addition (Figure 2.5) [87].  
 
Figure 2.5: Catalytic mechanism of LOX-linoleic acid reaction under aerobic condition, following 
arrows starting from the middle top. Fe2+-LOX: inactive state of LOX enzyme, Fe3+-LOX: active state 
of LOX enzyme, LA-HPOD: LA hydroperoxides. The linoleic acid structure is expressed only from 
C8-C14. Reproduced from [95] with modification. 
The iron in the active site of LOX plays an important role in the catalysed reaction. 













activated by an oxidising reagent such as a lipid hydroperoxide to oxidise LOX-Fe2+ 
into LOX-Fe3+. LOX-Fe3+ oxidises a fatty acid into a radical by hydrogen 
abstraction, re-forming LOX-Fe2+. The oxidised fatty acid radical is resonance 
stabilised through radical rearrangement, and subsequently reacts with molecular 
oxygen at a position [+2] or [-2] from the location of hydrogen abstraction. LOX-
Fe2+ donates an electron to the PUFA peroxide radical to form the anion and 
becomes the active LOX-Fe3+ for further catalysis. The peroxide anion is then 
protonated to form a hydroperoxy fatty acid containing a conjugated diene (Figure 
2.5) [95, 96]. The hydrogen abstraction and oxygen insertion steps result in the 
specific regio- and stereo-chemistry of the products [87, 90]. 
3.3. Substrates  
Fatty acids are mono-carboxylic acids with the aliphatic hydrocarbon chain 
numbered from the carboxyl end. The natural fatty acids usually have an even 
number of carbons (between 4 and 22) with C18 being the most common, and 
contain cis double bonds in their straight chains [97]. In humans and other 
organisms, fatty acids are a significant component of lipids, which is one of the three 
major constituents of biological matters along with carbohydrates and proteins. They 
exist in two forms: free fatty acids (FFA, Figure 2.6A) and esterified fatty acids 
(EFAs; eg. Figure 2.6B-D), and their main functions are energy storage and 
membrane structure [26]. EFAs include fatty acid methyl/ethyl esters (Figure 2.6B), 
triacylglycerols (TAG; Figure 2.6C), phospholipids (PL; including 
glycerophospholipids [Figure 2.6D] and sphingolipids) and glycolipids [98]. A fatty 
acid ester is formed from a carboxylic acid and an alcohol, and a TAG contains three 
fatty acids esterified to a glycerol backbone [98]. PLs consist of a glycerol backbone 
with two fatty acids and a polar head group containing phosphate [99]. The glycerol 
carbons of TAGs and PLs are labelled in the order of sn-1, sn-2, and sn-3 (Figure 
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2.6C-D). There is a stereocentre at the glycerol carbon sn-2 when R1 and R3 groups 
are different for TAGs [100] and R1 and R2 groups are different for PLs [99]. R1, 
R2 and R3 refer to aliphatic hydrocarbon chains with different length and number of 
double bonds.                   
Figure 2.6: Chemical structures of A) free fatty acid (R is an aliphatic hydrocarbon chain); B) fatty 
acid methyl/ether ester (R’: methyl/ethyl group); C) TAG with fatty acids R1, R2 and R3 at the sn-1, 
sn-2 and sn-3 positions; and D) PL with fatty acids R1 and R2 at the sn-1 and sn-2 positions.  
There are two types of fatty acids – saturated (containing no double bonds) and 
unsaturated (containing at least one double bond). Unsaturated fatty acids can be 
monounsaturated or polyunsaturated, depending on the number of double bonds (one 
or at least two double bonds, respectively) [98]. Polyunsaturated fatty acids are 
divided into two important subclasses: omega-3 and omega-6 polyunsaturated fatty 
acids (n-3 and n-6 PUFAs) [25]. The number 3 or 6 in their names expresses the 
position of the first double bond counted from the methyl end group of the fatty acid 
molecule [26].  
TAGs and PLs (types of EFAs) are of interest as substrates for SPM formation as 
they are common fatty acids in natural oils. Both EPA and DHA (SPM precursors) 







respectively. About 18% EPA and 12% DHA, the two major n-3 LC-PUFAs in fish 
oils, are present as TAGs at the sn-2 position [31]. In krill oil, there are high 
concentration of n-3 LC-PUFAs (EPA and DHA) in the form of PL, which are 
present in a substantial amount compared to FFAs, monoacylglycerols (fatty acid 
monoesters of glycerol), diacylglycerols (fatty acid diesters of glycerol) and 
triacylglycerols [31]. 
4. Soybean lipoxygenases 
LOX was first reported in soybean in 1932 as an enzyme for lipid peroxidation 
termed lipoxidase [86]. Soybean is an abundant source of LOXs and soybean LOX is 
well studied compared to other plant LOXs [88, 90]. There are two types of soybean 
lipoxygenases found in soybean seeds – type-1 LOX (LOX-1) and type-2 LOXs 
(LOX-2 and LOX-3) [88]. Type-1 LOX is commercially available and is used as a 
model LOX for mechanism studies, whereas type-2 LOX is not commercially 
available, due to lower activity and increased lability [56]. LOX-1 has optimum pH 
at 9 and only catalyses the dioxygenation of free PUFA substrates, forming 13-
hydroperoxide as the major product from LA, whereas type-2 LOX isozymes have 
optimum pH around 7, and accept both free PUFA and TAG substrates, forming 9- 
and 13-hydroperoxides in a ratio of approximately 1:1 with LA as a substrate [88, 
90]. As shown in a study regarding substrate specificity, LOX-2 preferred to catalyse 
AA at pH 6.1, whereas LOX-1 equally catalysed both LA and AA at pH 9 and the 
catalysis of LA by LOX-3 was more active at pH 6.5 [101]. Generally, soybean 
LOX-1 is best known to have exclusive S stereo-specificity, regardless of product 
regio-specificity [102-104], whereas a mixture of S and R products are formed by 
type-2 LOXs [105-107].  
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4.1. Product specificity hypotheses and mechanisms 
There are two main hypotheses to explain the regio-specificity of the products 
(positions of hydroxy groups on products) of LOX enzymes: the active site space-
filling theory and the substrate orientation in the catalytic pocket theory [87, 93]. In 
the space-filling theory, based on mammalian LOX research, it is proposed that 
either large histidine or phenylalanine residues, or small valine residues in the active 
site determine the depth the substrate can enter into the catalyst pocket. This results 
in positioning different parts of the substrate adjacent to the active site for radical 
rearrangement and oxygen accessibility, and therefore creating products with a 
different positional specificity. 13-LOX which has histidine or phenylalanine 
residues, and 9-LOX which has valine residues, are responsible for LA oxygenation 
at C-13 and C-9, respectively (Figure 2.7).  
 
Figure 2.7: Substrate alignment in the active site of 13-LOX and 9-LOX for the space-filling theory. 
H/F: Histidine or phenylalanine residue, V: Valine residue. Reproduced from [93]. 
Alternatively, different orientation of carboxyl or methyl end of the substrate into the 
active site of plant LOXs may result in distinct regio-specificity of oxygenation 
products [87, 93, 108]. 9-LOX was proposed to orient the substrate carboxylate end 
first (inverse-substrate orientation) for 9-hydroperoxy LA formation, whereas 13-
LOX is postulated to recognise the methyl end of the substrate (straight-substrate 
orientation) in the catalytic pocket for 13-hydroperoxy LA formation (Figure 2.8). 
This suggests only 13-LOX may be able to oxygenate EFAs as the large glycerol 
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backbone may be unable to penetrate the catalytic pocket, therefore esterified 
substrates can only be orientated with the methyl end first [108].  
 
Figure 2.8: Lipoxygenase substrate orientation as methyl or carboxyl end first in the active site 
proposed for 13-LOX and 9-LOX. Shown with linoleic acid and trilinolein as substrate. Reproduced 
from [108]. 
In barley, 9-LOX is a type-1 LOX and 13-LOX is a type-2 LOX, giving 9- and 13-
hydroperoxides, respectively. Only the type-2 LOX (13-LOX) is able to oxygenate 
esterified PUFAs [92], supporting the substrate orientation theory. However, in 
soybean 13-LOX is a type-1 LOX and only oxygenates free fatty acid substrates [88, 
90], which contradicts the orientation hypothesis. Further research on substrate 
orientation using soybean LOX-1 (13-LOX) with mutated active site residues 
showed that both LA and AA substrates approach the active site of catalytic pocket 
using the carboxyl end first, not methyl end first [109]. This could explain why EFAs 
are not oxygenated by soybean LOX-1 (13-LOX), because the large glycerol 
backbone cannot be inserted into the catalytic pocket. As these studies are 
contradictive, the exact mechanism of substrate orientation for regio-specific LOX-
catalysed PUFA reaction products is still not clear. 
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With regards to stereo-specificity, there has been some research into elucidating the 
mechanism using wild-type and mutant forms (where the residue alanine in the 
active site is mutated into glycine) of soybean LOX-1 with LA and AA substrates 
[48, 110]. The hydrogen with S stereo chemistry on C-11 of LA was identified to be 
involved in the step of hydrogen abstraction. S hydrogen abstraction is followed by 
oxygen insertion from the opposite side to the abstracted hydrogen to form S 
products using wild type soybean LOX-1. In contrast, both S and R products are 
formed with mutant soybean LOX-1 for both methyl end orientation (the first 
dioxygenation) and carboxylate end orientation (the second dioxygenation with AA 
as a substrate, and a second oxygen molecule was inserted onto the PUFAs) into the 
catalytic pocket [48]. For human 15S-LOX-2 and 12R-LOX, mouse 8S-LOX, and 
coral 8R-LOX, only one amino acid (alanine or glycine) in the active site is 
responsible for the stereo-specificity of hydroperoxides [110]. Alanine and glycine 
are conserved residues in LOX showing S- and R-activity with LA as a substrate, 
respectively. This is explained by both substrate orientation and the effect of 
shielding of the amino acid group on substrate alignment in the catalytic pocket 
(Figure 2.9). For S-LOX enzymes (Figures 2.9B and C), the methyl group of the 
alanine residue in the active site of the catalytic pocket shields either the C-9 or C-13 
position depending on substrate orientation, so oxygen molecule is unable to access 
these positions, and as a result, oxygen insertion at the other side of 1,4-pentadiene 
unit leads to the formation of 13S-LOX or 9S-LOX products, respectively. On the 
other hand, without the shield effect of the alanine group (Figures 2.9A and D), 9R-
LOX and 13R-LOX activities are preferentially exhibited in both substrate 




Figure 2.9: Alanine and glycine in the active site direct S or R stereo-specificity of products, 
respectively. B and C: for S-LOXs and both substrate orientation, oxygen inserts at the other side as 
alanine residue shields one side. A and D: for R-LOXs and both substrate orientation, oxygen inserts 
directly to the preferable side. Reproduced from [87]. 
4.2. Reaction conditions 
LOX enzymes can be used as catalysts for the biosynthesis of lipid hydroperoxides, 
and a few studies have fully optimised the reaction of soybean LOX using a 
commercial LOX, crude SBF extract or soymeal with different substrates [43, 59, 
111, 112]. pH, temperature, oxygen concentration, substrate and enzyme 
concentrations and ratio, and reaction time are all important variables in LOX-
catalysed PUFA reactions. pH 10, air saturation and 5°C were found to be the 
optimised conditions for the reaction of LOX-1 from a crude SBF extract with 
hydrolysed safflower oil to maximise LOX-1 activity and improve product 
specificity [59]. The optimised conditions for a 10 mL reaction of DHA and a 
commercial 15-sLOX-1 were pH 9 for di-hydroxy DHA products, room temperature, 
no oxygenation, 15 min reaction time, 50 mM borate buffer, 0.1 mM DHA and 5 mg 
15-sLOX-1. pH 12 was used to inhibit the double dioxygenation reaction in the 
presence of less enzyme (2 mg 15-sLOX-1) for the maximum formation of the 
mono-hydroxy DHA product [43]. The optimised conditions of the soymeal-
catalysed reaction with soybean oil were pH 6, 1.5 g soybean oil, 2 g soymeal, 





at 1 hour and then decrease, possibly because the enzyme can be inhibited by the 
increase of hydroperoxides or inactivated by co-oxidation of the enzyme [111]. The 
optimum conditions for maximum enzyme activity of the purified type-1 on LA were 
ternary micellar systems with 50 µM Tween 80 and 3.5% v/v octane, or 10 µM 
Tween 40 and 4% v/v iso-octane, in 0.1 M Tris-HCl buffer pH 9 at 15°C and 40°C, 
respectively [112]. However, the reaction in an aqueous medium was found to have 
the greatest enzymatic catalytic efficiency [112].  
Purified lipoxidase, previously known as a lipoxygenase enzyme without any other 
isozymes, was isolated from defatted soymeal using a lengthy method with many 
steps of precipitation, fractionation, dialysis and electrophoresis [113]. In a study by 
Holman, the purified lipoxidase-catalysed reaction was optimised using sodium 
linoleate as a substrate and the optimum pH was found to be at 9.4 and temperature 
was optimum at 30°C. In the studied temperature range of 0 to 37°C, higher 
temperatures gave higher initial rates but the rate slowed down over time compared 
to lower temperatures where it remained consistent [114]. Surrey found that purified 
soybean lipoxidase activity was optimum at pH 7.5 in the absence of non-ionic 
surfactant Tween 20, whereas the optimum shifted to lower pH at 7 in the presence 
of Tween 20. Enzyme activity decreased with increasing Tween 20 concentration 
and the optimum pH continued to shift to pH 6.5. In the presence of Tween 20, 
enzyme activity showed less variation than without surfactant in the pH range 6 – 
7.5, with the optimum ratio of linoleate to Tween 20 of 1:1. In contrast with the 
purified enzyme, crude lipoxidase extract had optimum conditions at a lower pH of 6 
in the presence of Tween 20 [115].  
Non-ionic polyoxyethylene surfactants such as Tween 20, Triton X-100 and Lubrol 
were found to inhibit the activity of purified LOX-1 and LOX-2, except at linoleate 
concentrations above 100 µM where LOX activity was significantly inhibited by 
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substrate concentration and substrate aggregation [116]. Under these conditions, the 
reaction rate increased in the presence of surfactant with the optimum surfactant 
concentration at 0.2 g/L. It was proposed that the LOX isoenzymes catalyse the 
reaction with free linoleate as a monomeric substrate in the reaction medium, but not 
linoleate incorporated into surfactant micelles, and the enzyme is not stimulated 
directly by surfactant [116]. Tween 20 was also found to enhance the thermal 
stability of purified LOX-1. LOX-1 was inactive completely at 54°C at pH 9 and the 
midpoint of the thermal inactivation temperature increased from approximately 44°C 
to 48°C in the presence of 10 mM Tween 20 [117]. 
Other additives such as solvents, mild reducing reagents and exogenous iron ions 
were also used to enhance the enzyme activity in some studies. Exogenous iron (Fe2+ 
and Fe3+) concentrations were optimised in the LA reaction with commercial 
soybean LOX, where it was shown that 0.5 µM of Fe3+ or 5 nM of Fe2+ could 
accelerate the initial and overall reaction rate. Their effects on the reaction could be 
due to Fe3+ rapidly converting inactive Fe2+-LOX back to the active Fe3+-LOX form 
in the aerobic catalytic cycle, or Fe2+ promoting oxidation of Fe2+-LOX to Fe3+-LOX 
[95]. In the presence of cysteine (at 1.5 – 2 times substrate concentration), the mild 
reducing agent could convert fatty acid hydroperoxides to hydroxides, eliminating 
product inhibition and increasing the reaction yield from 69% to 90% using a crude 
LOX extract from defatted SBF as the enzyme source and LA from hydrolysed 
safflower oil as a substrate [118]. 
The product specificity of LOX isozymes has been found to be affected by reaction 
conditions. Soybean LOX-1 is known to have 13S-hydroperoxy LA as the major 
product from LA, but product specificity decreased to form mixtures of different 
regio- and/or stereo-isomers at high temperature [59], low oxygen concentration 
[119] or at low pH [49]. Under these conditions, it was suggested that the 
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pentadienyl radicals could be released from the active site to react unspecifically 
with oxygen [49, 119]. Product specificity of LOX-2 varied significantly from about 
30:70 13-hydroperoxy LA:9-hydroperoxy LA to 80:20 depending on the reaction 
conditions used [106, 107, 120], whereas the product ratio for LOX-3 was found to 
be consistent at approximately 35:65 [55, 106]. 
The physical state of the substrate can also affect regio- and stereo-specificity of 
LOXs. At high pH (> 8.5) and in the presence of Tween 20, only 13S-hydroperoxide 
was found to form from the reaction of soybean LOX-1 and LA [49]. This is because 
the carboxylate group is deprotonated and unable to insert into the hydrophobic 
catalytic pocket and so only methyl end substrate orientation approaches the enzyme. 
In contrast, at pH between 6 and 8.5, a mixture of 9S- and 13S-hydroperoxides were 
formed, as LOX-1 can catalyse reaction with protonated LA in both straight and 
inverse substrate orientations (methyl end first and head to tail end first, 
respectively). However, LA methyl ester cannot be dioxygenated at the C9 position, 
and only the 13S-hydroperoxide forms, regardless of these changes in pH [49]. The 
effect of substrate structure on the positional specificity of the enzyme was 
thoroughly investigated [119]. AA is known to be oxidised mainly at C15 by 
soybean LOX-1, through insertion of the methyl end at the active site. The methyl 
tail of AA free fatty acid and methyl ester were modified into a carboxylic acid, an 
alcohol, and a tert-butyl group to change the distance between the methyl end and the 
bisallylic C13 and also the polarity and bulk of the ligand to potentially induce 
inverse substrate binding. Iodine modification at the methyl end was also tested with 
the free fatty acid. These AA analogues were sonicated for 30 seconds to disperse the 
substrate homogeneously before starting the reaction at pH 9 by adding LOX-1. The 
modifications at the methyl end of the AA FFA did not change the positional 
specificity of 15-lipoxygenation of AA, but did reduce substrate affinity and decrease 
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reaction rate. Only AA methyl ester with an added hydroxy group caused formation 
of 5-AA (37%), 12-AA (46%) and 15-AA (17%), which suggested some inverse 
substrate orientation activity by LOX-1 [119].  
In addition, regio-specificity of purified LOX-1 was investigated at pH 7.4 with LA 
and AA in phosphatidylcholine deoxycholate mixed (PDM) micelles as the substrate 
[121]. The result showed that pH optima for the reaction with LA and AA inserted 
into PDM micelles at low ionic strength were observed at both pH 7.4 and 10, 
whereas only one optimum (pH 9) was obtained with fatty acids in PDM micelles at 
high ionic strength. The reaction products of LA and AA in PDM micelles were 9- 
and 5-hydroperoxides respectively [121]. The reaction products from Tween 20 
solubilised LA and AA with purified LOX-1 were 13- and 15-hydroperoxides at the 
optimum pH 9 with no dependence on ionic strength. The carboxylic acid group of 
the fatty acids exposed outside of the PDM micelles may be utilised as a recognition 
site for LOX-1 activity. LA methyl ester (LA ME) was compared as a substrate in 
the study to confirm this. Purified LOX-1 activity with LA ME at pH 9 in the 
presence of Tween 20 was approximately 11% of that with LA as a substrate under 
the same conditions. LA ME inserted into PDM micelles as a substrate did not show 
any activity with purified LOX-1 in the pH range studied (6 – 11). This confirmed 
that the carboxylic acid of the substrates had an important function in purified LOX-
1 catalysed oxidation when the substrates were inserted into micelles [121]. 
The presence of different LOX isoenzymes in the reaction was also found to affect 
reaction conditions and product specificity significantly. Purified LOX-1 and LOX-2 
in the following studies were prepared using the same Christopher, Pisiorius and 
Axelrod method [122]. LOX-2 was used to make di-hydroxy products from AA with 
the reaction rate displaying mono-phasic properties (similar reaction rate for both the 
first and second dioxygenation reactions) at pH 6.8 [123]. This differed to results 
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found for soybean LOX-1, where the first oxygenation at optimum pH 9 occurred 
quickly, whilst the second oxygenation with optimum pH at 7.5 – 8 was slow [124]. 
Similarly for the reaction of LOX-1 and AA at pH 6.8, the mono-hydroperoxide was 
produced fast within the first minute, whereas a conjugated triene (a dihydroxy 
product) formed slowly in the following 20 minutes [125]. For LOX-1 and LA 
prepared in water containing 0.35% v/v Tween 20, under conditions using an oxygen 
saturated solution at 0°C, the 13-isomer was the dominant product at all pHs tested 
with the maximum ratio of 13-isomer to 9-isomer (90:10) at pH 9. In contrast, under 
conditions at 25°C, without oxygen saturation, a racemic mixture of 13- and 9-
isomers was observed at pH 7 – 9. With LOX-2 and substrate prepared as above, the 
9-isomer was favoured at pH 7 – 9 regardless of oxygen and temperature conditions 
[120].  
5. Soybean flour as a source of lipoxygenases  
Commercial soybean LOX has been widely investigated as a biocatalyst compared to 
LOX extracts or raw sources from soybean. Studies with commercial soybean LOX 
have commonly used the following substrates LA, alpha linolenic acid (ALA, 
C18:3n-3), gamma linolenic acid (GLA, C18:3n-6), and AA, for single 
dioxygenation reactions to produce mono-hydroxylated compounds [48-52], rather 
than other LC-PUFA substrates such as DHA, EPA and DPA. Double dioxygenation 
reactions for the production of di-hydroxylated compounds, such as SPM analogues, 
has been conducted less intensively but on a wide range of n-3 and n-6 LC-PUFAs 
containing 1,4-pentadiene structures with at least three double bonds, including DHA 
[53, 54, 70], EPA [126], DPAn-6 [67], AA [48, 103, 125], GLA and ALA [127, 
128], and DPA [67, 102].  
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Dobson et al. synthesised a variety of mono and di-hydroxy products including 13 
lipoxin, resolvin and protectin analogues using the commercial type-1 soybean 15-
LOX (15-sLOX-1) and various n-3 and n-6 LC-PUFA substrates in a simple and 
reproducible method [43]. However, the usefulness of these enzyme reactions with 
the commercial 15-sLOX-1 is limited by the high cost of acquiring the enzyme and 
maintaining activity. If an enzyme can be sourced cheaply from natural materials, 
then low cost methods may be developed for their industrial use. Another issue is 
that the soybean LOX-1 isozyme is unable to catalyse (or only reacts at a very low 
rate) with various EFAs compared to FFAs [129, 130], whereas other soybean LOX 
isozymes (LOX-2 and LOX-3) are more able to catalyse EFAs [122, 131], but are 
not commercially available.  
Some research has worked on isolating individual LOX isozymes. The method of 
Axelrod et al. [55] has been used to isolate the LOX isozymes from soybean and 
defatted SBF [56, 132]. These isozymes could then be used to catalyse different 
types of substrates such as free and esterified fatty acids to generate various 
oxygenated products (mono- and di-hydroxy fatty acids, etc.). However, the process 
of isozyme isolation is generally time-consuming and complex. For example, the 
purification of LOX-1 from defatted SBF includes crude extract preparation with one 
hour of stirring, followed by filtration and centrifugation, then saturation with 30% 
and 60% ammonium sulphate with one hour of stirring and centrifugation, overnight 
dialysis and column chromatography, a further 15 hour of dialysis and a second 
column re-chromatography [55]. Recently, the extraction method was improved to 
increase the recovery of enzyme activity but this required a further purification step 
using an aqueous two-phase system [133]. The extracted enzyme should be used 




A natural LOX source containing a variety of LOX types that is inexpensive and can 
be used directly in the reaction without extraction or purification, is highly desirable 
for industrial production of a range of compounds. SBF is a commercial product used 
as an alternative to wheat flour in a variety of products and is available as defatted or 
full-fat flours [57] which could be used directly as a source of LOX. In fact, SBF has 
long been used as an active LOX enzyme source in breadmaking to bleach wheat 
flour by co-oxidising LC-PUFAs and β-carotene [134]. SBF is also added to wheat 
flour to improve rheological and breadmaking properties [135]. SBF is not only an 
inexpensive raw material but it can also be used directly for the LOX-PUFA reaction 
without the need for purification. SBF is easy to store for long-term usage at 4°C, 
instead of storage at -80°C (15-sLOX-1) and for short-term usage at room 
temperature, instead of keeping on ice (15-sLOX-1). This is because the stability of 
lipoxygenase in SBF (especially type-2 LOX) was found to be significantly higher 
(50 times) compared to the isolated enzyme [56]. This could be because the enzyme 
is stabilised by natural immobilisation in a native microenvironment of the protein-
starch matrix in the SBF [56].  
Although SBF has many benefits as a LOX source, it also shows several 
disadvantages. SBF contains multiple types of LOX enzymes, which contributes to 
its tremendous potential for making a variety of products and reacting with various 
substrates including free and esterified fatty acids. However, it also means the 
reactions could be less specific. As SBF is not a pure LOX source, it contains various 
compounds and enzymes [136] which could interfere with the reaction and product 
extraction, and it generally needs to be used in higher volumes in the reaction 
(compared to purified enzymes). Hydroperoxide lyase, hydroperoxide peroxygenase, 
hydroperoxide isomerase enzymes, and other components (proteins, phospholipids, 
and vitamins) were recorded to be present in defatted SBF [137, 138]. LA and ALA 
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are the major LC-PUFA components of soybean oil. Defatted SBF still contains a 
small amount of oil. Therefore, it is possible that soybean LOX may catalyse the 
available LA and ALA in full fat or defatted SBF, and then 13-hydroperoxides may 
be metabolised into shorter chain compounds by available hydroperoxide lyase. 
Volatile compounds have been detected in SBF and crude soybean extracts [139, 
140]. One study showed that significantly higher amounts of volatile compounds and 
higher sensory off-flavour scores in SBF formed under light compared to in the dark 
at 30°C from 0 to 6 days. The formation of volatile compounds in SBF increased 
with increasing storage time for both light and dark conditions. Volatile compounds 
were isolated by SPME with CAR/PDMS fiber in a 30°C water bath for 40 min and 
analysed by GC-MS. A chemical mechanism involving singlet oxygen was proposed 
for the formation of volatile compounds in SBF stored under light [139].  
Another study showed that the crude soybean extract from grinding whole soybeans 
with phosphate buffer at pH 6.9 was able to significantly degrade 13-hydroperoxy 
LA, or oxidise LA and then convert the resulting hydroperoxide into various oxo, 
oxo-epoxy, and aldehyde compounds. The reaction was conducted at pH 6.9 and the 
substrates were emulsified in the presence of 0.5% Tween 20 [140]. In another study, 
volatile compound formation using a simple SBF extract was applied to increase 
green and fruity aromas in an olive oil extraction process [141]. Green and fruity 
notes (hexenals and hexenols) are formed in the industrial extraction of virgin olive 
oil and are regarded as indicators of fresh quality oil. Crude SBF extract (10% w/v in 
distilled water with centrifugation) was added to olive paste during the malaxation 
process to test if exogenous LOX could enhance olive oil aroma by increasing the 
formation of C6 volatile compounds. The results showed that in the presence of 
exogenous soybean LOX from SBF, the quality parameters of olive oil including 
peroxide value and acidity did not change significantly, but higher aroma content of 
40 
 
some volatile compounds was observed [141]. This demonstrated that the reaction 
products (PUFA hydroperoxides) could be used by hydroperoxide lyase in SBF to 
form volatile compounds. 
Soybean LOXs have been intensively studied in the literature, especially LOX-1, as 
it is commercially available, whereas much less work has been done on the use of 
SBF (either directly or as a crude extract) as a source of lipoxygenase. In the 
following sections, studies using SBF or soybean meal (SBM) as a LOX source will 
be considered. Common reaction conditions and major applications with specific 
findings on SBF characteristics will be discussed. SBF and SBM are treated 
separately in the following sections as they are slightly different. SBF and SBM are 
both processed from soybeans but differ in particle size, and SBM is a cruder 
material compared to SBF. Soybeans are cracked, de-hulled and pressed into flakes 
(0.25 – 0.3 mm thickness) which is called SBM. Flakes are grinded into smaller size 
(< 149 µm) thickness (> 97% pass through a 100 mesh sieve) and the resulting 
powder is called SBF. The finer grades of SBF are passed through 150, 200 and 325 
mesh sieves. Both SBM and SBF can be defatted to remove soybean oil by solvent 
extraction, or they can be left as full-fat products [57, 136, 142].   
5.1. Preparation conditions 
Both SBF and SBM (defatted and full fat) have been used as an active enzyme 
source of LOXs, either directly or with simple extraction (see Applications section, 
5.2, and references therein). In this section, the common methods for SBF or SBM 
preparation as a LOX source either directly or with simple extraction are described 
(all references in this section).  
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5.1.1. Direct use 
When being used as a LOX source, SBF and SBM have either been added directly 
into the reaction medium, or prepared in water or reaction buffer, with or without 
centrifugation and filtering. The SBF/SBM suspension or solution can then be mixed 
with the fatty acid substrate to initiate the reaction (see Applications section, 5.2 for 
examples). All LOX isoenzymes may be present in the reaction mixture and involved 
in the LOX-catalysed reactions. The presence of multiple isoenzymes could affect 
substrate specificity and product formation.  
5.1.2. Simple extraction 
Lipoxygenases from SBF and SBM have been extracted through simple protocols, 
and used as a crude LOX source. The crude extract contains specific LOX isoenzyme 
activity (mainly LOX-1 or LOX-2), which depends on the extraction pH. Activity of 
the major LOX isoenzyme (LOX-1 or LOX-2) in the crude extract may be 
significantly higher than the other LOXs, which may still be present in a smaller 
amount. No work on crude LOX-3 extraction has been found. LOX-3 has been 
removed along with LOX-2 at high temperatures in LOX-1 extractions to maximise 
the LOX-1/(LOX-2 + LOX-3) ratio [138, 143]. SBF and SBM are commonly 
prepared (without optimisation) in ~ 5 – 20 volumes of water or buffer. Typically, 
acidic pH is used to extract LOX-1, whilst neutral pH is used for LOX-2. Extractions 
are generally performed at low temperature (0 – 6°C) with stirring (up to 2 hrs) or 
using a homogeniser. The suspensions can be centrifuged and/or filtered to obtain a 
crude LOX solution (refer to Applications section, 5.2, for specific references). Only 
two studies, from the same research group, investigated the extraction conditions for 
LOX-1 and LOX-2 from defatted SBF in ~ 100 mL stirred tank reactors [137, 138]. 
Optimised extraction conditions are described below. 
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In the first study, the optimised conditions for LOX-1 extraction from defatted SBF 
were found to be water at pH 5.2 (adjusted using acetic acid), 40°C, stirring at ~ 5 
rps for 10 min [138]. In the same study, further heat treatment at 70°C for 5 min was 
applied to decrease LOX-2 and LOX-3 activity, giving enhancement of the LOX-
1/(LOX-2 + LOX-3) ratio [138]. This heat treatment was optimised in a previous 
study with different temperature, time, pH and ionic strength conditions using SBM. 
LOX-2 and LOX-3 have significantly lower thermal stability than LOX-1 [143]. In 
the second study, LOX-2 extraction from defatted SBF was found to be maximised 
in 0.05 M phosphate buffer at pH 6.5, 25°C, with stirring at ~ 5 rps for 10 min [137]. 
This extract may also contain LOX-1, but it is likely not as highly concentrated as in 
the acidic pH extraction. LOX-3 could also be present in the extraction. In scaling up 
to ~ 500 mL stirred tank reactors for industrial applications, both LOX-1 and LOX-2 
extractions were maximised at a slower agitation speed (3 rps instead of 5 rps) [137, 
138].  
5.2. Screening lipoxygenase activity 
A number of studies have used both SBF and SBM (defatted or full fat) either 
directly or after simple extraction to screen for LOX activity. These papers will be 
discussed in this section. Generally, LOX-1 activity was measured between pH 9 and 
10, while LOX-2 + LOX-3 activity was measure between pH 6.5 and 6.8, and 
sodium linoleate or linoleic acid were used as substrates. UV-vis spectrophotometry 
at 234 nm was commonly used to monitor the formation of hydroperoxides or 
alternatively oxygen consumption was used to monitor the LOX-catalysed reaction. 
Reaction temperatures between 15 and 25°C were used.  
Direct use 
Luquet et al. demonstrated the potential benefits of directly using SBF as an 
inexpensive LOX source compared to commercial LOX to produce oxygenated 
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products from both free and esterified LC-PUFAs [56]. In this research, full-fat SBF 
prepared in water (pH 6.8) was used as a crude LOX source. It was possible to 
generate oxygenated products from not only linoleic acid as a free fatty acid (reaction 
in borate buffer at pH 9.22 or without solvent), but also from EFAs – trilinolein (TL) 
and sunflower oil (without solvent). The crude preparation was found to have much 
higher activity with TL compared to a commercial LOX. The authors proposed that 
the type-2 LOXs present in the flour were active for the oxygenation of the intact 
TAGs. In the same study, lipoxygenases were also intensively extracted from the 
SBF following a lengthy procedure [144] requiring many time-consuming steps. This 
purified enzyme mixture was found to be significantly less stable than the crude SBF 
preparation [56].  
Simple extraction 
Only one study has used an acidic buffer to extract LOX from defatted SBM [145]; 
all other studies have used neutral pH. In this study, LOX activities and LOX-
1/(LOX-2 + LOX-3) activity ratios in 10 soybean cultivars, grown in Hungary over 3 
continuous years were investigated. Defatted SBM was extracted in sodium acetate 
buffer at pH 4.5, before adjusting to pH 6.8 and the crude extract was used as a LOX 
source for LOX activity screening. The activities of the LOX isozymes were found to 
be affected more significantly by the changes in weather conditions for a cultivar 
type over the years, than by differences in cultivar type within the same year, even 
though LOX isoenzyme biosynthesis in soybeans is genetically controlled [145].  
More work has been done using LOX-2 extracts (neutral extraction) compared to 
LOX-1 extracts and these will be discussed below. LOX activity from various 
soybean and plant species has been identified and compared. In one study, three 
LOX isozymes from soybean seed powder extracted in buffer at pH 6.8 were 
separated using HPLC ion-exchange chromatography [101]. The retention time was 
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matched with pure LOX isoenzyme standards and the mixture of all three pure 
isoenzymes. LOX-3 activity was specifically measured at 280 nm through the 
formation of ketodiene, whereas other LOXs were monitored at 234 nm. Two 
soybean mutants (PI-408251 and Wasenatsu) were tested using this method to 
determine the presence of different LOX isozymes and they were found to be absent 
of LOX-1 and LOX-2 + LOX-3 respectively [101]. In another study, crude extracts 
of SBF from 51 Indian soybean varieties and strains were tested to compare the 
LOX-1 and LOX-2 + LOX-3 activities [146]. SBF was homogenised in 100 volumes 
of phosphate buffer (0.2 M, pH 6.8) as a crude LOX source. Two varieties (Shilajeet 
and KhSb 2) were found to have lower activities from all LOX isozymes, and are 
therefore desirable for use in the food industry to produce less beany and off flavours 
(known to be caused by LOX products). Large variations between cultivars were 
found: ~ 150-3000 units/g SBF for LOX-1 and ~ 250-1500 units/g SBF for combined 
LOX-2 + LOX-3 activity [146]. In a study by Fauconnier and co-workers, the LOX 
activity of 35 plant species belonging to 5 different families was measured at pH 7 
using crude extracts, to find an effective LOX source for the synthesis of green note 
precursors [147]. The ground seed extracts were prepared from 1 g flour in 100 mL 
phosphate buffer (pH 7). LA substrate was emulsified with Tween 40 (0.25% w/v) at 
a 1:1 ratio and adjusted to pH 7. The 105 mL-scale reaction was conducted under 
oxygen saturation, and after 45 min the reaction mixture was diluted in ethanol to 
measure LOX activity at 234 nm with a UV-vis spectrophotometer. Species of the 
three genuses (Phaseolus, Trifolium, and Vigna) belonging to Fabaceae family were 
found to have as high LOX activity as the species Glycine max (soybean) which is 
also derived from the same family. Glycine max had the highest LOX activity per 
gram flour whereas Trifolium hybridum, Vigna angularis and Vigna unguiculata had 
higher LOX activities per gram protein than soybean. LOX activity of the four 
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species (Glycine max, Phaseolus coccineus, Vigna radiata and Vigna unguiculata) 
were also investigated in the range pH 4 – 12 for the optimum. Soybean activity was 
found to have 2 optimum pHs, at pH 10 (corresponding to LOX-1 activity) and pH 
6.5 (related to LOX-2 and LOX-3 activity). The other 3 species had only one 
optimum at pH 6. At pH 7, 13- and 9-hydroperoxy LA formed equally for all four 
species, whereas at pH 9, soybean (the only species active at this pH) was found to 
have higher regio-specificity, producing 80% 13-hydroperoxy LA (20% 9-
hydroperoxy LA) [147].  
Similar results regarding pH and LOX activity have been found in the following 
studies. Surrey showed that crude SBM extract had maximum activity at pH 6 in the 
range studied (pH 5 – 9) with sodium linoleate and Tween 20 (0.25% v/v), and 
continuous oxygen supply. The SBM (1 g) was extracted in 200 mL phosphate buffer 
at the reaction pH being tested [115]. In a study by Koch and colleagues, different 
types of substrates (free and esterified fatty acids) were used with crude defatted 
SBM extract as different LOX isoenzymes are present in the extract [131]. LA and 
TL were prepared in solvent (ethanol, and acetone: ethanol (1:1), respectively) to be 
used as substrates for the crude extract. The extract was prepared by suspending 
defatted SBM in water, and then the soluble fraction was further precipitated with 
calcium chloride to obtain the crude extract after centrifugation. LOX-1 (acid LOX) 
in the crude extract showed maximum activity with LA at pH 8.3, whereas type-2 
LOXs (triglyceride LOX) oxygenated TL at both pH 5.5 and 8.3. Enzyme amount 
used was 4 times higher for type-2 LOX compared to LOX-1 [131]. In another study, 
LOX-2 activity from defatted SBF extracted in phosphate buffer at pH 6.5 was 
measured using pure LA as substrate, for comparison between two different methods 
(a spectrophotometric method at 234 nm and an isotachophoretic method, to measure 
the increase in conjugated dienes and the decrease in LA concentration respectively) 
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[148]. The assay was conducted using phosphate buffer at pH 6.5 in the presence of 
Tween 80 (1%). Product concentration increased linearly over 30 min, while 
substrate concentration decreased over the first 15 min faster than the period after 15 
min [148]. 
Different types of SBM or SBF can affect LOX activity. In a study, crude soybean 
extracts from full fat or defatted SBM were found to have different LOX isozyme 
activities [149]. Pure LOX-1 (commercial), full-fat and defatted SBM extract 
activities were investigated with sodium linoleate through kinetic patterns. A kinetic 
curve was obtained by monitoring the increase of absorbance at 234 nm or 280 nm 
with a UV-vis spectrophotometer over 300 – 500 seconds for LOX-1 and LOX-2, or 
LOX-3 respectively. LOXs in the crude soybean extract from full-fat SBM at pH 6.1 
were identified to have mainly LOX-1 and LOX-3 activity (ratio of 3:1) but low 
LOX-2 activity. In contrast, the defatted extract of SBM at pH 4.5, 6.1 and 7.1 
contained LOX-3 as the major LOX and was low in LOX-1 and LOX-2. This study 
also showed that LOX-1 activity could be modified by enzyme/substrate ratio and 
buffer pH. Low pH and high enzyme substrate ratios were found to inhibit LOX-1 
activity [149]. In another study, the activities of LOXs from three defatted SBF 
(described as fully toasted, white and enzyme active) extracted in water (50 mg 
flour/mL) were measured for comparison [150]. The white SBF has minimal heat 
treatment as described by the manufacturer. A more dilute solution of the enzyme 
active SBF in water (1 mg/mL) was required to achieve readable results to monitor 
enzyme stability of defatted SBF over time (up to 180 days) at 23°C. The enzyme 
active SBF was found to have the highest LOX activity, compared to no activity 
detected from the fully toasted SBF, and close to zero activity of the white SBF. The 
activity of the enzyme active SBF decreased at an increasing rate over the storage 
period studied [150]. 
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5.3. Applications and LOX activity 
SBF and SBM have been used (directly or after extraction) as crude LOX sources for 
many applications. The two major applications investigated in this section are the 
bleaching of beta-carotene and the synthesis of lipid hydroperoxides for various 
purposes. LOX activity is also discussed in relation to these applications. 
5.3.1. Bleaching beta-carotene 
LOX was originally known as carotene oxidase, and was first identified in 1928 in 
soybean through its ability to bleach carotene (as cited in [151]). In 1932, an enzyme 
in soybean was identified and termed lipoxidase which oxidised unsaturated fats, and 
in 1940 carotene oxidase and lipoxidase were confirmed to be the same enzyme 
[151]. As a result, lipoxidase is also referred to be LOX. SBM has been used directly 
and after extraction in water as a LOX source to bleach beta-carotene and other 
carotenoids in the presence of oil. The bleaching activity is caused by LOX catalysis 
through the co-oxidation of beta-carotene and PUFAs. Hydroperoxides from LOX-
catalysed PUFA reactions are responsible for the oxidation of beta-carotene [152, 
153]. 
In one study, an aqueous extract of fat-free SBM was found to bleach carotene in the 
presence of highly unsaturated hemp-seed oil without saponification in a much 
shorter time than bleaching without hemp-seed oil or with excessive amounts of the 
oil [154]. The optimum temperature for the bleaching of carotene in the presence of 
water by the crude SBM extract was found to be 40 – 45°C [154]. Summer and 
Smith found that finely ground defatted SBM extracted with acidic water (acidified 
by acetic acid) was able to decolourise bixin, a more stable carotenoid than carotene, 
in the presence of neutralised fatty acids (saponified soybean oil) and gum arabic 
[151]. At pH 6.5, the highest activity of carotene oxidase was identified to be at 10°C 
(studied range 10 – 35°C) by measuring bleaching time in seconds [151]. This 
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optimum temperature was lower than the optimised temperature of the bleaching 
with hemp-seed oil (40 – 45°C) found in the study above [154]. In a different study, 
SBM in water was used to bleach the yellow colour of the carotene in cottonseed oil 
and other unsaturated fats [155]. The enzyme activity was measured by iodine-
thiosulfate titration. The optimum pH for the cottonseed oil bleaching reaction was 
found to be at pH 6.5 (phosphate buffer 0.1 N). The carotene oxidase activity 
decreased with increasing temperature in the studied range (15 – 30°C). The highest 
activity was found to be at 15°C, which is similar to the bleaching temperature in the 
saponified soybean oil reaction at 10°C [151]. When monitoring the reaction at 19°C, 
the rate was found to decrease over time [155].  
Different results have been reported for LOX isozyme activity on bleaching beta-
carotene [152, 153, 156]. The presence of LOX-1 was essential for bleaching beta-
carotene either with fatty acid hydroperoxides or fatty acids. LOX-1 bleached beta-
carotene at a higher rate in the presence of fatty acids compared to intermediate fatty 
acid hydroperoxides. The bleaching activity was measured spectrophotometrically at 
452 nm for the decrease of beta-carotene absorbance. [152]. Weber and co-workers 
found that type-2 LOXs were more active than type-1 LOX in bleaching beta-
carotene [156]. However, as LOX-1 is the major isozyme in SBF and more stable 
than other LOXs, it still may be the isozyme in SBF responsible for catalysing the 
cooxidation of beta-carotene and PUFAs [152]. A combination of LOX-1 + LOX-2 
or LOX-2 + LOX-3 was found to bleach beta-carotene more effectively than 
individual LOX isozymes [153].  
5.3.2. Synthesising lipid hydroperoxides  
Both full fat and defatted SBF or SBM have been used directly as a readily available 
and inexpensive LOX source, without complex extraction or purification, in many 
studies to produce fatty acid hydroperoxides in milligram to gram scale reactions. 
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SBF but not SBM has been used by adding directly into the reaction without prior 
preparation, whereas both SBF and SBM have been used with simple extraction in 
water or buffer (acidic, neutral pH buffer or pH used in the reaction). Fatty acid 
hydroperoxides have been mainly used as precursors for the synthesis of green note 
flavour compounds (Table 2.2). The conversion of hydroperoxides into flavour 
compounds is catalysed by different hydroperoxide lyase enzymes. Green note 
flavour compounds are volatile C6-C10 aldehydes and alcohols such as hexanal and 
hexenal, and are naturally produced in plants by LOX and hydroperoxide lyase as 
part of their defence system in response to wounds and pathogen attacks [60, 105]. 
These fresh green odour molecules are widely used in recovering vegetable and fruit 
flavours lost over time. Methods for the production of these compounds on an 
industrial scale for the food industry using inexpensive natural materials are in 
demand [60, 61, 157]. The major substrates used for hydroperoxide synthesis are 
C18 fatty acids (LA and ALA) as either pure substrates or from hydrolysed vegetable 
oils (sunflower, safflower, and linseed), as well as natural oils such as soybean oil 
and butterolein as EFAs (Table 2.2). An advantage of using SBF and SBM, is the 
potential to catalyse not only FFAs and hydrolysed natural oils but also EFAs (TL, 
soybean oil, and butterolein) due to the presence of stable type-2 LOX. SBF and 
SBM have been used to synthesise hydroperoxides at different pHs which are 
optimised for type-1 LOX (pH 8 – 10) or type-2 LOX (pH 6 – 7). Most studies have 
used temperatures between 0 and 25°C, and oxygen saturation before initiating the 
reaction or oxygen/air flow over the course of the reaction, for the synthesis (Table 
2.2). The conditions are dependent on the purpose of the study, and which isozyme is 
needed for the reaction as only type-2 LOXs can catalyse the oxidation of EFAs. 
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Table 2.2. Reports of simple soy flour preparations used for the synthesis of lipid hydroperoxides. 
No. Substrate pH Purpose Year Ref. 
1 Safflower and soybean oil 
soap 
9 – 10 Synthesis of hydroxy conjugated 
octadecadienoic acids 
1971 [158] 
2 Linoleic and linolenic acid 9.5 Production of natural green note 
flavour compounds 
1995 [157] 
3 Linoleic acid, linolenic acid 9.0 – 9.5 Green note compound synthesis 
(aliphatic alcohols and 
aldehydes)  
1995 [159] 
4 Hydrolysed safflower oil 10 Large scale production of 13-
HPOD from hydrolysed safflower 
oil 
1996 [59] 
5 Linoleic acid in hydrolysed 
safflower oil 
10 Synthesis of lipid hydroperoxides, 
for conversion to hydroxides for 
fine chemicals  
1998 [118] 
6 Hydrolysed safflower and 
linseed oils 
8.25 Green note compound synthesis 
(hexanal and hexenal) 
2002 [60] 
7 Linoleic acid, hydrolysed 
sunflower oil (66% w/w 
LA) 
9 Synthesis of hexanal 2002 [160] 
8 Hydrolysed linseed oil  9 2(E)-hexenal synthesis from 13-
HPOT  
2004 [161] 
9 Linolenic acid 6 or 8.7 Green note compound synthesis 2005 [105] 
10 Butterolein  7.0 Enzymatic synthesis of C6-C10 
flavour aldehydes 
2006 [61] 
11 Hydrolysed linseed oil 9.5 Development of a method for 
real time reaction monitoring 
2007 [162] 
12 Sodium linoleate 10 In comparison with 
hydroperoxide yield of mung 
bean lipoxygenase 
2007 [163] 
13 Hydrolysed linseed oil 9.0 Synthesis of cis-3-hexenal 2008 [164] 
14 Linseed oil fatty acids 9.5 Synthesis of hexanal 2009 [165] 
15 Hydrolysed linseed oil 9 Enzymatic synthesis of green 
notes and alcohols 
2009 [58] 
16 Soybean oil 6 Gram scale production of 
hydroperoxides 
2011 [111] 
17 Hydrolysed linseed oil 9.3 Preparing lipid hydroperoxide 






In some studies, characteristics of the LOX reaction used for hydroperoxide 
synthesis have been investigated and will be discussed below. These studies have 
been categorised into either direct use of SBF or prepared as a crude SBF extract. 
Direct use of SBF  
In a study by Emken and Dutton, sfLOX activity was compared between defatted 
SBF, defatted SBF extract (extracted at pH 10, as was also used in the reaction) and 
commercial purified LOX [158]. There was no difference in LOX activity between 
the crude SBF extract and the same SBF extract with further purification using 
CaCl2. Defatted SBF and the aqueous SBF extract were found to have significantly 
higher activity than a commercial purified LOX when using the same enzyme 
concentration under the two following reaction conditions: 1) 4 mg/mL substrate, 
10% ethanol, substrate/enzyme ratio of 80; and 2) 100 mg/mL substrate, 20% 
DMSO, substrate/enzyme ratio of 500. The commercial purified LOX was inactive 
and inhibited at high substrate/enzyme ratios (> 80), whilst at low substrate/enzyme 
ratios of 10 to 20, the enzyme had the same activity as the aqueous SBF extract. The 
reaction rate for defatted SBF and the percent oxidation of substrate decreased with 
increasing substrate concentration from 4 to 100 mg/mL with a constant 
substrate/enzyme ratio of 200 in the presence of 10% ethanol. Therefore, high 
substrate concentrations inhibited the enzyme. Under the conditions of 4 mg/mL 
substrate, 10% ethanol, substrate/enzyme ratio of 80, the aqueous SBF extract had 
dramatically higher activity than defatted SBF. However, increasing substrate 
concentration and substrate/enzyme ratio, the activities of both defatted SBF and the 
aqueous SBF extract were found to be comparable. High concentrations of solvent 
(more than 10% ethanol or from 30% DMSO) could denature the enzyme, which led 
to a decrease in reaction rate and total oxidation. 0.75% BHT was found to improve 
the reaction yield when high substrate concentrations were used. This work showed 
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the possibility for the economical and effective large-scale production of 
hydroperoxides using inexpensive fatty acids from soap stock and SBF as a direct 
LOX source without purification [158].  
Haefliger and Sulzer found that for pure ALA substrate, the optimum reaction times 
at pH 9.5 and 8.5 were at approximately 20 min and 45 min respectively and longer 
reaction times caused a loss of hydroperoxide yield as hydroperoxides were reduced 
into corresponding hydroxides [162]. The reaction at pH 9.5 was about 2.5 times 
faster than at pH 8.5, but did not increase the reaction yield. The reaction yield with 
ALA from hydrolysed linseed oil as a substrate (~ 75%) was much higher compared 
to the reaction yield with pure ALA (~ 45%). The research suggested that the 
presence of other non-oxidised fatty acids such as oleic acid and steric acid in the 
hydrolysed linseed oil may help the emulsification process for better interaction 
between the substrate and water-soluble enzyme [162]. In a study by Kohlen and co-
workers SBF LOX (sfLOX) and commercial purified LOX-1 activities on LA and 
TL were also compared [61]. The results showed that in the studied range (pH 5 – 
10) sfLOX had significantly higher activity with TL at pH 7 than other pHs, whereas 
there was no activity for the reaction between purified LOX-1 and TL. With LA as a 
substrate, both sfLOX and purified LOX-1 had the same optimum at pH 9. 
Moreover, sfLOX activity was expressed over a broad pH range (pH 5 – 10), 
whereas LOX-1 activity significantly decreased at lower pHs [61]. 
In a milligram scale study, Fukushige and Hildebrand reacted ALA (2 mg) with 
defatted SBF (10 mg) in 2 mL phosphate buffer. LOX-1 and LOX-2 present in the 
SBF were targeted to produce hydroperoxides at pH 8.7 and 6, respectively [105]. 
LOX-2 was responsible for the highest production of hexenals in a one step reaction 
of hydroperoxide synthesis and hexanal conversion at pH 6 as this is the optimum pH 
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for both LOX-2 and hydroperoxide lyase. The hydroperoxide lyase was from 
watermelon overexpressing the enzyme in leaf tissues. LOX-1 also gave a high 
hexanal yield but the conversion required two steps as LOX-1 and hydroperoxide 
lyase have different optimum pH, at 8.7 and 6 respectively. LOX-3 gave a lower 
yield of 13-hydroperoxides compared to the other LOXs and further converted 
products into ketodienes, therefore the use of SBF lacking LOX-3 was found to 
signficantly increase hexanal formation [105].  
Crude SBF extract 
Two studies by Elshof et al. applied a crude extraction method using defatted SBF 
extracted in sodium acetate buffer pH 4.5 to oxygenate LA in hydrolysed safflower 
oil [59, 118]. In the first study, the optimum conditions were found to be pH 10, 5°C 
and air saturation with 80% yield and high product regio-specificity of > 95% 13-
hydroxy LA and stereo-specificity of > 95% S. Stability of the LOX-1 extract kept at 
4°C was tested over 65 days. The activity decreased significantly over the first few 
days and then the degradation rate slowed down [59]. In the second study, the LOX 
reaction was conducted at pH 10 under constant air flow. Cysteine, a mild reducing 
agent, was used to investigate the direct reduction of hydroperoxides into hydroxides 
during the reaction to increase the reaction yield as hydroperoxides are known to 
inhibit the LOX enzyme. The results showed that a molar cysteine:substrate ratio of 
1.5 – 2:1 gave a higher yield of approximately 90% compared to the yield of without 
cysteine of almost 69% 13-hydroxy LA [118].  
Other studies have applied the optimal conditions from the above study by Elshof et 
al. without cysteine to produce 13-hydroperoxides with minor modifications [160, 
161, 165]. In one such study by the Nemeth group, defatted SBM was extracted in 
0.05 M acetic acid (pH 5.2) and then heated at 70°C for 5 min to obtain specific 
LOX-1 activity. The synthesis of 13-hydroperoxy ALA (62% yield) as a precursor 
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for the production of 2(E)-hexenal was conducted at pH 9, 0 – 5°C and continuous 
air flow using linolenic acid (100 mM) from hydrolysed linseed oil as a substrate 
[161]. Santiago-Gomez and co-workers used SBF extracted in acidified water (pH 
4.5) to oxidise linseed oil fatty acids (ALA and LA), in the presence of Tween 20, 
pH 9.5 (LOX-1 optimal pH for 13-hydroperoxide selectivity), oxygen saturation, 
20°C, 30 min reaction time. The resulting hydroperoxides were then used to 
synthesise hexanal, and the reaction was optimised [165]. In a study by Marczy and 
colleagues, SBM was extracted in 0.05 M acetic acid and followed by heat treatment 
at 70°C for 5 min to minimise type-2 LOXs [160]. The reaction was conducted at pH 
9 (corresponding to LOX-1 activity), 0 – 5°C to increase oxygen solubility and 
reduce side reactions and 2 bar oxygen pressure using LA as a substrate. The yield of 
the reaction (500 mL scale) was 72% 13-hydroperoxy LA [160]. 
Cai and co-workers found that SBM could be used to synthesise TAG 
hydroperoxides from soybean oil, under the optimum conditions at pH 6 (lower than 
the optimum pH for free fatty acids), 10% ethanol, 2 – 3 hours, 20°C. Crude defatted 
SBM extract in phosphate buffer (pH 6) gave a much lower hydroperoxide yield (< 
30%) compared to the direct use of SBM (61%) [111]. Chow and colleagues found 
that the pH of crude extracts did not affect soybean LOX activity significantly with 
sodium linoleate as a substrate in the first step to form hexanal using hydroperoxide 
lyase from bell pepper fruits [163]. Three buffers (pH 4.5 acetate buffer, pH 6.5 
phosphate buffer, pH 9 borate buffer) were used to extract LOX from freshly crushed 
soybeans. For extraction at pH 4.5, LOX had much less total protein content but 
higher specific LOX activity (unit/mg protein) compared to the extracts at pH 6.5 
and pH 9. Therefore, the research suggested that high amount of proteins at high pHs 
may be unspecific and could inhibit the reaction. As for LOX reaction pH, there were 
two optima at pH 6 – 6.5 and pH 9.5 – 10 corresponding to LOX-2 + LOX-3 and 
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LOX-1 activity respectively. Extraction at pH 4.5 and reaction at pH 10 were used to 
form LOX products for hexanal production. These optimal reaction pHs were only 
observed for LOX extracted at pH 4.5 and 6.5, whereas the alkaline optimum was not 
clearly detected for LOX extracted at pH 9. In this work, fresh crushed soybean was 
homogenised with a high speed homogeniser at 10,000 rpm for 4 min [163]. 
6. Esterified fatty acids as substrates for hydro(pero)xylated 
compound synthesis 
LOX reactions with FFAs as substrates have been well-studied in comparison to 
LOX reactions with EFA substrates (such as fatty acid methyl esters, triacylglycerols 
and phospholipids). LOX enzymes are known to catalyse FFAs as preferred 
substrates compared to EFA substrates [167]. However, soybean, barley, cucumber 
and other plant LOXs have been shown to have activities with EFAs in a number of 
studies (all references below). In this section, the use of soybean LOX and other 
plant LOXs to catalyse reactions with EFA substrates is described. The activities of 
different LOX isozymes on various EFAs and substrate preparations are investigated 
in these studies. 
6.1. Soybean lipoxygenases  
LOX-1 generally catalyses FFAs such as LA and ALA with high enzyme activity, 
whilst type-2 LOXs catalyse both FFAs and EFAs [88, 90]. However, in a number of 
studies, LOX-1 has been found to catalyse various EFAs at a low rate under specific 
conditions after optimisation [129, 168, 169]. In two studies, the optimum pH for the 
reaction of TL and 1,3-dilinolein with LOX-1 was identified to be at pH 8 – 9 in the 
studied range of pH 5 to 11 [129, 169]. This pH is the same as the optimum pH for 
LOX-1 catalysed reactions with FFAs. Three studies showed that the presence of a 
bile salt, deoxycholate (5 – 10 mM), acting as an emulsifier, was essential for the 
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reaction to occur, and could not be replaced by other surfactants such as Tween 20, 
Tween 80 and Triton X-100 [129, 168, 169]. The substrates used in these studies 
were egg yolk L-α-phosphatidylcholine (a phospholipid species) [168], TL [129] and 
1,3-dilinolein [169]. Piazza et al. found that the oxidation rate for LOX-1 and 1,3-
dilinolein decreased 2 – 3 fold when the reaction medium was changed from a 
multicomponent buffer (a mixture of four buffers) to a one component buffer [169].  
Piazza and co-workers also investigated the relative oxidation rate of a range of 
EFAs with LOX-1 after normalising to the LA and LOX-1 reaction rate as 100% 
[129, 130, 169]. The reactions were conducted under optimum conditions at pH 8 – 9 
with a multicomponent buffer and in the presence of 5 – 10 mM deoxycholate. Most 
EFAs reacted with LOX-1 at lower rates than LA [129, 130, 169]. The rate of 1,3-
dilinolein oxidation was 40% of LA [129, 130]. No significant activity with 1,3-
dilinolein was observed when deoxycholate was replaced with the surfactant, Tween 
20, or in the absence of all surfactants [169]. TAGs containing moieties of LA, oleic 
acid and steric acid had an oxidation rate of 15% compared to LA [129]. In contrast, 
LA ME and 1-monolinolein were found to be oxygenated at a similar rate or slightly 
higher than LA respectively. However, the rate of LA ME and 1-monolinolein 
oxidation was much lower in the presence of Tween 20 or without any surfactant. 
LOX-1 showed approximately double the reaction rate with 1-monolinolein 
compared to its reaction with 1,3-dilinolein, whereas the oxidation rate of TL with 
LOX-1 (3% of the LA rate) was significantly lower than the rate of 1,3-dilinolein 
with LOX-1 (55% compared to LA rate). The results demonstrated that adding more 
linoleoyl residues to the glycerol backbone decreased LOX activity [169].  
In a study by Nakashima et al., monogalactosyl diacylglycerol (MGDG, sonicated in 
the presence of deoxycholic acid) was also found to be a substrate for purified LOX-
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1 catalysis at pH 9, whereas no activity was observed in the absence of the detergent 
[170]. MGDG containing mainly linolenate acyl moieties was extracted and purified 
from clover leaves. The optimum concentration of detergent for maximum enzyme 
activity was 6.9 mM, and at this concentration possible formation of mixed micellar 
aggregates recognised by the enzyme was suggested to be the mechanism for the 
catalysis of EFAs. The reaction had high product specificity for 13-hydroperoxy-
ALA as the primary acyl moiety. Both mono- and di-hydroperoxy MGDGs were 
detected, and no preference for the hydroperoxy group on mono-hydroperoxy 
MGDGs at either sn-1 or sn-2 position was observed [170].  
Different reaction conditions in the absence of the bile salt have been used in other 
studies. Kermasha, Dioum and Bisakowski found that LOX-1 had low activity with 
monolinolein, dilinolein and TL (less than 10% relative specific activity compared to 
LA) in aqueous media at pH 9 [112]. In addition, LOX-1 was found to have higher 
activity with monolinolein (up to 46% in comparison with LA) in ternary micellar 
organic solvent systems containing a buffer at pH 9, either octane or isooctane (3.5 – 
4%) and a surfactant Tween 40 or Tween 80 (10 – 50 µM), whereas no significant 
increase was observed for dilinolein or TL [112]. Tayeb and co-workers used TL 
sonicated in buffer for 10 minutes to be catalysed by LOX-1 at pH 9 without 
surfactant [171]. Analysis of TL before and after LOX-1 treatment using 1H-NMR 
indicated oxidation of TL. The study demonstrated that TL can be oxygenated by 
LOX-1, but characterisation of the products and calculation of the reaction yield 
were not performed [171]. Fukuzawa and colleagues reported that a commercial 
LOX-1 can catalyse phosphatidylethanolamine and egg yolk PC effectively in buffer 
at pH 9 in the presence of 20% methanol or 1% Triton X-100 to disturb the 
membrane structure of substrate vesicles [172]. This allowed an increase in substrate 
available to be accessed by the enzyme. The enzyme concentration required for the 
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reaction with EFAs was 1000 times higher than the reaction with LA free fatty acid. 
A longer reaction time was also observed for the LOX-1 catalysed EFA reactions 
[172]. 
In several studies, the activities of purified LOX-1 and LOX-2 (or type-2 LOX) have 
been compared for the oxygenation of EFAs. Christopher, Pisiorius and Axelrod 
fully isolated two types of LOX from defatted SBF to measure activities with LA, 
LA ME and TL (pH 4.5 – 10) [122]. Both pure enzymes were active on all substrates 
but had different optimum pH and relative activities. LOX-1 showed higher activity 
with LA than LOX-2 at all pHs, with a sharp optimum at pH 8. LOX-2 had optimum 
activity with LA at pH 7. LOX-2 catalysed the oxidation of LA ME and TL 
(prepared in acetone:ethanol (40:60)) more effective than LOX-1 at all pHs tested. 
LOX-1 showed a broad optimum pH between 8 and 10 for both LA ME and TL. 
LOX-2 activity on LA ME was optimum at pH 8, whereas a broad optimum pH (7 – 
9) was observed for the LOX-2 catalysed TL reaction [122]. Koch, Stern and Ferrari 
found that 20°C was the optimum temperature for both purified LOX isozymes. In 
the absence of surfactant, LOX-1 was active with LA at pH ~ 8, whereas LOX-2 had 
two pH optima for the reaction with TL (prepared in acetone:ethanol (40:60)), at pH 
~ 5.5 and 8 with the activity at pH ~ 5.5 greater than that at pH ~ 8 [131].  
Christopher et al. used LA ME as substrate to be catalysed by purified LOX-1 and 
LOX-2, at both pH 7 and 9 with low yield (~ 10 – 18%). LOX-1 formed more 13-
isomer than LOX-2 and LOX-2 produced almost the same ratio of 13- and 9-isomers 
at both pHs [120]. In a study by Roza and Francke, methyl esters of LA, ALA and 
GLA (50 mg) were emulsified in buffer (50 mL) containing 1 mg Tween 60 to be 
catalysed by purified LOX-1 and LOX-2 from soybean at pH 9 and ambient 
temperature, with oxygen saturation, and the results were compared to reactions with 
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their respective FFAs [173]. Product profiles were more complex with the methyl 
esters compared to their respective FFAs, but only methyl ester mono-
hydroperoxides were investigated in this study. Similar product profiles between 
methyl esters and FFAs was observed for both LOX-1 and LOX-2. Only the 13-
hydroperoxy methyl ester isomer was observed for LOX-1 catalysed reactions with 
LA ME and ALA ME, whereas more isomeric mono-hydroperoxides were produced 
from GLA ME. For LOX-2, a mixture of isomers was detected for all substrates. 
However at pH 7, a range of isomers was found for all substrates in both LOX-1 and 
LOX-2 reactions [173].  
In a study by Bild and colleagues, the activities of the three purified soybean LOX 
isozymes were compared at pH 9 for LOX-1 and pH 6.8 for LOX-2 and LOX-3 for 
the catalysis of nonpolar substrates. LOX-2 showed much higher activity with LA 
ME, linolenyl acetate and linoleyl methane sulfonate compared to the other 
isozymes, but the activity was still much lower than LOX-1 activity on LA [174]. In 
a few studies, only LOX-2 or certain LOXs have been shown to catalyse EFAs, 
whereas no activity was observed for the other LOXs. Maccarrone and co-workers 
found that purified LOX-2 from soybean seedlings can catalyse the dioxygenation of 
biomembranes (neutral lipids and phospholipids), LA and ALA, and their methyl 
esters as suspensions in buffer when tested for 30 min at room temperature in the 
presence of oxygen and without surfactant [175]. LOX-1 was unable to oxygenate 
the esterified lipids. Different salts in buffer (10 mM Tris/HCl, 10 mM MgCl2 and 1 
M NaCl) at pH 7 were used as a medium for the LOX reactions. High regio- and 
stereo-specificity was observed in the reaction between LOX-2 and biomembranes 
compared to FFAs and their methyl esters. Membrane-embedded FFAs were not 
substrates for either LOX-1 or LOX-2 [175]. Muller et al. reported that two out of the 
five LOX isoenzymes present in soybean leaves were able to oxygenate all three LA 
60 
 
moieties in TL at pH 7.4 and the reaction products were found to be mainly 13S 
derivatives of LA. TL (10 mM) was prepared in ethanol and then sonicated to form 
micelles as the substrate. LOX isoenzymes from soybean leaves and soybean seeds 
are different [176].  
6.2. Other sources of lipoxygenases 
6.2.1. Barley  
Compared to soybean LOX, barley LOX isoenzymes are known to have the opposite 
product specificity with LA as substrate; barley LOX-1 (9-LOX) produces mainly 9-
hydroperoxides, whereas barley LOX-2 (13-LOX) primarily produces 13-
hydroperoxides and has a higher affinity for EFAs than LOX-1 [32]. Yabuuchi 
investigated the activities of partially purified LOX-1 and LOX-2 from germinating 
barley embryos on EFAs [177]. LOX-1 is present in both germinating and 
ungerminated embryos, but LOX-2 was only found in germinating embryos. At pH 
7.5, barley LOX-2 was found to have higher activity than barley LOX-1 with LA ME 
and TL (1 mM) as substrates. LOX-2 and LOX-1 activities with LA were normalised 
to be 100% and their activities with LA ME and TL were compared with LA. For LA 
ME, LOX-2 and LOX-1 had relative activity of 40% and 18%, respectively. For TL, 
LOX-2 had relative activity of 32%, whereas LOX-1 only showed trace activity 
[177]. Yang, Schwarz and Vick also found that barley LOX-2 catalysed the 
dioxygenation of LA ME and TL solubilised in aqueous solution by Tween 20 at a 
significantly higher rate than LOX-1 at pH 6.5. However, barley LOX-2 had low 
relative activities with LA ME and TL of approximately 10 – 20% when compared to 
barley LOX-2 activity on LA. Barley LOX-1 was found to have an optimum pH at ~ 
6.3, whereas two pH optima were obtained for barley LOX-2, at pH 6 and 8 with the 
studied range between pH 5 – 9 [178].  
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Holtman and co-workers also showed that purified germinating barley LOX-2 was 
able to catalyse various EFAs – TL, dilinolein, LA ME and C16/LA-PC (1.1 mM) at 
pH 6.5, with a much higher reaction rate than LOX-1 (~ 2 – 3-fold) [92]. The barley 
LOX-2 reaction rates with these substrates were compared to its rate with LA. The 
relative reaction rates for LA ME, dilinolein, TL and C16/LA-PC with barley LOX-2 
were 32, 49, 16 and 7%, respectively. Substrates (24 mM) were prepared as an 
emulsion by sonication in the presence of 15% (w/v) gum arabic in tris/HCl pH 7.5. 
Analysis of total lipid extracts from barley demonstrated that LOX-2 was responsible 
for the oxidation of EFAs in storage lipids as only 13-HLA derivatives were formed. 
It was suggested that oxidation of storage lipids may be involved in the onset of 
germination. Lipid  hydroperoxides were suggested to act as substrates for beta-
oxidation to produce acetyl-CoA, and to serve as a carbon and energy source for 
embryo growth [92].  
In a study by Garbe and colleagues, pure LA ME, TL, dilinolein, monolinolein and 
C16/LA-PC, as well as polar and nonpolar lipid extracts (2.12 mM) were 
dioxygenated with catalysis by purified LOX-1 and LOX-2 from germinating barley 
or green malt at pH 6.5 [179]. Again, barley LOX-2 activity was much higher than 
barley LOX-1. Relative LOX activities with EFA substrates were calculated after 
normalising to LOX activities with LA. For barley LOX-2, LA ME and monolinolein 
had quite high relative activity of 39.5 and 46.9% respectively, whereas only 6.5 and 
14.1% activity was observed with TL and dilinolein respectively. Substrates 
equivalent to 8 mM LA were prepared by emulsification with a sonifier in the 
presence of 1% Tween 20. Higher autoxidation products were reported for barley 
LOX-1 compared to barley LOX-2 with EFA substrates. Products from the LOX-2 
catalysed reaction with TL had higher regiospecificity (13-hydroperoxy LA : 9-
hydroperoxy LA = 94:6) compared to LOX-1 and LA reaction products (13-
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hydroperoxy LA : 9-hydroperoxy LA = 87:13). Mainly S-chirality was detected for 
13-hydroperoxy LA formed by the LOX-2 for all EFA substrates, but 9-hydroperoxy 
LA was observed to have predominantly R-chirality after LOX-2 biocatalysis due to 
autoxidation. LOX-1 had the highest regio- and stereo-specificity with C16/LA-PC 
compared to other substrates [179]. 
6.2.2. Cucumber 
Cucumber LOX (cotyledons, roots and lipid body) including recombinant cucumber 
LOX has been found in several studies to catalyse TL and 1,3-dilinolein 
dioxygenation across a broad optimum pH range between 7 and 9. TL has been 
prepared as an emulsion in gum arabic solution using the method developed by 
Holtman et al. [92]. TL (20 – 25 mM) in tris/HCl buffer pH 7.5 or 8.5 containing 5% 
w/v or 15% w/v gum arabic was sonicated at highest power for 30 seconds under N2 
[180-183]. Feussner and co-workers proved that in vitro a purified lipid body LOX 
(LOX localised at the lipid storage organelles) from cucumber seedlings, could 
oxygenate TL and 1,3-dilinolein at pH 8.5 to form mono-, di- and tri-hydroperoxide 
derivatives by analysing the reaction products with HPLC and GC-MS after 
reduction and hydrolysis [183]. This suggested that oxygenated storage lipids 
detected in cucumber seedlings at different stages of germination in vivo were 
products of lipid body LOX catalysis. The structure of oxygenated storage lipids 
after extraction from cucumber seedlings was elucidated by HPLC, GC-MS and 1H-
NMR and the ratios of LA to LA hydroxides and LA hydroperoxides to LA 
hydroxides were included to confirm the action of lipid body LOX in vivo [183]. In 
another study by Feussner and co-workers, they showed that soybean LOX-1 formed 
28% oxidation products from TL compared to the amount of oxidation products 
formed from recombinant lipid body LOX and TL at pH 9 (optimum pH for soybean 
LOX-1) [180]. Soybean LOX-1 only produced mono-hydroperoxide derivatives of 
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TL at the sn-1 or sn-3 position. Recombinant lipid body cucumber LOX oxidised TL 
at all three positions, and almost equal amounts of mono- and tri-hydroperoxy TLs 
were observed at pH 9. Di-hydroperoxy TL (~ 20% of total products in molar ratio) 
was also detected at this pH. At the optimum pH of 7.2, the main product was a TL 
trihydroperoxide derivative [180].  
A low optimum pH of 5 – 6 has been found in two studies for the reactions of 
recombinant cucumber root LOX-1 and cucumber cotyledon LOX with FFAs, 
whereas pH 7 – 9 was the optimum pH for TL oxygenation. FFAs (50 mM) 
sonicated in the presence of 2 mg/mL Tween 20 were used, whilst TL was prepared 
as an emulsion in either gum arabic or Tween 20 [181, 182]. Matsui and Kajiwara 
found that cucumber cotyledon LOX was able to catalyse TL as an insoluble 
substrate at the lipid/water interface of emulsion droplets but not as a soluble 
substrate in an aqueous reaction medium [182]. The enzyme was pre-incubated with 
a triolein emulsion and afterwards was unable to catalyse TL. LOX activity 
decreased with increasing triolein emulsion concentration which may have been due 
to irreversible adsorption of the enzyme. No difference in LOX activity with TL 
emulsified with either gum arabic or Tween 20 was observed [182]. Matsui and 
colleagues also showed that recombinant cucumber root LOX-1 had maximum 
activity with TL over a broad pH range from pH 7 to pH 9, whereas the enzyme had 
highest activity with ALA at pH between 4.5 and 6. TL was prepared as an emulsion 
by sonication in the presence of gum arabic (50 mg/mL), and ALA was dispersed 
with Tween 20 (2 mg/mL) [181].  
6.2.3. Other plants 
Other plant LOXs have been shown to catalyse the dioxygenation of LA, LA ME and 
TL at different optimal pHs: pH 6 (broad beans), 9 – 10 (pea seeds, LOX-1) and 7.5 
(canola seeds). Reynolds and Klein found that purified LOX-1 activity in pea seeds 
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with LA ME and TL as substrates was approximately 30% compared to its reaction 
with LA [184]. LOX-1 activity was much lower than type-2 LOX activity at the 
optimum pH of 6 – 7. LA was prepared either in ethanol or as a salt with Tween 20 
and KOH, whereas LA ME and TL were in acetone:ethanol (40:60) [184]. Khalyfa, 
Kermasha and Alli showed that partially purified canola seed LOX extract was able 
to catalyse the dioxygenation of various EFAs with lower activity than LA in the 
following order LA>monolinolein>dilinolein>TL [185]. Substrates were prepared in 
buffer at pH 7.3 in the presence of Tween 20 and Na2CO3. Cyanide ions stimulated 
the enzyme activity with optimum concentration at 40 mM. The enzyme extract 
showed higher affinity to the canola lipid extract than LA and its esters. The 
optimum pH was at pH 7.5 which was close to the optimum pH of soybean LOX-2 
(pH 6 – 7) but lower than LOX-1 optimum pH (pH 9 – 9.5) [185].  
In another study, Abbas and co-workers used crude extracts and more purified LOX 
preparations from broad beans as a LOX source to test activity with different 
substrates in the presence and absence of calcium ions (Ca2+) [186]. Substrates were 
prepared in aqueous solution and solubilised by Tween 20. The active LOX 
preparations, A, B and C, were obtained from crude extracts after further purification 
with ammonium sulphate fractionation, one step and two steps of chromatography, 
respectively. The active enzyme in the crude extracts and preparation C was 
activated by Ca2+ over a broad range of concentrations from 0.2 to 1.6 mM. At pH 7 
the enzyme was found to be most affected by Ca2+. Preparation C was found to 
oxidise both FFAs (LA) and EFAs (LA ME and TL) at an optimum pH of 6. 





As shown in this literature review, SBF can be used directly or prepared as a crude 
extract at either acidic or neutral pHs as a LOX source for the synthesis of 
hydroperoxides from hydrolysed vegetable oils (mainly C18 LC-PUFAs) to further 
produce volatile compounds. Overall, the best reaction conditions for maximum 
yield were found to be 5°C, air saturation, pH 10 and in the presence of cysteine at a 
ratio of 1.5 – 2 compared to the substrate concentration. The method could be 
applied to green note compound synthesis on an industrial scale for the food 
industry. Some work with purified and commercial LOXs on C20-22 LC-PUFAs has 
been reported but not directly with SBF. The commercial 15-sLOX-1 can be used to 
produce pure mono-hydroxy PUFAs (at pH 12 with a low enzyme concentration) and 
di-hydroxy PUFAs (at pH 9 using a high enzyme concentration) with high regio- and 
stereo-specificity. 
In soybean seeds, EFAs are not preferred substrates for LOX-1, and LOX-1 is only 
able to catalyse EFAs under specific conditions at a much lower rate compared to 
reactions with LA. The presence of a bile salt (deoxycholate, 5 – 10 mM) as an 
emulsifier and a multicomponent buffer are essential to initiate the reaction at the 
optimum pH 9 of LOX-1. For both soybean and barley, LOX-2 is more effective 
than LOX-1 in catalysing EFAs at a large range of optimum pHs from acidic to 
neutral. In plant LOX-catalysed reactions, EFA substrates are commonly prepared as 
emulsions using a homogeniser or sonicator in the presence of an emulsifier. In 
comparison with LOX-catalysed FFA reaction, the dioxygenation reactions on EFAs 
catalysed by LOX were published in a limited number of studies and not thoroughly 
investigated with full product characterisation and optimum product formation. The 
physical state of substrates has an important role in LOX catalysed reactions in 
aqueous solution. For optimum enzyme activity, FFA substrates should be in 
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nonmicellar form, whereas EFA substrates are favoured in micellar forms in the 
presence of an emulsifier. 
As C18 LC-PUFAs have already been demonstrated to be suitable substrates for SBF 
for the synthesis of hydroperoxides, it is likely that SBF can also be used without 
purification to catalyse dioxygenation of a wider range of substrates, including C20-
22 LC-PUFAs and esterified LC-PUFAs. Furthermore, SBF may be more versatile 
than the commercially available 15-sLOX-1 in both product formation efficiency and 
ability to catalyse a range of substrates. The different LOX isozymes in SBF may be 
able to catalyse free and esterified FAs selectively under specific reaction conditions 
(pH, temperature, additives). In this thesis, sfLOX-catalysed reactions with DHA, TL 
and tuna oil will be investigated, with product characterisation and comparison with 
the commercial LOX enzyme. These results will be presented in Chapters 3 to 5. In 
Chapter 6, the bioactivity of the synthesised resolvin and protectin analogues from 
the sfLOX-catalysed C20-22 LC-PUFA reactions will be tested in two different cell 
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ENZYMATIC SYNTHESIS OF RESOLVIN 
ANALOGUES FROM DHA USING SOYBEAN FLOUR 
LIPOXYGENASE 
1. Introduction 
Uncontrolled inflammation is an underlying factor contributing to a range of diseases 
such as cardiovascular disease, diabetes and cancer. Endogenously synthesised 
specialised pro-resolving mediators (SPMs) actively switch acute inflammation into 
resolution of inflammation, which was previously believed to be a passive process 
[17, 83]. SPMs act as immunoresolvents, whereas the current anti-inflammatory 
drugs are immunosuppressants causing undesirable side effects [68, 187]. Therefore, 
SPMs have emerged as a potential class of anti-inflammatory drugs following the 
natural pathway of resolution of inflammation. The new approach is promising as it 
may not show any side effects and could be the most effective solution to resolve 
inflammation. In fact, a range of SPMs such as lipoxin A4, resolvin E1, protectin D1 
and some analogues have been tested in clinical trials and have shown positive 
results in various inflammatory-mediated diseases [10, 79, 83, 188]. SPM active, a 
product containing SPM analogues (17-HDHA and 18-HEPE), is being sold by 
Metagenics® as a supplement to support a healthy immune system [76].  
The most common method to synthesise SPMs is total chemical synthesis. The 
procedures are normally lengthy and complex involving toxic chemicals to obtain 
specific double bond configuration, and stereo- and regio-specificity of the bioactive 
compounds [35-38]. In contrast, enzymatic synthesis is much simpler and operates 
under mild conditions to obtain products with high stereo- and regio-specificity. 
However, it is expensive to use purified enzymes for the efficient development of 
large scale SPM synthesis. Soybean flour (SBF) is a cheap lipoxygenase (LOX) 
source and has been used in a small number of studies to synthesise precursor 
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hydroperoxides on a gram scale for volatile compound synthesis [111, 157, 158, 164, 
165]. However, no work has been done on SPM synthesis using SBF as a LOX 
source.  
In this work, for the first time, SBF LOX (sfLOX) has been used to synthesise SPMs 
from a range of biologically important omega-3 and omega-6 long chain 
polyunsaturated fatty acids (n-3 and n-6 LC-PUFAs). DHA was used as a model 
substrate as it is the key precursor of various SPM families including resolvin D 
series, protectins and maresins. DHA is also found predominantly in brain and has 
important functions in brain health [189]. In addition, DHA (along with EPA) is 
present in significant amounts compared to other PUFAs in fish oils [31]. This work 
represents the first time SBF has been used to oxidise PUFAs with 20 and 22 
carbons, and to produce di-hydroxy products from DHA.  
The sfLOX-catalysed reaction of DHA was optimised to produce the maximum 
amount of di-hydroxylated DHA compounds. The reaction products were 
characterised with a variety of analytical techniques, including NP-HPLC, RP-HPLC 
and GC-MS. The reaction products were confirmed to be mainly 7,17-diHDHA 
(resolvin D5) and 10,17-diHDHA (protectin DX), and their chirality was identified to 
be specifically S,S (> 99.5%). The reaction yield was approximately 75%. Product 
formation per milligram substrate was comparable to that obtained with 15-sLOX-1 
(a commercially available soybean LOX-1) in synthesising resolvin D5 and protectin 
DX from DHA. The optimised reaction conditions of DHA were applied to other 
biologically relevant LC-PUFAs (EPA, AA, DPAn-3 and DPAn-6). sfLOX and 15-
sLOX-1 showed the same efficiency in synthesising the anti-inflammatory lipid 
mediator analogues from LC-PUFAs. These methods may be suitable for the large 
scale production of these bioactive molecules for pharmaceutical, nutraceutical and 
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functional food applications using SBF as an alternative cost-effective LOX source 
to commercial LOX.   
2. Materials and methods 
2.1. Materials 
Soy flour (Kialla Pure Foods, certified organic) was purchased from Organic 
Wholefoods (Brunswick East, Vic, Australia). Soybean 15-lipoxygenase (15-sLOX-
1, EC 1.13.11.33, P1, 9.42 Munits/mL, 15.2 mg of protein/mL, 0.62 Munits/mg of 
protein, Cayman Chemical), 7S,17S-dihydroxy DHA (Cayman Chemical), 10S,17S-
dihydroxy DHA (Cayman Chemical) and prostaglandin B2 (PGB2; Cayman 
Chemical) were purchased from Sapphire Bioscience (Redfern, NSW, Australia). 
The fatty acids DHA, EPA, ARA, DPAn-3 and DPAn-6 (Nu-Chek Prep) were 
obtained from Adelab Scientific (Thebarton, SA, Australia). 2,2-Dimethoxypropane 
(Fluka), Dess-Martin periodinane (DMP), ferric chloride, glycine, L-cysteine, 
methylene blue, N,O-bis(trimethylsilyl)trifluoroacetamide (with 1% 
trimethylchlorosilane), platinum(IV) oxide, potassium phosphate monobasic, 
potassium phosphate dibasic, pyridine (>99%), sodium borohydride, sodium dodecyl 
sulphate (SDS), Trizma® base, Tween® 20, trifluoroacetic acid, 
(trimethylsilyl)diazomethane (2 M in diethyl ether), tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP), β-carotene, SupelcleanTM LC-Si solid phase extraction (SPE) 
tubes (6 mL, 1 g, Supelco Analytical) and SPE vacuum apparatus (Supelco 
Analytical) were purchased from Sigma Aldrich (Castle Hill, NSW, Australia). 
Agilent Bond Elut 500 mg, 3 mL SPE tubes and Vac Elut SPE vacuum apparatus 
were from Agilent Technologies (Mulgrave, VIC, Australia). Heptane (99 %, 0.2 
micron filtered) and isopropanol were obtained from Fisher Scientific (Scoresby, 
VIC, Australia). Hydrochloric acid (32%) and sodium tetraborate were purchased 
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from APS Chemicals Ltd (Seven Hills, NSW, Australia). Ethanol, diethyl ether, 
dichloromethane, methanol and urea were purchased from Chem-Supply (Gilman, 
SA, Australia). Acetonitrile (Scharlau, Spain), acetic acid (BDH Lab Supplies, UK) 
and sodium hydroxide (Fisher Chemicals, UK) were purchased from Science Supply 
(Mitcham, VIC, Australia). Triton X-100TM was obtained from Ajax Chemicals 
(Sydney, NSW, Australia). 4× Laemmli sample buffer, broad range SDS-PAGE 
standard, precision plus protein dual colour standard, dithiothreitol, and 7.5 and 12% 
SDS-PAGE gels (Mini-PROTEAN TGX Precast Protein gels) were purchased from 
Bio-Rad (Gladesville, NSW, Australia). Hydrogen, nitrogen and oxygen gases were 
obtained from Coregas Pty Ltd (Yennora, NSW, Australia). MilliQ water was 
obtained in lab by Milli-Q® Advantage A10 Ultrapure water purification system from 
Merck Millipore. 
2.2. Lipoxygenase-catalysed reaction optimisation for maximum product 
formation 
DHA (as a model free fatty acid substrate) was prepared at 0.1 mM (from 10 mM 
stock solution in ethanol) in 10 mL buffer (50 mM) with a range of pHs and buffer 
types (Table 3.1) [43]. 25 µL SBF extract was added to initiate the reaction [56]. The 
SBF extract was prepared by suspending 1 g SBF in 20 mL water [56], followed by 
shaking for 1 min and allowing to settle for at least 3 min. Aliquots of the crude SBF 
extract were used for the reactions without re-suspending the settled SBF. The 
extract should be used from 20 min up to 2 hours after preparation for the optimum 
LOX activity and stability. After addition of the SBF extract, the reaction mixture 
was stirred, and the reaction conducted at room temperature (23ºC) for 15 min and 
without oxygenation as the initial conditions. The reaction temperature was 
controlled by performing the reaction on ice, or in a water bath as required. Nitrogen, 
air or oxygen was used to sparge the buffer for 5 min, until saturation to alter the 
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dissolved oxygen concentration before adding substrate. The oxygen concentration 
of the buffer solution was measured by dissolved oxygen meter (Mettler Toledo). 
Surfactant and other additives were added as required prior to the addition of the 
SBF extract. 
Table 3.1: Three types of buffer used and the pH ranges studied. 
Buffer type pH 
Phosphate 5 – 8 
Tris-HCl 7 – 9 
Borate 8 – 11 
 
The reaction was stopped by the addition of sodium borohydride (1 M solution in 
water, 200 µL for a 10 mL reaction) which reduced the hydroperoxides to hydroxy 
groups. This was stirred for at least 15 min. The mixture was then acidified with 
glacial acetic acid (50 µL for a 10 mL reaction), and further stirred for approximately 
30 min. Prostaglandin B2 (PGB2) was used as an internal standard and was added 
(20 µL of 1 mg/mL solution in ethanol) into the reaction mixture prior to extraction 
as required.  
The products were extracted by solid phase extraction (SPE) under vacuum. C18 
SPE cartridges were conditioned with 1 column volume (3 mL) of methanol and 1 
column volume of water. The sample was then loaded onto the column before 
washing with 1 column volume of water. The column was then dried under vacuum 
for 5 – 15 min and the product eluted with 1 column volume of ethanol. The total 
solvent was evaporated under a stream of nitrogen or under vacuum [43, 56].  
For reactions using higher volumes of SBF extract (≥ 300 µL), solvent extraction 
was used to extract the products, as an alternative to SPE as the SBF in the reaction 
73 
 
mixture blocked the SPE columns. The reaction mixture was adjusted to pH 3 with 
hydrochloric acid (4 M) and was extracted with diethyl ether (2 × 10 mL for a 10 mL 
reaction). The combined solvent after extraction was evaporated under vacuum.  
The reaction was optimised to determine the conditions for the synthesis of the 
maximum amount of di-hydroxy products. Three variables, pH, buffer type and SBF 
extract volume (25, 100, 200, 300 and 400 µL), were examined at the same time. The 
best conditions were chosen as initial conditions for further optimisation, with the 
remaining variables tested one at a time (Table 3.2). The conditions with the best 
results were kept for further optimisation experiments and for the final optimised 
conditions.  
The optimised sfLOX-catalysed DHA reaction was compared to the optimised 15-
sLOX-1 and DHA reaction as described by Dobson et al. [43]. No detection of di-
hydroxy DHA from autoxidation was observed in blank controls performed under the 
same reaction conditions without SBF or DHA. 
Table 3.2: Reaction variables optimised in the sfLOX-catalysed reaction with DHA. 
Variable Range studied 
DHA concentration (mM) 0 – 1 
Surfactant concentration (% w/v) 0 – 0.1 
Reaction time (min) 1 – 180 
Oxygenation Oxygen, Nitrogen, Air, None 
Temperature (°C) 0 – 40 
Cysteine concentration (mM) 0 – 10 
Ferric chloride concentration (mM) 0 – 0.2 
 
For optimisation of individual reaction variables, experiments were repeated between 
1 and 3 times to ensure a clear trend and optimum was observed. Values from a 
74 
 
single representative experiment are shown in the results section for each variable. 
Results at different reaction conditions for each variable were considered to be 
different when the results varied by greater than ± 5%. The final optimised reaction 
conditions were repeated five times a day for three consecutive days. Average results 
were presented with error bars indicating (±) one standard deviation.  
2.3. Monitoring reaction product formation by NP-HPLC  
sfLOX-catalysed DHA reaction products were separated by NP-HPLC [43] using an 
Agilent Technologies 1200 series instrument, including a solvent degasser, 
quaternary pump, autosampler and diode array detector (DAD). An LC-diol column 
(Supelco Analytical, 25 cm × 3 mm, 5 µm particle size) was used. The composition 
of mobile phase was 95% v/v solvent A (heptane with 0.1% v/v acetic acid, 0.1% v/v 
2,2-dimethoxypropane) and 5% v/v solvent B (isopropanol). Samples were separated 
under isocratic conditions within 35 min at 10°C with a flow rate of 0.5 mL/min. 
Elution of mono- and di-hydroxy products was monitored at 210 nm (substrate), 
234 nm, 250 nm, 270 nm and 280 nm (PGB2). Samples were prepared in 1 mL 
mobile phase and the injection volume was 15 µL. Reproducibility was confirmed by 
repeat injections. Data was processed using Agilent Technologies ChemStation for 
LC 3D system B.04.01 software. 
2.4. Determination of hydroxy group positions on reaction products by 
GC-MS 
Positions of hydroxy groups on the sfLOX-catalysed DHA reaction products were 
determined by GC-MS [43] after hydrogenation and conversion to trimethylsilylated 
derivatives (see below). An Agilent Technologies 6890N Network GC system with a 
5975 mass selective detector (electron impact) and a BPX5 column (30.0 m × 0.25 
mm, 0.25 µm film thickness; SGE, Ringwood, VIC, Australia) was used. Injection 
volume was 2 µL, helium carrier gas, flow rate 1.2 mL/min (average velocity of 
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42 cm/second) with an inlet temperature of 250°C and a split ratio of 20:1. Initial 
oven temperature was 150°C held for 2 min, increased to 300°C at a rate of 5°C/min 
over 30 min and held for 13 min. Total ion chromatograms were collected and data 
processed with Agilent Technologies MSD ChemStation D.02.00.275 software. 
Hydrogenation 
The optimised sfLOX-catalysed DHA reaction products after solvent extraction and 
evaporation were re-dissolved in 2 mL ethanol. PtO2 catalyst (10 mg) was added and 
the reaction was stirred under a stream of H2 for 25 min. The mixture was filtered 
through a 0.45 µm filter and solvent evaporated under nitrogen. 
Silylation 
After hydrogenation, products were heated at 100°C for 1 hour in the presence of 
200 µL of pyridine and 200 µL of N,O-bis(trimethylsilyl)trifluoroacetamide 
(BSTFA). The samples were analysed by GC-MS. 
2.5. Determination of stereochemistry of reaction products by chiral RP-
HPLC 
sfLOX-catalysed DHA reaction products after methylation (see below) were stereo-
specifically separated by chiral RP-HPLC. An Agilent Technologies 1260 Infinity 
series instrument, including a solvent degasser, quaternary pump, autosampler and 
diode array detector (DAD) was used. A Lux 5u Amylose-2 column (Phenomenex, 
100 × 4.6 mm, 5 µm particle size) was used. The mobile phase contained solvent A 
(acetonitrile) and solvent B (0.1% v/v trifluoroacetic acid). Different gradient 
conditions were used to separate the four 7,17-diHDHA methyl ester stereoisomers 
(40% to 47.5% solvent A over 45 min at 1 mL/min, 40ºC), and the four 10,17-
diHDHA methyl ester stereoisomers (35% to 50% solvent A over 30 min at 
0.5 mL/min, 10ºC). Elution of the stereoisomers was monitored 
spectrophotometrically at 210 nm, 234 nm, 250 nm and 270 nm. Samples were 
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prepared in acetonitrile and injection volumes of 1 to 10 µL were used. 
Reproducibility was confirmed by repeat injections. Data was processed using 
Agilent Technologies ChemStation for LC 3D system software (B.04.03). 
Methylation 
After extraction of reaction products by solvent extraction and evaporation of the 
solvent, 200 µL methanol and 200 µL (trimethylsilyl)diazomethane were added and 
the reaction mixture was kept at room temperature for one hour in a sealed vial. The 
solvent was evaporated, and products dissolved in 1 – 3 mL heptane for extraction by 
SPE. An LC-Si cartridge was conditioned with 3 column volumes of heptane (3 × 
6 mL) before the sample mixture was loaded. The SPE cartridge was washed with 1 
column volume of heptane and dried under vacuum for 5 – 15 min. The methylated 
products were eluted with 1 column volume of isopropanol. After evaporation of the 
solvent under nitrogen gas or vacuum, the sample was diluted in 1 mL acetonitrile 
and analysed by chiral RP-HPLC. The standards of 7S,17S-dihydroxy DHA and 
10S,17S-dihydroxy DHA and synthesised racemic product mixture (see below) were 
methylated using the same procedure prior to chiral RP-HPLC. 
Synthesis of racemic dihydroxy DHA mixture 
To develop the chiral RP-HPLC separations, a racemic mixture of 7,17-dihydroxy 
DHA and 10,17-dihydroxy DHA isomers containing the four stereoisomers (SS, RR, 
SR and RS) of each compound was synthesised. The racemic mixture was generated 
from the enzymatic reaction product mixture, by oxidising the hydroxy groups to 
ketones then reducing them back to hydroxy groups. Briefly, the extracted enzymatic 
sfLOX-DHA reaction products (~ 0.7 mg of 7,17-diHDHA and 10,17-diHDHA) 
were dissolved in 1 mL of dry dichloromethane in a round bottom flask and ~ 10 mg 
of Dess-Martin periodinane (DMP) was added. Before use, the DMP was purified by 
dissolving in dichloromethane and filtering to remove insoluble 2-iodoxybenzoic 
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acid (IBX). The reaction mixture was sealed and stirred for 20 min at room 
temperature, to form a cloudy solution. Completion of the reaction was monitored by 
TLC, using a solvent system of n-heptane/diethyl ether/acetic acid (40:60:1). 
Complete conversion of starting material (Rf 0.1) to oxidized ketone products (Rf 
0.2) was observed. The solvent was evaporated under nitrogen and the products were 
dissolved in ethyl acetate (4 mL). The reaction products were washed with two 
volumes of sodium thiosulfate (100 g/L), stirring for 10 min each, followed by two 
volumes of water and dried over anhydrous sodium sulfate. The isolated oxidized 
product was yellow. The solvent was filtered and evaporated under nitrogen.  
The oxidised products were then dissolved in 1 mL methanol and 10 mL water was 
added. Sodium borohydride in water (1 M, 200 µL) was added and the mixture 
stirred for 5 – 15 min to reduce the oxidized products. The yellow colour disappeared 
within 5 min. The reaction was stopped by adding 100 µL glacial acetic acid. The 
reduced products were extracted with 2 × 20 mL diethyl ether and the solvent was 
evaporated under vacuum. Completion of the reaction was confirmed by TLC using 
the same solvent system as above. 
2.6. Assessment of enzyme kinetic parameters 
The optimised reactions (3 mL scale) were performed in a quartz cuvette (4 mL, 
10 mm path length) containing 2.5 mL buffer (50 mM, pH 8) saturated with oxygen, 
50 µL DHA (10 mM) and 25 µL Triton X-100 (1% w/v) at room temperature. 
200 µL of SBF extract (1 g in 20 mL water) was added to initiate the reaction. The 
enzyme kinetics were characterised by measuring the reaction rate (Abs/min) on a 
Cary 300 UV-Vis spectrophotometer (Agilent Technologies) with increasing DHA 
concentrations in the range (50 µM – 0.4 mM). The conjugated triene was monitored 
at 270 nm for 1 min with data averaging time of 0.1 second. A sample without SBF 
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extract was used as a reference. The activity was measured immediately after adding 
SBF. All measurements were conducted until three reproducible results were 
obtained. The Michaelis-Menten kinetic model, r = Vmax[S]/(Km+[S]) was used to 
calculate kinetic parameters [67]. 
2.7. Colorimetric test for LOX isozyme detection 
Three visual screening tests developed previously by Suda et al. [190] were used to 
detect the individual LOX isozymes in the SBF and commercial enzyme 
preparations. The tests are based on the bleaching activities of the isozymes on 
methylene blue and β-carotene by co-oxidation with sodium linoleate. For each test 
0.5 mL commercial enzyme solution or SBF suspension and 2 mL of dye-substrate 
solution were used. The dye-substrate compositions of the three tests are listed 
below: 
- Test I for LOX-1 detection: sodium linoleate substrate (1.25 mM) and 
methylene blue (12.5 µM) in sodium borate buffer (50 mM) pH 9. 
- Test II for LOX-2 detection: sodium linoleate substrate (1.25 mM), 
dithiothreitol (25 mM), methylene blue (12.5 µM) and 12.5% v/v acetone in 
sodium phosphate buffer (200 mM) pH 6. 
- Test III for LOX-3 detection: sodium linoleate substrate (1.25 mM) and 
12.5% w/v β-carotene in sodium phosphate buffer (200 mM) pH 6.6. 
50% w/v β-carotene in acetone was used as the stock solution. 
SBF suspension was prepared as 0.1 g (test I and III) or 0.2 g (test II) in 20 mL 
water. The commercial 15-sLOX-1 enzyme was diluted in water; 140 µg (test I and 
III) or 280 µg (test II) in 0.5 mL. The SBF suspension was settled for 3 – 10 min 
before adding the dye-substrate solution. The colour change was checked after 3 min 
for test I and III, 5 min for test II. One control and three samples were conducted for 
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every test. 0.5 mL water was used instead of enzyme solution or SBF suspension for 
the controls. 
2.8. Protein separation of soybean flour and commercial lipoxygenase 
preparations by SDS-PAGE 
Denaturing, reducing, discontinuous 1D SDS-PAGE was conducted according to 
Laemmli [191], with modifications. All SDS-PAGE analyses were performed using 
7.5 and 12% acrylamide MiniPROTEAN® TGX precast gels (Bio-Rad) in a Mini-
PROTEAN Tetra Vertical Electrophoresis cell (Bio-Rad) using a Tris-Glycine buffer 
system. SBF extract samples were prepared by adding 5 mg SBF to 250 µL sample 
loading buffer (475 µL 4× Laemmli sample buffer (Bio-Rad), 0.2 M dithiothreitol 
(DTT), 5 M urea) and incubated for 30 min. Urea was added to the loading buffer 
based on works carried out by Kitamura et al [192, 193]. The suspension was 
centrifuged at 13,300 rpm (Heraeus 17 Pico centrifuge, Thermo Scientific) for 3 min 
to remove insoluble material and the supernatant retained for further dilution. The 
commercial LOX preparations (unpurified and purified 15-sLOX-1) were diluted 
with sample loading buffer 10 and 5 times, respectively. Before loading samples on 
the gel, further dilutions from 1 in 2 to 1 in 8 as required were used to obtain 
adequate band intensity on the gel. Samples were incubated in a water bath at 80°C, 
50°C or room temperature for 10 min. Aliquots (20 µL) of the samples were loaded 
onto the gel. A molecular weight standard was also loaded onto each gel as a mass 
reference, with either a Broad-Range SDS-PAGE standard (Bio-Rad, prepared by 
adding 2 µL of standard to 18 µL of sample loading buffer, 5 µL loaded) or Precision 
Plus Protein Dual Colour Standard (Bio-Rad, 3 µL loaded directly onto the gel) used. 
The 7.5% and 12% SDS-PAGE gels were electrophoresed for 30 min at 100 V, 
followed by 2 hr (7.5% gel) or 5 – 6 hr (12% gel) at 160 V at 4°C. After 
electrophoresis, each gel was stained with Bio-Safe Coomassie G-250 Stain with 
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agitation for 1 hr, followed by destaining in water with agitation overnight. Gels 
were imaged using a Molecular Imager® Gel DocTM XR+ Imaging System (Bio-
Rad).  
3. Results 
3.1. Optimisation of reaction conditions for maximum product formation 
Luquet et al. used SBF suspended in water as a crude LOX source without any 
complex preparation in the reaction with free fatty acids to produce oxygenated 
products. The reactions were performed with 0.3 mM LA, 50 µL suspended SBF 
solution (1 g per 20 mL water) in 20 mL borate buffer (pH 9.22) with 0.032 % 
Tween 20 [56]. DHA (Figure 3.1A) is the precursor of important biological 
compounds including RvD5 and PDX, which are anti-inflammatory and pro-
resolving lipid mediators [19, 70]. These bioactive compounds have previously been 
synthesised successfully from DHA and commercial 15-sLOX-1 [43, 53, 54]. 
Dobson et al. used the following optimised conditions: 0.1 mM DHA, ~ 1.5 MUnits 
15-sLOX-1, 10 mL borate buffer pH 9, without any surfactant in 15 min [43]. In this 
study, the three main products of DHA were synthesised and characterised. They 
were a mono-hydro(pero)xy product, 17S-hydro(pero)xydocosahexa-
4Z,7Z,10Z,13Z,15E,19Z-enoic acid (17S-H(P)DHA; Figure 3.1B) with one 
conjugated diene; and two di-hydroxy products, 7S,17S-hydro(pero)xydocosahexa-
4Z,8E,10Z,13Z,15E,19Z-enoic acid (7S,17S-diH(P)DHA; Figure 3.1C) known as 
RvD5 with two conjugated dienes, and 10S,17S-hydro(pero)xydocosahexa-
4Z,7Z,11E,13Z,15E,19Z-enoic acid (10S,17S-diH(P)DHA; Figure 3.1D) also known 
as PDX which has a conjugated triene. One oxygen molecule per substrate molecule 
is required to form mono-hydroxy products, whereas two molecules of oxygen are 




Figure 3.1: Chemical structures of hydroxylated products of DHA from the reaction with commercial 
15-sLOX-1. A) DHA, B) 17S-H(P)DHA, C) 7S,17S-diH(P)DHA with the two conjugated dienes 
highlighted in box, D) 10S,17S-diH(P)DHA with the conjugated triene highlighted in box. 
Based on these two references [43, 56], the initial reaction conditions chosen were: 
0.1 mM DHA (as a model substrate for sfLOX and LC-PUFA reaction), 25 µL SBF 
extract (1 g SBF in 20 mL water), 10 mL buffer, ambient temperature, no surfactant, 
15 min reaction time. The optimisation process aimed to identify the ideal conditions 
to produce the maximum amount of di-hydroxy DHA products. The formation of di-
hydroxy and mono-hydroxy DHA products from the sfLOX-DHA reaction at 
different conditions was monitored by NP-HPLC with DAD. These compounds were 
separated and identified by their distinctive absorption spectra. The first di-hydroxy 
DHA product had two absorption maxima at 226 and 246 nm in the spectrum, 
consistent with the presence of two conjugated dienes (Figure 3.2 - orange trace). 







two shoulders at 260 nm and 280 nm in the spectrum, consistent with a conjugated 
triene structure (Figure 3.2 - green trace). Mono-hydroxy DHA products had 
maximum absorbance at 234 nm, consistent with a single conjugated diene (Figure 
3.2 - blue trace). By comparison with the retention times and absorbance spectra of 
the products from the commercial 15-sLOX-1 catalysed reaction of DHA under the 
same NP-HPLC conditions [43], the two di-hydroxy DHA products and a major 
mono-hydroxy product from the sfLOX-catalysed DHA reaction were tentatively 
identified as 7,17-diHDHA, 10,17-diHDHA and 17-HDHA, respectively. 
 
Figure 3.2: Absorption spectra recorded by NP-HPLC DAD for mono- (17-HDHA) and di-hydroxy 
DHA products (7,17- and 10,17-diHDHA) from the sfLOX-DHA reaction. 
3.1.1. Effect of buffer type, pH and volume of SBF extract on product formation 
It is important to optimise the pH of the sfLOX-catalysed DHA reaction, as the LOX 
reaction is known to be pH-dependent due to the different LOX isoenzymes present 
and physical state of the substrate [90, 91]. To determine the optimum pH of the 
sfLOX-catalysed DHA reaction, a large pH range (5 – 11) was studied using three 
different buffers (phosphate pH 5 – 8, Tris-HCl pH 7 – 9 and borate pH 8 – 11) and 
























paragraph. At low pH (5.0 – 6.5), formation of all products was suppressed. The 
major mono-hydroxy DHA (17-HDHA) product increased significantly with 
increasing pH and a range of other mono-hydroxy products were also formed in 
small amounts. In contrast, di-hydroxy DHA formation was maximised at pH 7.5. To 
further optimise this, the optimisation was continued by increasing the volume of 
SBF extract, to increase the amount of LOX enzyme for the potential conversion of 
the remaining mono-hydroxy DHA into di-hydroxy DHA products. This was 
examined across a narrower pH range (7 – 10). At higher volumes of SBF extract 
(≥ 100 µL), the optimum pH shifted to pH 8. The di-hydroxy products dramatically 
increased approximately 10 times for 10,17-diHDHA and 15 times for 7,17-diHDHA 
at pH 8 (phosphate buffer) when the volume of SBF extract was increased from 25 to 
300 µL; whereas product formation began to decrease at 400 µL SBF extract (Figure 
3.3). With 300 µL SBF extract, DHA was fully converted into di-hydroxy DHA 
products and a minimal amount of mono-hydroxy product remained. Mono product 
specificity was improved with increasing SBF extract volume until only two mono-




Figure 3.3: Effect of buffer pH and SBF extract volume on 10,17-diHDHA production from sfLOX-
DHA reaction (25 – 400 µL SBF extract; pH 7 – 8: 50 mM phosphate buffer; pH 8.5 – 10.0: 50 mM 
borate buffer). Reaction conditions: 0.1 mM DHA, 10 mL buffer, ambient temperature, no surfactant, 
15 min reaction time. The results are combined from multiple sets of experiments. 
SBF extract volume was re-optimised in the range of 200 to 400 µL, and 300 µL 
remained the optimum value. Phosphate buffer showed higher product formation 
compared to borate and Tris-HCl buffers at high volumes of SBF extract (≥ 100 µL). 
The optimised conditions found through the simultaneous optimisation of the three 
variables (buffer type, pH and volume of SBF extract) were phosphate buffer (pH 8) 
and 300 µL SBF extract (Figure 3.3). A small amount of DHA (≤ 5 %) remained in 
the reactions using 25 µL SBF extract, whereas no DHA was observed under any 
conditions using higher volumes of SBF extract (> 25 µL). 
Two unknown compounds eluted on NP-HPLC approximately 10 min after the two 
di-hydroxy products; unknown I had two absorption maxima at 226 nm and 246 nm, 
and unknown II had an absorption maximum at 270 nm with two shoulders at 260 
nm and 280 nm in the absorbance spectrum, which indicated that they may have two 
85 
 
conjugated dienes and a conjugated triene, respectively. They appeared randomly in 
small amounts, under different reaction conditions, including at different pH and 
buffer types when using 100 µL SBF extract or higher. The unknown compounds 
have not been identified.  
3.1.2. Effect of DHA concentration on product formation 
At low substrate concentrations, substrate can be limiting in the reaction. In contrast, 
at high substrate concentrations, the reaction can be inhibited by substrate and/or 
products [194-197], and anaerobic reaction conditions can develop [43]. Therefore, it 
is important to optimise substrate concentration. DHA concentration was optimised 
in the range (0.025 – 1 mM), using 300 µL SBF extract and 10 mL phosphate buffer 
(pH 8, 50 mM). In the DHA concentration range studied, the formation of products 
increased significantly with increasing DHA concentration before reaching a 
maximum at 0.2 mM. At this DHA concentration, 7,17-diHDHA and 10,17-diHDHA 
increased by approximately 35% and 10% respectively, compared to at 0.1 mM 
DHA, or approximately 4-fold compared to at 0.025 mM DHA (Figure 3.4). 
However, the di-hydroxy DHA products decreased substantially to a minimal amount 
at 0.5 mM DHA, and then stayed constant up to 1 mM DHA. Instead, 17-HDHA 
increased significantly and two new products (unknown III and IV) were formed in 
large amounts. Unknown III eluted earlier than DHA by 2 min with λmax = 240 nm 
and unknown IV (also detected for reactions using 0.3 mM DHA) eluted 3 min after 
17-HDHA and before the di-hydroxy DHA products with λmax = 235 nm. These 
compounds generated at high substrate concentrations may result from the 
development of anaerobic conditions. In a study by Dobson and colleagues, two 
similar compounds were also found in 15-sLOX-1 catalysed DHA reaction at DHA 
concentration > 0.1 mM, in which one compound was identified to be 17-
oxoheptadeca-4Z,7Z,10Z,13Z,15E-pentaenoic acid and the other was suggested to be 
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a DHA dimer [43]. The optimum DHA concentration was determined to be 0.2 mM. 
At the new optimised DHA concentration, only a small amount of 17-HDHA 
remained. Volume of SBF extract was re-optimised across a larger range of 200 – 
800 µL, but there was no change in the optimum SBF extract volume.  
 
Figure 3.4: Effect of DHA concentration (0.025 - 1 mM) on sfLOX-DHA reaction under the 
conditions: 300 µL SBF extract, 10 mL phosphate buffer (pH 8, 50 mM), ambient temperature, no 
surfactant, 15 min reaction time. The results are combined from two sets of experiments (0.025 – 0.2 
mM and 0.2 – 1 mM) presenting DHA concentration effect on product formation. 
3.1.3. Effect of surfactant concentration on product formation 
Non-ionic surfactants including Triton X-100 and/or Tween 20 have previously been 
demonstrated to increase the solubility of fatty acids in water, enhance LOX activity 
[116, 198, 199] and extract membrane-bound LOXs effectively from plant sources 
[200, 201]. As a result, Triton X-100 and Tween 20 were tested for their ability to 
increase the sfLOX-catalysed DHA reaction yield in making di-hydroxy DHA 
products. The concentration of both surfactants was optimised in the range 0.001 – 
0.1% w/v. Increasing Triton X-100 concentration resulted in an increase in the 
production of both di-hydroxy DHA products up to an optimum in the range 






















for 10,17-diHDHA compared to the reaction without Triton X-100. Then product 
formation of the two di-hydroxy DHA products tended to decrease at higher Triton 
X-100 concentrations (> 0.05% w/v) (Figure 3.5). The same patterns of surfactant 
effect were observed with Tween 20 but a lower overall yield of di-hydroxy DHA 
products was obtained compared to that with Triton X-100. Increasing surfactant 
concentration increased the formation of 17-HDHA. Triton X-100 was therefore the 
preferred surfactant for the reaction and the selected concentration for further 
experiments was 0.01% w/v. 
 
Figure 3.5: Effect of Triton X-100 concentration (0 – 0.1% w/v) on the sfLOX-catalysed DHA 
reaction under the conditions: 0.2 mM DHA, 300 µL SBF extract, 10 mL phosphate buffer (pH 8, 
50 mM), ambient temperature, 15 min reaction time. The results from a single representative 
experiment present Triton X-100 effect on product formation. 
3.1.4. Effect of reaction time on product formation 
To monitor product formation over time for the maximum yield, large-scale reactions 
were performed (100 mL, 10 times the normal 10 mL reaction volume) and 10 mL 
aliquots were taken at specific time points (1 min to 180 min) after the reaction was 
initiated. The di-hydroxy DHA products were rapidly formed within the first minute 























diHDHA increased by more than double, whilst 7,17-diHDHA increased by 1.5-fold, 
compared to product formation at 1 min. After 30 min, both products gradually 
decreased (Figure 3.6A), although the amount of 17-HDHA was still significant and 
available for conversion. Unknown I and II were also detected, and in contrast to the 
main di-hydroxy DHA products, reached a maximum concentration at 1 min then 
declined substantially over 20 – 30 min, and continued to decrease slowly over the 
remaining time (Figure 3.6B). The optimum reaction time was chosen to be 30 min.  
 
Figure 3.6: Product formation over time (1 – 180 min) in the sfLOX-catalysed DHA reaction; A) di-
hydroxy DHA products, and B) unknown I and II. Reaction conditions: 0.2 mM DHA, 300 µL SBF 
extract, 0.01% v/v Triton X-100, 10 mL phosphate buffer (pH 8, 50 mM), ambient temperature. The 













































3.1.5. Effect of oxygenation on product formation 
Oxygen is an essential reagent, as it is also a substrate of the LOX-catalysed PUFA 
reaction, so oxygen concentration has a strong influence on the reaction. The sfLOX-
catalysed DHA reaction using the conditions: 0.2 mM DHA, 300 µL SBF extract, 10 
mL phosphate buffer (pH 8, 50 mM), Triton X-100 (0.01% w/v), ambient 
temperature, and 30 min reaction time, was optimised with different oxygen 
concentrations in the buffer. 10 mL buffer vials were sparged with pure oxygen, air, 
nitrogen for 5 min, or left untreated to obtain different oxygen concentrations from a 
maximum of 35 mg/L with oxygen sparging to a minimum of close to 0 mg/L with 
nitrogen sparging before the reactions were initiated. During the reaction time, these 
vials were sealed by balloons containing the same gas to help maintain the oxygen 
concentration over the reaction time. Saturation of the buffer with oxygen before 
adding the SBF extract resulted in an increase in mono- and di-hydroxy DHA 
product formation of approximately 16% and 30%, respectively. Purging air into the 
buffer solution did not significantly affect the generation of both mono and di-
hydroxy DHA products, as expected. All product formation was suppressed when 
oxygen was removed from solution under nitrogen-sparged conditions (Figure 3.7). 
Instead, a major product, unknown IV (λmax = 235 nm), previously observed at high 




Figure 3.7: Effect of oxygen concentration on the sfLOX-catalysed DHA reaction. Reaction 
conditions: 0.2 mM DHA, 300 µL SBF extract, 0.01% v/v Triton X-100, 10 mL phosphate buffer (pH 
8, 50 mM), ambient temperature, 30 min reaction time. The results from a single representative 
experiment present oxygen effect on product formation. 
For the reactions performed under saturated oxygen conditions, no significant 
difference in product formation was observed between reaction vials covered with an 
oxygen-filled balloon and vials that were left open to the air (results not shown). 
Therefore, sealing the reaction with the relevant gas was not required for further 
experiments. Under oxygen-saturated conditions, 17-HDHA was present at a high 
amount and could potentially be converted into di-hydroxy DHA products. 
Therefore, the SBF extract volume was re-optimised over the range from 300 µL to 
1000 µL. Increasing the SBF extract volume resulted in a significant increase in the 
amount of di-hydroxy DHA products and a decrease in mono-hydroxy DHA 
products remaining, reaching an optimum at 800 µL SBF extract (Figure 3.8). 10,17-
diHDHA and 7,17-diHDHA increased by approximately 60% and 35%, respectively. 
The optimum conditions for the reaction after re-evaluation were oxygen saturated 

























Figure 3.8: Effect of SBF extract volume re-optimisation (300 – 1000 µL) on the sfLOX-catalysed 
DHA reaction. Reaction conditions: 0.2 mM DHA, 0.01% v/v Triton X-100, 10 mL phosphate buffer 
(pH 8, 50 mM) saturated with oxygen, ambient temperature, 30 min reaction time. The results from a 
single representative experiment present the effect on product formation. 
3.1.6. Effect of temperature on product formation 
Temperature is an important variable to be optimised in the LOX-catalysed reaction. 
High temperatures could inactivate the enzyme [117], lower the dissolved oxygen 
concentration and promote non-specific oxidation [59]; while, low temperatures 
decrease the solubility of the fatty acid substrates and so could lower the interaction 
between substrate and the enzyme. The sfLOX-catalysed DHA reaction was 
optimised in the temperature range 0 – 40°C. The 30°C and 40°C reactions were 
heated in a water bath on a heating plate, the 0°C reaction was kept on ice, and the 
10°C reaction was performed in an ice water bath with temperature monitored by a 
thermometer.  
In the range studied, 10,17-diHDHA significantly increased from 0°C, reaching a 
maximum at ambient temperature 21 – 23°C (> 2-fold increase), and then decreased 
up to 40°C (roughly 3.5-fold compared to the maximum at ambient temperature). 

























produced in the temperature range 0°C to 30°C (approximately 40% increase at 
ambient temperature compared to at 0°C), whereas there was an approximate 55% 
decrease at 40°C compared to at ambient temperature (Figure 3.9). Di-hydroxy DHA 
products were maximised at ambient temperature and suppressed at both low and 
high temperatures, and little 17-HDHA amount was formed across the temperature 
range studied. Two compounds, unknown I and II, appeared at the highest amounts 
at 0°C, compared to higher temperatures. They were formed at about 30% of 7,17-
diHDHA and 10% of 10,17-diHDHA, respectively, compared to at ambient 
temperature. At 40°C, approximately 15% of the DHA remained unreacted at the end 
of the reaction. No increase in non-enzymatic products was observed when 
increasing temperature. The optimum temperature for the reaction was found to be 
ambient temperature (21 – 23°C). 
 
Figure 3.9: Effect of temperature (0 – 40°C) on the sfLOX-catalysed DHA reaction. Reaction 
conditions: 0.2 mM DHA, 800 µL SBF extract, 0.01% v/v Triton X-100, 10 mL phosphate buffer (pH 
8, 50 mM) saturated with oxygen, 30 min reaction time. The results from a single representative 






















3.1.7. Effect of other additives on product formation 
The sfLOX-catalysed DHA reaction was optimised in the presence of ferric chloride 
(FeCl3, 0 – 0.2 mM) and L-cysteine (0 – 10 mM). These two additives have been 
previously shown to positively affect the sLOX-catalysed LA reaction to either 
improve the overall reaction rate or increase the reaction yield [95, 118], as discussed 
in detail in Chapter 2. However, in this work, the two additives did not show any 
positive effects on the sfLOX-catalysed DHA reaction for the formation of di-
hydroxy DHA products. 
TCEP, another water-soluble reducing agent, was previously shown to increase the 
17-HDHA yield significantly in gram scale synthesis using the sLOX-1 catalysed 
DHA reaction. In the presence of TCEP, the reaction was reported to proceed slower 
but was able to continue oxidation for a longer time, and a higher amount of DHA 
was consumed [202]. TCEP can reduce PUFA hydroperoxides into PUFA hydroxides 
directly in the reaction, so a separate reduction step with sodium borohydride is not 
required. TCEP was applied in the above optimised sfLOX-catalysed DHA reaction 
using 0.2 mM DHA. TCEP concentrations of 0.4, 0.6 and 0.8 mM were tested. No 
significant difference in product formation between the TCEP concentrations tested 
was detected. TCEP did not increase total di-hydroxy DHA formation, however the 
ratio of the two dihydroxy products changed, with the generation of 10,17-diHDHA 
(containing a triene) decreasing and 7,17-diHDHA (containing two conjugated 
double bonds) increasing (Figure 3.10). In the presence of 0.6 mM TCEP, the 
reaction was further optimised with regards to reaction time (1 – 75 min) and DHA 
concentration (0.1 – 0.5 mM). Product formation did not improve. DHA (0.3 mM) 
was tested with increasing SBF extract volume (800 – 2000 µL). Again, no 




Figure 3.10: The sfLOX-catalysed DHA reaction products in the presence and absence of 0.6 mM 
TCEP. Reaction conditions: 0.2 mM DHA, 800 µL SBF extract, 0.01% v/v Triton X-100, 10 mL 
phosphate buffer (pH 8, 50 mM) saturated with oxygen, ambient temperature, 30 min reaction time. 
The results from a single representative experiment present TCEP effect on product formation. 
3.1.8. Final optimised conditions for maximum product formation 
The final optimised conditions were found to be: 800 µL SBF extract, 0.2 mM DHA, 
phosphate buffer (pH 8, 50 mM), oxygen saturation, Triton X-100 (0.01% w/v), 
ambient temperature, 30 min reaction time. Di-hydroxy DHA formation at optimised 
conditions increased approximately 40-fold compared to at the initial conditions 
(0.1 mM DHA, 25 µL SBF extract, 10 mL buffer, no surfactant, no oxygen 
saturation, 15 min reaction time). The reproducibility of the sfLOX-catalysed DHA 
reaction at optimised conditions in generating di-hydroxy DHA products was 
measured by repeating five reactions per day for three days. The averaged results are 
shown in Figure 3.11. The relative standard deviation (%RSD) of the inter-day 
results (15 reactions across the three days) was less than 5% for both compounds 
(7,17-diHDHA: 3.2% and 10,17-diHDHA: 4.8%). For the intraday results (each of 






















Figure 3.11: Reproducibility of the optimised sfLOX-catalysed DHA reaction in producing di-
hydroxylated products (intraday and interday reproducibility shown, average results presented, error 
bars indicate (±) one standard deviation). Reaction conditions: 0.2 mM DHA, 800 µL SBF extract, 
0.01% v/v Triton X-100, 10 mL phosphate buffer (pH 8, 50 mM) saturated with oxygen, ambient 
temperature, 30 min reaction time. Day 1 – 3: n=5; Overall: combined results from Day 1 – 3: n=15. 
Yield 
The yield of the reaction was estimated from the NP-HPLC peak area of di-hydroxy 
DHA products relative to the internal standard (PGB2). The yields of di-hydroxy 
DHA products were calculated by comparing the quantities produced in the 
optimised reaction with the maximum amount of di-hydroxy DHA products that 
could be produced (if all DHA was converted into di-hydroxy DHA products). The 
quantities of di-hydroxy DHA products were calculated through the Beer-Lambert 
equation based on the known concentration of PGB2 (0.02 mg PGB2 for 10 mL 
reaction) and their known peak area. Molar extinction coefficients were used to 
correct for differences in UV absorbance: PGB2 (280 nm) 30,000 M-1 cm-1 [203]; 
7S,17S-diHDHA (234 nm) 33,500 M-1 cm-1 [103]; and 10S,17S-diHDHA (270 nm) 
38,000 M-1 cm-1 [67]. The estimated yield for the optimised reaction was 25% 























3.2. Product characterisation 
To confirm the identities of the major products of the sfLOX-catalysed DHA 
reaction (17-HDHA, 7,17-diHDHA and 10,17-diHDHA), GC-MS and chiral RP-
HPLC were used. 
3.2.1. Determination of hydroxy group positions on reaction products by GC-
MS 
The reduced reaction products were derivatised to compounds more volatile and 
thermally stable by saturation of double bonds and trimethylsilylation of hydroxy 
groups for GC analysis. The fully hydrogenated and trimethylsilylated (TMS) 
derivatives of the optimised sfLOX-catalysed DHA reaction products were analysed 
by GC-MS. The hydroxy positions of the mono- and di-hydroxy DHA products were 
identified by interpreting fragmentation patterns of derivatives. Two major di-
hydroxy DHA products and two mono-hydroxy DHA products were detected while 
only one mono- and two di-hydroxy DHA products were observed by NP-HPLC. 
The two mono-hydroxy DHA products eluted between 26 and 27 min, and the two 
di-hydroxy DHA products eluted between 28 and 29 min (Table 3.3).  
Table 3.3: Important m/z fragments of the hydrogenated, trimethylsilyl derivatives of mono and di-
hydroxy products from sfLOX-catalysed DHA reaction under optimised conditions. 
Retention time 
(min) 
Product Important m/z fragments 
26.62 10-HDHA 73, 117, 271, 309, 331, 395, 485 
26.94 17-HDHA 73, 117, 173, 309, 395, 429, 485 
28.81 10,17-diHDHA 73, 117, 173, 331, 359, 427, 517, 573 




The four products were identified as fully hydrogenated, TMS derivatives of 10-
HDHA and 17-HDHA (two mono-hydroxy DHA products), and 7,17-diHDHA and 
10,17-diHDHA (two di-hydroxy DHA products). 10,17-diHDHA (Figure 3.12) and 
7,17-diHDHA co-eluted partially, but separate fragmentation patterns could be 
distinguished. The results confirmed the presence of three compounds including one 
mono-hydroxy DHA product, 17-HDHA, and two di-hydroxy DHA products, 7,17-
diHDHA and 10,17-diHDHA, which matched the NP-HPLC results. An additional 
mono-hydroxy DHA only identified by GC-MS was 10-HDHA. 
Figure 3.12: Structure showing assignment of important fragments, and mass spectrum of fully 
hydrogenated tri-TMS-10,17-diHDHA. 
3.2.2. Determination of stereochemistry of reaction products by chiral RP-
HPLC 
Soybean lipoxygenase is commonly known to produce products with S chirality, 























[49, 102]. To determine if the S specificity was preserved when using SBF as a LOX 
source, product chirality was identified by chiral RP-HPLC. The di-hydroxy DHA 
products of the sfLOX-catalysed reaction were methylated to produce less polar 
compounds to increase retention and improve peak shape prior to chiral RP-HPLC 
analysis. The racemic mixture of 10,17-diHDHA and 7,17-diHDHA stereoisomers (4 
compounds for each di-hydroxy DHA product) synthesised from sfLOX-catalysed 
DHA reaction products could be distinguished by chiral RP-HPLC. 7,17-diHDHA 
from the sfLOX-catalysed DHA reaction (5 times dilution) was identified to be 
7S,17S-diHDHA by matching its retention time with 7S,17S-diHDHA standard and 
one of the compounds of the racemic mixture (Figure 3.13A). 7,17-diHDHA was 
also tested undiluted by chiral RP-HPLC to confirm the chiral purity of the product 
(S,S ≥ 99.5%), and no other stereoisomers were detected (Figure 3.13B). 10,17-
diHDHA from the DHA reaction catalysed by sfLOX was identified to be 10S,17S-










Figure 3.13: Chiral RP-HPLC chromatogram of A) standard 7S,17S-diHDHA, racemic mixture of 
sfLOX-catalysed DHA reaction product and 7,17-diHDHA from sfLOX-catalysed DHA reaction 
(diluted 1:5) after methylation; B) racemic mixture of sfLOX-catalysed DHA product ME and 7,17-
diHDHA from sfLOX-catalysed DHA reaction after methylation. 
3.3. Application of the optimised reaction conditions to other biologically 
relevant substrates 
The optimised conditions of the sfLOX-catalysed DHA reaction were applied to 
other biologically relevant substrates (AA, EPA, DPAn-3 and DPAn-6). The results 
showed that all substrates were able to react with sfLOX to form di-hydroxy PUFA 
























































mono-hydroxy PUFA product remained at the end of the reactions (Figure 3.14). The 
ratio between the two di-hydroxy PUFA isomers was significantly different between 
substrates. For EPA, the reaction formed similar amounts of both isomers; for DHA 
and AA, the ratio was approximately 2.5:1 with the conjugated triene (the hydroxy 
groups separated by 7 carbons) as the preferred isomer; for DPAn-6, the ratio was 
approximately 7:1 in favour of this isomer. Only the DPAn-3 reaction produced 
significantly more of the double conjugate diene isomer (the hydroxy groups 
separated by 10 carbons) than the conjugated triene with a ratio of approximately 
15:1. This was similar to previous results obtained from the commercial 15-sLOX-1 
reaction [43].  
 
Figure 3.14: Application optimised sfLOX-catalysed DHA reaction conditions to other biologically 
relevant substrates (EPA, AA, DPAn-3 and DPAn-6). Reaction conditions: 0.2 mM PUFA, 800 µL 
SBF extract, 0.01% v/v Triton X-100, 10 mL phosphate buffer (pH 8, 50 mM) saturated with oxygen, 
ambient temperature, 30 min reaction time. The results from a single representative experiment 
present product formation from different substrates. 
Due to the low formation of 7,17-diDPAn-6 compared to 10,17-diHDPAn-6 in the 
DPAn-6 reaction, TCEP 0.6 mM was applied to possibly increase the yield of 7,17-
diHDPAn-6 as demonstrated above in Section 3.1.7 with DHA as substrate. As 
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the yield of 7,17-diHDPAn-6 by ~ 40%, although 10,17-diHDPAn-6 yield slightly 
decreased (~ 20%) (Figure 3.15). 
 
Figure 3.15: Chromatograms of sfLOX-catalysed DPAn-6 reaction products under the optimised 
sfLOX-catalysed DHA reaction conditions with and without 0.6 mM TCEP. Reaction conditions: 
0.2 mM DPAn-6, 800 µL SBF extract, 0.01% v/v Triton X-100, 10 mL phosphate buffer (pH 8, 
50 mM) saturated with oxygen, ambient temperature, 30 min reaction time. The results from a single 
representative experiment present TCEP effect on product formation. 
3.4. Comparison between sfLOX and 15-sLOX-1 
3.4.1. Product formation  
Double the amount of DHA was used in the sfLOX-catalysed DHA reaction at 
optimised conditions compared to the optimum conditions found for the 15-sLOX-1 
catalysed DHA reaction in previous work [43]. Correspondingly, roughly double the 
amount of di-hydroxy DHA products were produced by the sfLOX-catalysed 
reaction compared to the 15-sLOX-1 catalysed reaction (Figure 3.16A). This means 
that at the same reaction volume, sfLOX converted twice as much DHA into 
products as 15-sLOX-1. By comparing the conversion per milligram of DHA 
substrate, sfLOX showed approximately the same efficiency as 15-sLOX-1 in 



























Figure 3.16: 15-sLOX-1 and sfLOX activity in producing di-hydroxylated products from DHA under 
conditions optimised for each enzyme: A) Total amount produced (peak area to PGB2); B) Amount 
produced per milligram DHA (peak area to PGB2 per mg DHA). Reproducibility shown, average 
results presented and error bars indicate (±) one standard deviation (n=3). 
3.4.2. Enzyme kinetic parameters  
The reaction kinetics of the sfLOX-catalysed DHA reaction under the optimised 
















































formation of the conjugated triene-containing product (10,17-diHDHA). The 
calculated values were compared to previous work (enzyme kinetics of 15-sLOX-1 
catalysed DHA reaction under its optimised conditions) [43]. Comparison of results 
(Table 3.4) revealed that sfLOX had higher maximum rate, but required higher DHA 
concentration to reach 50% of the maximum reaction rate compared to 15-sLOX-1. 
Overall, the sfLOX-catalysed reaction proceeded much faster than the 15-sLOX-1 
catalysed reaction with higher substrate capture (Vmax/Km). However, sfLOX was 
found to have less affinity with DHA compared to 15-sLOX-1 in making the di-
hydroxy conjugated triene as the sfLOX-catalysed DHA reaction had a higher Km 
value. 
Table 3.4: Reaction kinetics for the formation of 10,17-diHDHA from DHA catalysed by sfLOX 
measured in this work, and by 15-sLOX-1 determined in previous work [43].  
Parameter Vmax (µM/min) Km (µM) Vmax/ Km (min-1) 
sfLOX-DHA 237.0 271.4 0.87 
15-sLOX-1 DHA 26.6 49.5 0.54 
 
3.4.3. Colorimetric test for LOX isozyme detection 
Three different tests (I, II and III) developed by Suda et al. [190] were conducted to 
determine the presence of three LOX isozymes (LOX-1, LOX-2 and LOX-3) in SBF. 
In these tests, radicals formed in the reaction of sodium linoleate catalyzed by sfLOX 
isozymes are involved in redox reactions with methylene blue and β-carotene, 
resulting in bleaching of their colours. The results showed that in test I (LOX-1 
activity, methylene blue, pH 9) the colour of methylene blue was bleached quickly 
(within 2 min) to colourless as expected, indicating the presence of LOX-1; whereas 
the blue colour of test II (LOX-2 activity, methylene blue and dithiothreitol, pH 6) 
completely lost colour much more slowly, taking up to 10 min. This indicates LOX-2 
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is present in SBF but at low concentration and/or activity as the bleaching time was 
longer than expected (within 5 min in the original paper). LOX-3 was detected by the 
colour change of β-carotene (from yellow to colourless) within 4 min in test III 
(LOX-3 activity, β-carotene, pH 6.6) which was similar to the expected time of 
3 min, indicating the presence of LOX-3 (Table 3.5). As a result, the SBF used in 
this study for LC-PUFA oxidation was identified to contain three individual LOX 
isozymes: LOX-1, LOX-2 and LOX-3.  




















I:   LOX-1 2.5 0.5 1.5-2 + 140 0.5 0.75-1 + 
II:  LOX-2 5.0 3-5 9-10 + 280 10-15  20-25 * 
III: LOX-3 2.5 0.5 3.5-4 + 140 0.5 2.5-3 + 
 
Similarly, a commercial 15-sLOX-1 used for comparison of enzyme activities with 
sfLOX was also tested. Test I had a quick response (within 1 min) as expected, 
which confirmed the presence of LOX-1. The LOX-2 test was inconclusive as the 
bleaching time (20 - 25 min) was unclear and much longer than the original test. In 
test III, bleaching of the colour occurred within the expected time of 3 min, 
indicating the presence of LOX-3 in the commercial solution. It is possible to have 
multiple isozymes in the commercial preparation as it was only partially purified. A 




3.4.4. Protein separation by SDS-PAGE 
To further determine which LOX isozymes were present in the SBF, SBF and two 
commercial sLOX preparations (15-sLOX-1, unpurified and purified) were analysed 
by SDS-PAGE. To achieve better separation of the isozymes which have very similar 
molecular weights, electrophoresis was run for long durations, which meant that 
lower molecular weight species migrated off the gel. After running a gel for 2 hours 
(Figure 3.17), the molecular weights of LOXs in SBF and the commercial LOX 
preparations were confirmed to be in one major band at ~ 94 – 97 kD by comparison 
with the molecular weight standard. A thick band below the LOX band in SBF (lane 
2 and 3), not observed with either of the commercial LOX preparations, was 
expected to be the α′ subunit of 7S globulin (β-conglycinin), as previously 
determined [192].  









Figure 3.17: SDS-PAGE analysis of SBF and commercial lipoxygenase enzyme preparations (15-
sLOX-1, unpurified and purified). 7.5% acrylamide gel was used and stained with Bio-Safe 
Coomassie G250 Stain. Samples were heated at 80°C before running SDS-PAGE. Lane 1: molecular 
weight standard, lane 2 and 3: SBF extract (diluted 1 in 8), lane 4: unpurified 15-sLOX-1 (diluted 1 in 
4), lane 5: unpurified 15-sLOX-1 (diluted 1 in 8), lane 6: purified 15-sLOX-1 (diluted 1 in 2), lane 7: 








Previous studies indicated that the order of LOX isoenzymes on the gel should be 
LOX-3, LOX-2 then LOX-1, from highest to lowest molecular weight [204, 205]. 
However, on the gel, only one major band was observed at ~ 95 kD for all samples 
and there were no other bands accounting for LOX-2 and LOX-3 with higher 
molecular weight than this band (and lower than 97.4 kD). This suggests that the 
bands for the three isozymes were not separated under the running condition of this 
gel. There were also two minor bands with lower molecular weights underneath the 
major LOX band in commercial LOX samples (lane 4 – 8). These bands were 
unknown and not present in SBF. 
In order to get separation of the isozyme bands, a 12% acrylamide gel was used and 
run for 5 – 6 hours. Heating of the sample at a lower temperature (50°C), and no 
heating before electrophoresis was tested, as LOX-2 is much less stable than LOX-1 
at high temperature [122]. A better separation was observed with a 6 hour run time 
and without sample heating (lane 1 – 5, Figure 3.18). The LOX-1 band was expected 
to be the most intense as LOX-1 is the most abundant isozyme in soybean, and LOX-
2 and LOX-3 should be minor bands. A major band was observed between the 75 
and 100 kD molecular weight standard on the gel for both SBF and 15-sLOX-1 
(lanes 1 – 5, Figure 3.18), confirming the presence of LOX-1. Above this band, SBF 
showed one minor band close to LOX-1 (lanes 2 – 4), whereas 15-sLOX-1 had two 
minor bands further from LOX-1 (lane 5). These three bands were not matched to 





Figure 3.18: SDS-PAGE analysis of SBF and commercial lipoxygenase enzyme preparation of 15-
sLOX-1 (unpurified). 12% acrylamide gel was used and stained with Bio-Safe Coomassie G250 Stain. 
Lanes 1 – 5 (samples without heating before running SDS-PAGE), lane 6 – 10 (samples heated at 
50°C before running SDS-PAGE). Lane 1 and 10: molecular weight standard, lane 2 – 4 and 6 – 8: 
SBF extract (diluted 1 in 4, 1 in 8 and 1 in 16 respectively), lane 5 and 9: 15-sLOX-1 (diluted 1 in 8). 
4. Discussion 
Lipoxygenase-catalysed reaction optimisation 
The three LOX isozymes (1, 2 and 3) were indicated to be present in SBF using a 
colorimetric screening method. LOX-2 in SBF appeared to be more active and/or 
higher in concentration than in a commercial 15-sLOX-1 preparation, as the 
commercial LOX required significantly longer time (20 – 25 min) to bleach the 
colour in test II than SBF (9 – 10 min). This supports previous findings that LOX-2 
is unstable when purified, but the activity is more stable in the protein-starch matrix 
in flour, which acts as a natural immobiliser [56]. As for SDS-PAGE, LOX-1 was 
conclusively detected but less conclusive evidence was observed for LOX-2 and 
LOX-3 detection above LOX-1 in both SBF and commercial 15-sLOX-1, as these 
bands had significantly less intensity compared to the LOX-1 band. The type-2 
LOXs in SBF and 15-sLOX-1 used in this work may not be present at high enough 
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on the gel, SBF may have more LOX-2, whereas 15-LOX-1 may contain more LOX-
3 isozymes (LOX-3a and LOX-3b).  
Previous work has shown that SBF can be used to catalyse reactions with C18 fatty 
acids for the formation of mono-hydroxy fatty acid products as precursors of volatile 
compounds (appropriate references in Table 2.2, Chapter 2). This is the first time 
SBF has been used directly to convert omega-3 and omega-6 LC-PUFAs (C20-22 
fatty acids) into not only mono- but also di-hydroxy PUFAs for one step production 
of resolvin analogues. The results of the optimisation revealed many interesting 
characteristics of the sfLOX-catalysed reaction, which in part differed to the reaction 
catalysed by commercial 15-sLOX-1 in previous work [43], with both using DHA as 
the substrate.  
The optimised pH of the sfLOX-catalysed DHA reaction for the synthesis of di-
hydroxy products was pH 8. This pH is not the optimum pH for LOX-1, LOX-2 or 
LOX-3 (pH 9, 6.5 and 6, respectively) [88]. A previous study found that the optimum 
pH of LOX-1 was at pH 9 for the generation of di-hydroxy products from DHA [43]. 
A LOX-1 catalysed AA reaction was also performed at pH 9 to produce di-hydroxy 
AA products [125]. Purified LOX-2 was shown to oxygenate LA [120, 122] and AA 
[123] at neutral pH, whilst pH 9 – 10 is commonly used for LOX-1 in SBF [105, 
157, 158, 164]. LOX-2 in SBF has also been used at pH 6 [105] to oxygenate free 
fatty acids for the formation of mono-hydroxy PUFA products as precursors of 
volatile compounds. The optimum pH found for the sfLOX-catalysed DHA reaction 
in this work may represent a compromise between the optimum pH of the three 
isozymes. This optimum pH is supported by other studies. For example, the optimum 
pH for LOX-1 in converting mono-hydroxy AA into di-hydroxy AA products 
(second dioxygenation) was found to be pH 7.5 – 8, and occurred at a significantly 
lower rate compared to the first dioxygenation at pH 9 [55, 124]. Moreover, a 
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previous study showed that a crude LOX extract from defatted SBF had maximum 
activity on hydrolysed safflower oil (composed mainly of linoleic acid) at pH 8 
although higher pH showed higher product specificity for the formation of 13-
hydroperoxy linoleic acid [59].  
In this work, the reaction was specific in forming mono-hydroxy DHA products with 
17-HDHA as the dominant product at pH 7.5, whereas there was no specific mono-
hydroxy product formed at lower pHs (≤ 7). Moreover, 17-HDHA formation 
increased significantly with increasing pH (7.5 – 11) and reached a maximum at pH 
11. These findings are supported by previous studies which showed that LOX had 
high specificity with single dioxygenation at high pHs [43, 59, 91]. It is likely that at 
high pH values (≥ 7.5) fatty acid is fully deprotonated for better solubility in water, 
and preferably inserted methyl end first (not the charged carboxyl end) into the 
catalytic pocket in the active site of the enzyme [49]. Furthermore, the second 
dioxygenation reaction is not favoured at high pHs leading to a higher concentration 
of mono-hydroxy products remaining.  
Both di-hydroxy DHA products increased significantly with increasing DHA 
concentration and reached a maximum at 0.2 mM DHA. At higher DHA 
concentrations (> 0.2 mM), formation of both di-hydroxy DHA isomers decreased 
significantly. This could be due to a number of reasons including substrate inhibition, 
product inhibition and low oxygen concentration. A small amount of hydroperoxides 
is required to initiate the LOX-catalysed reaction by converting the inactive form of 
LOX-Fe2+ into the active form, LOX-Fe3+ [95]. However, hydroperoxide binding can 
be prevented at high initial substrate concentrations [194, 195]. Moreover, the 
enzyme prefers to bind to product than substrate [196, 197], therefore high product 
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concentration can interfere with substrate binding which prevents the reaction from 
proceeding.  
Air-saturated water at 20°C contains only 0.29 mM oxygen whereas 0.2 mM DHA 
requires 0.4 mM oxygen to fully convert DHA into di-hydroxy DHA products. 
Oxygen will be limiting in the reaction and anaerobic conditions may develop during 
the reaction, although extra oxygen can enter the reaction medium slowly from the 
atmosphere over the course of the reaction. At high substrate concentrations 
(> 0.2 mM), di-hydroxy DHA formation was suppressed and there was an increase of 
17-HDHA, and unknown III and IV formation. This could be because there was not 
enough oxygen to generate di-hydroxy DHA products from 17-HDHA, and unknown 
III and IV may form from the anaerobic conditions. Under anaerobic conditions the 
LOX pathway has been shown to form a range of by-products instead of 
hydroxylated compounds [88]. For example, anaerobic products of LOX-catalysed 
linoleic acid reaction were fatty acid radicals which combined to form dimers with a 
conjugated diene on each fatty acid molecule, 13-oxo-9,11-octadecadienoic acid, 13-
oxotridecadienoic acid compounds and racemic hydroperoxides [91]. An oxo 
compound also formed from 17-HDHA was identified and a dimer formed from 
DHA radicals was proposed in a previous study by Dobson et al. [43]. The aerobic 
cycle competes constantly with the anaerobic cycle, especially at high substrate and 
enzyme concentrations, where the oxygen diffusion is not good enough to take over 
the reaction rate [96]. Therefore, maintaining oxygen at a sufficient level is necessary 
for the sfLOX-catalysed DHA reaction to produce a good yield of di-hydroxy DHA 
compounds. 
The formation of di-hydroxy DHA products increased with increasing SBF 
concentration. Previous work showed that sufficient levels of enzyme are required 
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for a good reaction yield, to transport oxygen effectively to the substrate [91]. It may 
also be because of enzyme inactivation by product inhibition [43, 125], therefore 
enough enzyme is required to balance these effects. However, at a certain point, 
adding higher volumes of SBF extract decreased product formation. This could result 
from self-inactivation/product inhibition [53], the development of anaerobic 
conditions and interference or inhibition of the reaction from other components in 
SBF.  
Surfactant showed a significant contribution to enhancing sfLOX activity on DHA. 
A few studies showed that LOX-1 activity can be enhanced at low surfactant 
concentrations but inhibited at high surfactant concentrations [131, 198]. No 
inhibition was observed with sfLOX in this work. Surfactants have functions in 
solubilising fatty acids [116], increasing thermal stability of LOX [117], stabilising 
protein structure [198] and reducing induction period [206]. A study also found that 
in the presence of Triton X-100, sLOX-1 was inhibited at low enzyme concentration, 
whereas the activity was enhanced at high enzyme concentration [131]. At 0.01 – 
0.05% v/v surfactant concentration, di-hydroxy DHA product yield was maximised, 
in the presence of a high volume of SBF; however, at higher concentrations of 
surfactant (> 0.05% w/v), the enhancement of enzyme activity appeared to decrease. 
This may have been caused by the formation of an emulsion during solvent 
extraction, which could interfere with product extraction. Also, it has been proposed 
that the enzyme inhibition and enhancement observed from the addition of 
surfactants result from changes in non-micellar substrate concentration due to 
partitioning of the substrate into surfactant micelles [116]. 
After reaching the optimum reaction time, the two di-hydroxy DHA products 
decreased slowly, whereas this was not observed with 15-sLOX-1 in the previous 
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work [43]. This suggests that other enzymes in SBF and soybean meal such as 
hydroperoxide lyases and hydroperoxide isomerases [137, 138] may be active in SBF 
extract and may be converting di-hydroxy DHA reaction products into other 
compounds (although these were not detected). As the sfLOX-catalysed DHA 
reaction used double the substrate concentration compared to 15-sLOX-1 catalysed 
DHA reaction, anaerobic conditions may also develop and cause degradation of 
hydroperoxides [207].  
Oxygen concentration also had a significant effect on di-hydroxy DHA formation, 
whilst previous work showed no effect on 15-sLOX-1 catalysed DHA (0.1 mM) 
reaction [43]. It is likely that the dissolved oxygen concentration at room temperature 
(~ 0.26 mM) is enough for converting 0.1 mM DHA (in the reaction catalysed by 15-
sLOX-1) into di-hydroxy DHA products, but is not enough for converting 0.2 mM 
DHA (in the reaction catalysed by sfLOX) into di-hydroxy DHA products, which 
would require 0.4 mM oxygen. Saturation of oxygen (~ 1.1 mM) into the buffer 
solution satisfied the oxygen demand for the sfLOX-catalysed DHA reaction 
resulting in increased product formation. Additional oxygen was not required, and so 
an oxygen-filled balloon covering the reaction to preserve the oxygen-rich 
environment was not needed and did not affect the results. Under oxygen-depleted 
conditions, the normal reaction products were not formed and probable anaerobic 
products (unknown III and IV) were formed instead.  
Temperature was also found to have a significant effect on the reaction. At both low 
(0 – 10ºC) and high (30 – 40ºC) temperatures, enzyme activity was decreased 
compared to at ambient temperature (~ 22ºC). With increasing temperature, substrate 
solubility and mass transfer increases whereas oxygen concentration decreases and 
vice versa. Enzyme deactivation or product degradation could happen at higher 
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temperatures. As previously reported, LOX-1 in soybean was identified to be 
inactive at 54ºC at pH 9 and have a midpoint inactivation temperature at 44 ± 1ºC 
[117]. The room temperature optimum may be a compromise between substrate and 
oxygen solubility, mass transfer, enzyme activity and stability. An increase in 
different product isomers or non-enzymatic products at higher temperatures was not 
observed in this work, which was consistent with previous work using 15-sLOX-1 
and DHA [43].  
Two compounds (unknown I and II) were formed under certain conditions: 0ºC, 1 
min reaction time and high volume of SBF extract (≥ 100 µL). Unknown I appeared 
to contain two conjugated dienes and unknown II appeared to contain a conjugated 
triene based on the absorbance spectra, so they may potentially be di-hydroxy DHA 
products. These two compounds have not been identified. 
Less than 5% DHA remained at the end of the reaction using 25 µL SBF extract at 
different pH and buffer types. Approximately 15 – 20% DHA was detected at 40ºC. 
No DHA was detected under any other conditions, even where di-hydroxy DHA 
formation was much less compared to the final optimised conditions. However, there 
was no new compounds observed in the HPLC chromatograms to account for the 
loss of DHA. The reason for the missing DHA and/or products during the reaction is 
unknown. However, some side reactions on DHA or DHA hydroperoxides may have 
metabolised these compounds to volatile or shorter chain polar compounds, which 
were lost or not extracted in the solvent extraction step prior to detection by NP-





Comparison between sfLOX and 15-sLOX-1 
The sfLOX has achieved similar efficacy to 15-sLOX-1 in the reaction with DHA for 
di-hydroxy DHA formation. The reaction at optimised conditions can produce double 
the amount of di-hydroxy DHA products. Based on the cost difference between soy 
flour and the commercial enzyme, it is approximately 28,000 times cheaper when 
SBF is used to replace 15-sLOX-1 in the production of di-hydroxylated compounds 
per mg DHA. These data demonstrated that SBF is a feasible alternative to 
commercial 15-sLOX-1 to reduce the synthesis cost of resolvin and protectin 
analogues. sfLOX was able to catalyse oxidation of other biologically important 
PUFAs as previously shown with 15-sLOX-1 [43]. The ratio of the two di-hydroxy 
isomer formation was comparable for DHA, EPA and AA as substrates, whereas one 
isomer was formed in significantly larger amount than the other with DPAn-3 and 
DPAn-6 as substrates. The reason for the differences in the ratios of the two major 
di-hydroxylated PUFA products between substrates catalysed by sfLOX is currently 
unknown. Similar results were also observed with 15-sLOX-1 and these PUFA 
substrates [43]. 
However, there are some potential issues when using SBF directly as a crude enzyme 
source in comparison with 15-sLOX-1. The optimised conditions required a large 
volume of SBF extract (800 µL ~ 40 mg SBF) because the enzyme concentration is 
much less concentrated than commercial LOX. The more complex mixture can 
interfere with product extraction by SPE. When using 300 µL or more of SBF 
extract, the SPE method cannot be used to extract products from the reaction mixture 
as high amounts of particulate and insoluble material from the flour blocks the SPE 
tubes. Therefore, solvent extraction is required as an alternative method to isolate 
products. The presence of more LOX-2 in SBF than in 15-sLOX-1 identified by the 
colorimetric test, may cause the sfLOX-catalysed DHA reaction to be less specific in 
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product biosynthesis than commercial 15-sLOX-1, although this was not observed in 
the current experiments.  
For sfLOX catalysis on DHA, substrate was not detected under almost all reaction 
conditions while product formation did not account for the loss of substrate. This was 
also observed in some cases with the commercial enzyme [43]. There are some 
reasons that could account for this. LOX-2 in SBF may be responsible for making n-
hexanal as volatile green flavour compounds, as previously reported in a study 
between LA and sLOX-2 [208]. Other enzymes such as hydroperoxide lyases and 
hydroperoxide isomerases in the flour could take part in some side reactions in which 
the reaction products may be metabolised into undesirable compounds such as 
aldehydes and oxo-acid compounds [209]. However, in this work these compounds 
were not detected. 
5. Conclusion 
For the first time, SBF has been used directly, without purification, as an alternative 
to commercial purified LOX for synthesizing both mono- and di-hydroxy PUFA 
resolvin and protectin analogues from a range of biologically important n-3 and n-6 
PUFAs. The reaction conditions are mild and the conversion is rapid. The 
synthesised products using sfLOX and 15-sLOX-1 are identical in terms of regio- 
and stereo-specificity. This method could potentially be applied to a low-cost 
industrial scale synthesis of these anti-inflammatory SPM compounds for 
pharmaceuticals, nutraceuticals and functional food applications. However, when 
using SBF, other compounds and enzymes present are also present and may interact 
with reaction product and/or substrate in side reactions or may interfere with the 
LOX catalysed reaction, affecting overall product yield.  
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Below is a flow diagram (Figure 3.19) summarising the process of resolvin analogue 
synthesis from DHA under the optimised conditions. 
 
Figure 3.19: Summarised process of resolvin analogue synthesis from DHA into pure 7S,17S-
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SOYBEAN FLOUR LIPOXYGENASE CATALYSIS OF 
TRILINOLEIN AS A TRIACYLGLYCEROL MODEL 
1. Introduction 
A triacylglycerol (TAG) molecule consists of three fatty acids attached to a glycerol 
backbone. TAGs are the major components (approximately 95%) of natural oils such 
as fish and vegetable oils [210]. Dioxygenation of PUFAs as free fatty acids by 
sfLOX has been demonstrated in Chapter 3 for the synthesis of potential bioactive 
compounds such as resolvin and protectin analogues. Free fatty acid substrates are 
commonly obtained from natural oils after hydrolysis with or without purification. It 
would be of great interest for PUFA containing TAGs to be oxygenated directly for 
bioactive compound synthesis without the extra hydrolysis step.  
LOX is a versatile enzyme for catalysing the dioxygenation of PUFAs containing 
1,4-pentadiene units. Soybean is a rich source of LOX and soybean LOX is well 
studied compared to other plant LOXs [55, 90]. In soybean seeds, the two types of 
LOXs, type-1 LOX (LOX-1) and type-2 LOX (LOX-2 and LOX-3), have distinct 
characteristics. Type-1 LOX is known to catalyse the oxygenation of free fatty acids 
effectively at optimum pH 9, whilst esterified fatty acids are not a preferred 
substrate. In contrast, type-2 LOX can oxygenate not only free fatty acids but also 
esterified fatty acids (EFAs) directly without prior to hydrolysis at optimum neutral 
pH [88, 90]. Only LOX-1 is commercially available; type-2 LOXs are not, most 
likely in part because they are unstable after purification [56]. LOXs can be used to 
synthesise various bioactive compounds such as eicosanoids and docosanoids [86]. 
These compounds, especially the di- and tri-hydroxy conjugated PUFAs, can act as 
specialised pro-resolving mediators with anti-inflammatory and pro-resolving 
activity at very low doses [6].  
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Less studies have reported the oxygenation of EFAs catalysed by soybean LOX 
compared to free fatty acids. Type-2 LOX has been shown to have much higher 
activity than LOX-1 in the catalysis of EFA substrates such as trilinolein and methyl 
linoleate [122, 131]. However, a number of studies have still investigated LOX-1 
catalysis on various EFAs [129, 130, 168, 169, 211-213]. Importantly, LOX-1 was 
found to catalyse reactions with EFAs such as trilinolein and 1,3-dilinolein under 
specific conditions in the presence of a bile salt and a multicomponent buffer to 
increase the reaction rate, however the rate is still generally low compared to when 
LA is the substrate [129, 169]. Although there have been some studies on type-2 
LOX-catalysed reactions with EFAs [122, 131, 175, 214], mainly investigating 
reaction pH and comparisons between LOX isozymes, a full optimisation of reaction 
conditions for maximum product formation has not been performed. Further 
investigation of type-2 LOX and EFA is needed and would be useful for a better 
understanding of LOX catalysis on EFAs. Soybean flour (SBF) is a useful LOX 
source, as it contains both LOX types in a stable, natural form. SBF is especially 
valuable as a source of type-2 LOX, which can be used directly to react with EFAs 
effectively and without prior hydrolysis.  
In this chapter, optimisation of the sfLOX-catalysed reaction on trilinolein for the 
maximum tri-hydroperoxylated product formation is described. The approximate 
yield of the reaction was also calculated. Trilinolein was used as a model TAG 
substrate, containing three linoleate moieties. The TAG reaction products can contain 
up to three hydroxy groups (one on each fatty acid), and these compounds were 
characterised with a range of analytical techniques including HPLC-DAD, GC-MS 
and NMR. The optimised conditions were compared between the reaction of 
trilinolein (TL) and a commercial enzyme (15-sLOX-1) or SBF to confirm the 
versality of SBF in reacting with EFAs. The reaction products are highly stereo- and 
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regio-specific hydroxy linoleate moieties in mono-, di- and tri-hydroxy TL. This 
model system may be applicable to more complex natural oils containing a variety of 
TAGs such as fish oils with high percentage of n-3 LC-PUFAs (DHA and EPA), 
where the n-3 LC-PUFAs will be selectively oxygenated to produce potential anti-
inflammatory compounds with high bioavailability.  
2. Materials and methods 
2.1. Materials 
Soybean flour (Kialla Pure Foods, certified organic) was purchased from Organic 
Wholefoods (Brunswick East, VIC, Australia). Trilinolein (Nu-Chek Prep) was 
obtained from Adelab Scientific (Thebarton, SA, Australia). Acetyl chloride (Fluka), 
butylated hydroxytoluene (BHT), citric acid, ferric chloride, gum arabic, L-cysteine, 
methyl tricosanoate, N,O-bis(trimethylsilyl)trifluoroacetamide (with 1% 
trimethylchlorosilane), potassium phosphate monobasic, potassium phosphate 
dibasic, potassium iodide (KI), platinum(IV) oxide, pyridine (>99%), sodium 
borohydride, sodium thiosulfate (Na2S2O3), starch, sodium citrate dihydrate, 
Trizma® base, Tween® 20 and (trimethylsilyl)diazomethane (2 M in diethyl ether) 
were purchased from Sigma Aldrich (Castle Hill, NSW, Australia). Agilent Bond 
Elut 500 mg, 3 mL SPE tubes and Vac Elut SPE vacuum apparatus were from 
Agilent Technologies (Mulgrave, VIC, Australia). Heptane (99%, 0.2 micron 
filtered) and isopropanol were obtained from Fisher Scientific (Scoresby, VIC, 
Australia). Hydrochloric acid (32%) and sodium tetraborate and were purchased 
from APS Chemicals Ltd (Seven Hills, NSW, Australia). Ethanol, diethyl ether, 
methanol, potassium bicarbonate and sodium chloride were purchased from Chem-
Supply (Gilman, SA, Australia). Acetonitrile (Scharlau, Spain), acetic acid (BDH 
Lab Supplies, UK) and sodium hydroxide (Fisher Chemicals, UK) were purchased 
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from Science Supply (Mitcham, VIC, Australia). Triton X-100TM, toluene and 
chloroform were purchased from Ajax Finechem (Taren Point, NSW, Australia). 
Genistein (Toronto Research Chemicals, Canada) was purchased from Sapphire 
Bioscience (Redfern, NSW, Australia). Hydrogen, nitrogen and oxygen gases were 
obtained from Coregas Pty Ltd (North Geelong, VIC, Australia).  
2.2. Lipoxygenase-catalysed reaction optimisation for maximum product 
formation 
1 mL stock TL emulsion solution (10 mg/mL) was freshly prepared in 50 mM tris-
HCl buffer pH 7.5 with 15% w/v gum arabic and sonicated by an ultrasonic 
processor (500 W, 20 kHz, amplification 20%) with 10 pulses [92]. The SBF 
suspension [56] was prepared by suspending 1 g SBF in 20 mL water, followed by 
shaking for 1 min. The reaction mixture was prepared with stirring and contained 
0.1 mg/mL TL emulsion in 10 mL buffer (50 mM) with a range of pH and buffer 
types (Table 4.1). Other additives if required were added and then 25 µL SBF 
suspension was added to initiate the reaction. The reaction was conducted at room 
temperature (23°C) with stirring for 15 min. 50 µL glacial acetic acid was added at 
the end of the reaction and the reaction mixture was stirred for approximately 
30 min. For short reactions (less than 15 min), the reactions were stopped by adding 
20 mL diethyl ether to the reaction mixture after adding the 50 µL acetic acid. 
Table 4.1: Three types of buffer used and the pH ranges studied. 
Buffer type pH 
Phosphate 5 – 8 
Borate 
Citrate 
8 – 11 




The reaction products were extracted by solid phase extraction (SPE) under vacuum 
as described in Chapter 3, Section 2.2. For the reactions using high volumes of SBF 
suspension (≥ 150 µL), solvent extraction was used as an alternative to SPE, because 
the reaction mixtures blocked the SPE columns. The reaction mixtures were adjusted 
to pH 3 by HCl (1 M) and were extracted with diethyl ether (2 × 20 mL) and the 
combined solvent after extraction was evaporated under vacuum. The sample was 
diluted in 1 mL methanol with 0.1% v/v acetic acid or methanol:isopropanol (80:20) 
with 0.1% v/v acetic acid for RP-HPLC analysis. Blank reactions either without 
substrate or SBF were performed. They showed minimal autoxidation products (less 
than 5% of total products).  
The reaction was optimised to determine the ideal conditions for the synthesis of the 
maximum amount of tri-hydroperoxy products and also total products. Three 
variables of pH, buffer type (see Table 4.1) and SBF suspension volume (25, 100, 
200, 300 and 400 µL), were investigated at the same time. The best conditions were 
chosen as initial conditions for further optimisation, with the remaining variables 
tested one at a time (Table 4.2). The conditions with the best results were kept for 




Table 4.2: Reaction variables optimised in the sfLOX-catalysed reaction with TL. 
Variable Range studied 
TL amount (mg) 0 – 10 
Reaction time (minutes) 1 – 120 
Oxygenation Oxygen, Nitrogen, Air, None 
Temperature (°C) 0 – 40 
Ferric chloride concentration (µM) 0 – 10 
Genistein concentration (mM) 0 – 1 
Butylated hydroxytoluene - BHT 
(mg/mL ethanol) 
0 – 0.2 
 
For optimisation of individual reaction variables, experiments were repeated between 
1 and 3 times to ensure a clear trend and optimum was observed. Values from a 
single representative experiment are shown in the results section for each variable. 
Results at different reaction conditions for each variable were considered to be 
different when the results varied by greater than ± 5%. The optimised reaction 
conditions were conducted in triplicate. 
2.3. Reduction of trilinolein hydroperoxides 
sfLOX-catalysed TL reaction products (TL hydroperoxides) after solvent 
evaporation under vacuum, were reduced to produce TL hydroxides. Initially, the 
products were dissolved in 1 mL methanol and the reaction was initiated by adding 
200 µL sodium borohydride (NaBH4, 1 M), and the reaction mixture was stirred for 
15 min. The reaction was stopped and acidified by adding 50 µL acetic acid, 
followed by stirring for 15 – 30 min. 10 mL water was added and the reduced 
products were extracted with diethyl ether (2 × 20 mL). The combined solvent after 
extracting was evaporated under vacuum before diluting in 1 mL of mobile phase for 
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RP-HPLC analysis. The following reaction variables were optimised, in duplicate 
(Table 4.3), to convert TL hydroperoxides into TL hydroxides and minimise the 
formation of undesirable side products. To obtain the same amount of TL 
hydroperoxides as starting materials for each reaction, a 100 mL scale reaction (10 × 
10 mL reaction conditions) was conducted. The TL hydroperoxide products were 
dissolved in 13 – 15 mL methanol and 1 mL was used for each reaction. Reactions at 
each condition were performed in duplicate. 
Table 4.3: Reaction variables optimised for the reduction of sfLOX-catalysed TL reaction products. 
Variable Range studied 
Extra water volume (µL) 0 – 800 
NaBH4 volume (µL) 0 – 200 
NaBH4 concentration and volume (M) 1 – 4 M and 200 – 50 µL 
Reaction time (minutes)  1 – 45 
 
2.4. Hydrolysis of trilinolein hydroxides 
Hydrolysis of EFAs [215, 216] was conducted on TL hydroperoxides with 
modifications. The reduced sfLOX-catalysed TL reaction products were dissolved in 
1 mL ethanol in a 10 mL vial and 1.5 mL aqueous NaOH 50% (w/v) was added. The 
reaction mixture was sealed and stirred at 65°C for 90 min. Then water was added, 
up to 10 mL, to dilute the sample to avoid harsh conditions which may cause side 
reactions before adjusting pH with HCl (4M). The sample was acidified until the 
solution turned cloudy (approximately pH 2 – 3). Additional acid was avoided 
because it can cause an increase in undesirable side reaction products. The 
hydrolysed products were extracted by diethyl ether (2 × 20 mL), followed by 
evaporating solvent under vacuum. The final sample was diluted in 1 mL methanol 
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with 0.1% v/v acetic acid for further product characterisation by RP-HPLC, chiral 
RP-HPLC or GC-MS analysis. Reactions were performed in triplicate. 
2.5. Monitoring reaction product formation by RP-HPLC 
sfLOX-catalysed TL reaction products including mono-, di- and tri-hydroperoxy TL 
were separated by RP-HPLC [92]. An Agilent Technologies 1260 series instrument, 
including a solvent degasser, quaternary pump, autosampler and diode array detector 
(DAD) was used. A C8 column (Phenomenex, 15 cm × 4.6 mm, 5 µm particle size) 
was used. The composition of mobile phase was A: 0.1% v/v acetic acid in water and 
B: methanol with 0.1% v/v acetic acid. Samples were separated under gradient 
conditions from 90% to 100% B over 20 min, at 1 mL/min, 23ºC. The elution of 
mono-, di- and tri-hydro(pero)xy products was identified spectrophotometrically 
through absorption at 210 nm, 234 nm, 250 nm and 270 nm. Injection volume was 
15 µL unless otherwise stated and reproducibility was confirmed by repeat 
injections. Data was processed using Agilent Technologies ChemStation for LC 3D 
system B.04.03 software. 
For reaction yield, all samples were dissolved in 1 mL mobile phase. Standards (TL 
and TL-3OOH) and reaction product samples were injected with 5 µL, whereas 
hydroxy LA samples were analysed with 1 µL injection volume.  
2.6. Determination of stereochemistry of reaction products by chiral RP-
HPLC 
Reduced and hydrolysed sfLOX-catalysed TL reaction products at the final 
optimised conditions were separated by chiral RP-HPLC. An Agilent Technologies 
1260 Infinity series instrument, including a solvent degasser, quaternary pump, 
autosampler and diode array detector (DAD) was used. A Lux 5u Amylose-2 column 
(Phenomenex, 100 × 4.6 mm, 5 µm particle size) was used to separate products. The 
mobile phase contained, A: 0.1% v/v acetic acid in water and B: acetonitrile with 
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0.1% v/v acetic acid. 13-hydroxy LA (13-HLA) obtained from reducing and 
hydrolysing sfLOX-catalysed TL reaction products was separated for the two 
enantiomers (13S-HLA and 13R-HLA) under gradient conditions from 20% to 80% 
B over 20 min at 0.5 mL/min, 23°C. The elution of two chiral compounds of 13-
HLA was identified spectrophotometrically through absorption at 210 nm, 234 nm, 
250 nm and 270 nm. Samples were prepared in acetonitrile with 0.1% v/v acetic acid. 
Injection volume was 15 µL and reproducibility was confirmed by repeat injections. 
Data was processed using Agilent Technologies ChemStation for LC 3D system 
B.04.03 software. 
2.7. Determination of hydroxy group positions on reaction products by 
GC-MS 
The sfLOX-catalysed TL reaction products were reduced and hydrolysed to obtain 
hydroxy LA. The positions of hydroxy groups on hydroxy LA were determined by 
GC-MS [43] after hydrogenation and conversion to trimethylsilylated derivatives 
(see Chapter 3, Section 2.4.). An Agilent Technologies 6890N Network GC system 
with a 5975 mass selective detector (electron impact) and a BPX5 column (30.0 m × 
0.25 mm, 0.25 µm film thickness; SGE, Ringwood, VIC, Australia) was used. GC-
MS analysis was fully described in Chapter 3, Section 2.4. 
2.8. Calculation of reaction product yield by GC-FID 
The yield of the sfLOX-catalysed TL reaction was estimated through monitoring the 
consumption of linoleate from the starting material, TL, by GC-FID [217]. An 
Agilent Technologies 6890N Network GC system with flame ionisation detector and 
an SGE BPX70 column (30 m × 0.25 mm, 0.25 µm film thickness) were used. 
Injection volume was 1 µL, helium carrier gas, flow rate 1.5 mL/min (average 
velocity of 38 cm/second) with an inlet temperature of 250°C and a split ratio of 
50:1. Initial oven temperature was 140°C held for 5 min increased to 220°C at a rate 
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of 4°C/min and held for 5 min. Samples were converted to fatty acid methyl esters 
(FAMEs) prior to analysis. Approximately 2 mg of sfLOX-catalysed TL reaction 
products from 10 mL optimised reaction, 2 mg TL or 4 mg TAGs extracted from 
25 mg SBF suspension were dissolved in 1 mL toluene. 200 µL methyl tricosanoate 
(5 mg/mL toluene) as internal standard and 200 µL BHT (1 mg/mL toluene) as 
antioxidant were added. 2 mL of acidic methanol reagent (10% v/v acetyl chloride 
was added dropwise into methanol put on ice and stirred for at least 1 hour) was 
added and kept overnight in a stoppered test tube in an oven at 50°C. After the 
solution was cooled down, 5 mL of sodium chloride solution (5% w/v in water) was 
added. Heptane (2 × 5 mL) was used to extract the methyl ester products from the 
mixture. The combined heptane layers were washed with 5 mL potassium 
bicarbonate (2% w/v in water) and dried over sodium sulphate before evaporation of 
the solvent under a stream of nitrogen or under vacuum. All samples were performed 
in duplicate and the experiment was repeated. 
2.9. Product structure identification by NMR spectroscopy  
1D 1H-NMR, 13C-NMR and 2D 1H, 1H-COSY-NMR experiments were conducted on 
an Advance 500 MHz high resolution NMR spectrometer (Bruker) at 10°C unless 
otherwise stated. The 10 mL sfLOX-catalysed TL reaction under the final optimised 
conditions (see Section 2.2 above) were scaled up 20 times for the large-scale 
synthesis of TL hydroperoxides. The reaction products were purified using NP-
HPLC as described in Chapter 6 (see Section 2.3). Purified products (~ 10 – 30 mg) 
were dissolved in 600 µL deuterated chloroform and transferred to an NMR tube. For 
1H NMR, 8 – 16 scans were accumulated and the residual chloroform peak was used 
as a reference (7.26 ppm) for all chemical shifts. The residual chloroform peak was 
also used as a reference (77.36 ppm) for 13C NMR for all chemical shifts, and 
~15,000 scans were accumulated over ~ 20 hours. 
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2.10. Calculation of reaction product yield by iodometric titration 
A modified iodometric titration method for peroxide value [218, 219] was also used 
to determine the yield of the final optimised sfLOX-catalysed TL reaction. The 
reaction products (2 mg) after solvent evaporation were dissolved in 6 mL 
chloroform:acetic acid (2:3) and transferred to 50 mL conical flask. 100 µL of 
freshly prepared saturated potassium iodide (KI) solution was added with mixing and 
left for 1 min. 6 mL water was added into the yellow mixture and samples were 
titrated using sodium thiosulfate (Na2S2O3, 0.001 N) with vigorous stirring. 100 µL 
starch solution 0.5% (w/v) as an endpoint indicator was added when the yellow 
colour had almost disappeared, turning the mixture dark blue. The titration was 
continued until the colour fully disappeared. Na2S2O3 volume was used to calculate 
the amount of hydroperoxide in samples. Titrations of sfLOX-catalysed TL reaction 
product samples were conducted in triplicate. Hydroperoxides in blank SBF and 
blank TL samples were also identified as controls.  
The reaction mechanism is described below 
ROOH + 2H+ + 2I-  ROH + H2O + I2 (iodine) 
I2 + 2Na2S2O3  Na2S4O6 + 2NaI 
I2 + I-  I3- (triiodide and starch give the solution a dark blue colour) 
The number of moles of hydroperoxide present is equivalent to half the number of 
moles of Na2S2O3 required for the titration, which was calculated from the titration 
volume and the known concentration. The yield of hydroperoxide groups added 
during the sfLOX-catalysed TL reaction was calculated by comparing the moles of 





3.1. Optimisation of sfLOX-catalysed TL reaction conditions for 
maximum product formation 
Luquet et al. used crude SBF suspended in water as a type-2 LOX source to react 
directly with pure TL, without any purification to produce oxygenated products. The 
result showed that SBF had significantly higher activity than commercial sLOX-1 in 
oxygenating pure TL in the absence of solvent, but did not do any product 
characterisation [56]. Purified germinating barley LOX-2 was demonstrated to 
oxygenate TL at a substantially higher rate than barley LOX-1. TL was prepared as 
an emulsion in tris-HCl buffer pH 7.5 containing 15% w/v gum arabic by a sonifier 
with ultra tip (100 W). Three groups of products were detected by RP-HPLC through 
absorbance at 234 nm but characterisation of product regio- and stereo-specificity 
was not obtained [92]. The products contained 1 to 3 hydroperoxy groups, with each 
hydroperoxy group on a linoleate moiety of TL. They were mono-hydroperoxy TL 
(TL-OOH), di-hydroperoxy TL (TL-2OOH) and tri-hydroperoxy TL (TL-3OOH, 
Figure 4.1).  
 
Figure 4.1: Chemical structure of TL-3OOH from sfLOX-catalysed TL reaction. R: 13-hydroperoxy 
linoleoyl group (as shown in the structure for the first acyl moiety) 
Based on these references and the sfLOX and DHA work in Chapter 3, the initial 












substrate for sfLOX-catalysed TAG reaction), 25 µL SBF suspension (1 g SBF in 
20 mL water), 10 mL buffer, ambient temperature, no surfactant, 15 min reaction 
time. Product formation was monitored by RP-HPLC DAD through absorption at 
234 nm, corresponding to the formation of conjugated double bonds. The three 
groups of TL hydroperoxides eluted from highest to lowest polarity on a reverse 
phase C8 column. Their elution order and maximum absorption were matched to the 
reaction products from TL emulsion and germinating barley LOX-2 reaction 
previously analysed under similar RP-HPLC conditions [92]. The compounds were 
expected to be TL-3OOH (highest polarity), TL-2OOH and TL-OOH (lowest 
polarity), eluting at approximately 6.5, 11 and 16.5 min respectively (Figure 4.2).  
 
Figure 4.2: RP-HPLC chromatogram of sfLOX-catalysed TL reaction products at these reaction 
conditions – 10 mL citrate buffer (50 mM, pH 5), 200 µL TL emulsion, 500 µL SBF suspension, 
ambient temperature, 15 min reaction time. 
3.1.1. Effect of buffer type, pH and soybean flour suspension volume on product 
formation 
Different buffer types (citrate, phosphate and borate) were tested in the pH range 3 – 
11 with increasing SBF suspension volume (25 – 400 µL) to obtain the optimum pH 


























borate buffers were used. Citrate buffer (studied range: 3 – 6) showed that the 
optimum pH was at pH 4.5 – 5. TL-3OOH, TL-2OOH and total products increased 
with increasing pH from 3 – 5, reached a maximum at pH 5 and decreased up to pH 
6, whereas TL-OOH formation was maximised at pH 4.5 (Figure 4.3). The optimum 
pH for the sfLOX-catalysed TL reaction was found to be pH 5 citrate buffer, based 
on the maximum product formation of TL-3OOH and total products.  
For the following HPLC results (15 µL injection), a peak area of 9,500 corresponds 
to ~ 0.02 mg/mL or 0.021 mM TL-3OOH, and a peak area of 4,500 corresponds to ~ 
0.02 mg/mL or 0.023 mM TL in the 10 mL reaction. 
 
Figure 4.3: Effect of pH (3 – 6) on sfLOX-catalysed TL reaction under the conditions: 100 µL TL 
emulsion, 200 µL SBF suspension, 10 mL citrate buffer (50 mM), ambient temperature, 15 min 
reaction time. The results from a single experiment represent pH effect on product formation. 
SBF suspension volume was optimised in a larger range (25 – 1500 µL) using the 
optimum pH 5 citrate buffer. From 25 to 100 µL, product formation changed 
significantly. TL-3OOH and TL-2OOH increased ~ 3 and 1.5 times respectively, 
whereas TL-OOH decreased ~ 25%. At higher SBF suspension volume (> 100 µL), 




















optimum SBF suspension volume to obtain the maximum amount of TL-3OOH, 
although total products were slightly lower due to the decrease of TL-2OOH and TL-
OOH. SBF is an inexpensive LOX source so using a high amount of SBF in the 
reaction is not an economic issue. 
 
Figure 4.4: Effect of SBF suspension volume (25 – 1000 µL) on sfLOX-catalysed TL reaction under 
the conditions: 100 µL TL emulsion, 10 mL citrate buffer (50 mM, pH 5), ambient temperature, 
15 min reaction time. The results from a single experiment represent SBF suspension volume effect 
on product formation. 
3.1.2. Effect of trilinolein emulsion volume on product formation 
TL emulsion volume was optimised in the range 100 – 1000 µL, using 500 µL SBF 
suspension, 10 mL citrate buffer (50 mM, pH 5), 15 min reaction time. Total product 
formation increased significantly (~ 2 – 7 fold) with increasing TL emulsion volume 
in the studied range from 100 to 500 µL, except that TL-3OOH stayed constant from 
200 to 500 µL (Figure 4.5A). At higher TL emulsion volume (> 500 µL), no 
significant change in total products was observed (results not shown). The catalytic 
efficiency of sfLOX in forming TL hydroperoxides was measured by considering 





















Figure 4.5: Effect of TL emulsion volume (100 – 500 µL) on sfLOX-catalysed TL reaction under the 
conditions: 500 µL SBF suspension, 10 mL citrate buffer (50 mM, pH 5), ambient temperature, 
15 min reaction time. A) Peak area, B) Peak area per mg TL versus TL emulsion volume. The results 
from a single experiment represent TL emulsion volume effect on product formation. 
100 µL TL emulsion (10 mg/mL) was equal to 1 mg TL in the 10 mL reaction. The 
sfLOX catalytic efficiency for total product formation reached the maximum at 2 mg, 
and decreased significantly at higher TL amounts (> 2 mg). The optimum TL 
emulsion volume for the sfLOX-catalysed TL reaction was found to be 200 µL (2 mg 
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optimised TL emulsion volume, SBF suspension volume was re-optimised in the 
range of 400 to 1000 µL. SBF suspension volume did not affect product formation 
significantly. Therefore, 500 µL was kept for further optimisation. 
3.1.3. Effect of reaction time on product formation 
In order to monitor the time course of the reaction, a 100 mL reaction (10 times the 
normal 10 mL reaction volume) was conducted and aliquots (10 mL) of reaction 
mixture were taken at specific time points (1 – 75 min) after the reaction was 
initiated. All product types formed quickly in the first minute of the reaction. TL-
OOH concentration reached a maximum at 1 to 5 min, which was much faster than 
maximums for TL-2OOH and TL-3OOH were reached. It took 15 min to reach 
maximum TL-2OOH levels, while TL-3OOH concentration was maximised between 
30 and 60 min. All product formation tended to decrease after 60 min (Figure 4.6). 
The substrate TL decreased significantly from 1 to 30 min and then decreased very 
little up to 75 min, which matched with the increase of TL-3OOH and the conversion 
of TL-OOH into TL-2OOH and TL-2OOH into TL-3OOH. The optimum reaction 





Figure 4.6: Product formation over time (1 – 75 min) in the sfLOX-catalysed TL reaction under the 
conditions: 200 µL TL emulsion, 500 µL SBF suspension, 10 mL citrate buffer (50 mM, pH 5), 
ambient temperature. The results from a single experiment represent reaction time effect on product 
formation. 
3.1.4. Effect of oxygenation on product formation 
The following sfLOX-catalysed TL reaction conditions were used to optimise 
oxygen concentration in buffer: 200 µL TL emulsion, 500 µL SBF suspension, 
10 mL citrate buffer (50 mM, pH 5) and 45 min reaction time. Oxygen concentration 
in the 10 mL buffer was varied from a maximum of 35 mg/L to a minimum of close 
to 0 mg/L by sparging the buffer with oxygen, air or nitrogen until saturation 
(approximately 5 min) or leaving untreated before the reaction was initiated. During 
the reaction time, the nitrogen-saturated reaction was sealed in order to maintain low 
oxygen concentration. Oxygen is a critical component of the LOX reaction to form 
FA hydroperoxide products. Unexpectedly, the sfLOX-catalysed TL reaction was not 
affected significantly by oxygen concentration. Under low oxygen conditions (buffer 
saturated with nitrogen), product formation did not decrease substantially (Figure 
4.7). Further experiments were conducted to make sure no oxygen was remaining in 















TL-3OOH TL-2OOH TL-OOH TL
136 
 
continuously sparged with nitrogen gas during the reaction time to maintain an 
oxygen concentration at 0 mg/L (confirmed by dissolved oxygen meter). There was 
almost no product formation in the total absence of oxygen (results not shown). In 
the literature, products such as dimers and oxo compounds have been reported under 
anaerobic conditions [220]. However, there were no new products formed at nitrogen 
saturated conditions (low oxygen concentration and 0 mg/L oxygen). The reason for 
the high amount of product formation at low oxygen concentration is unclear. As 
there was no significant difference in product yield, no gas sparging was used in 
further experiments.  
 
Figure 4.7: Effect of buffer oxygenation on the sfLOX-catalysed TL reaction under the conditions: 
200 µL TL emulsion, 500 µL SBF suspension, 10 mL citrate buffer (50 mM, pH 5), ambient 
temperature. The results from a single experiment represent oxygenation effect on product formation. 
Under the above reaction conditions with buffers either at low oxygen concentration 
(nitrogen sparged condition) or sufficient oxygen (untreated condition, control), the 
reaction was investigated using various substrate preparations to search for the 
source of oxygen in the nitrogen sparged reaction conditions. TL in solvent with or 




















were tested. Oxygen is an essential substrate for oxygenation of PUFAs catalysed by 
LOXs, therefore product formation depends on oxygen concentration. When a 
decrease in product formation was observed with a decrease in oxygen concentration, 
this observation was referred to as ‘having an oxygen effect’. In contrast, when 
product formation did not change when oxygen concentration was decreased, ‘no 
oxygen effect’ was observed. For both gum arabic concentrations (0 and 15% w/v), 
emulsions were formed by sonication, but the emulsion in the absence of the 
emulsifier was significantly less stable than the one with 15% gum arabic. There was 
no oxygen effect with TL emulsions containing 0 or 15% w/v gum arabic. However, 
oxygen effect was observed when TL was prepared in solvent (acetone:ethanol = 
1:1), with or without sonication, instead of as a TL emulsion. TL in solvent with 
sonication cannot form an emulsion. As a result, sonication of aqueous solution to 
make the TL emulsions may contribute to the elimination of the oxygen effect.  
3.1.5. Effect of temperature on product formation 
The sfLOX-catalysed TL reaction was optimised in the temperature range 0 – 40°C 
using the following conditions: 200 µL TL emulsion, 500 µL SBF suspension, 
10 mL citrate buffer (50 mM, pH 5), 45 min reaction time, and buffer without gas 
sparging. The 0°C reaction was conducted on ice, the 10°C reaction was kept in an 
ice water bath with temperature monitored by a thermometer, and the 30°C and 40°C 
reactions were heated in a water bath on a heating plate. In the temperature range 
studied, TL-3OOH formation was found to be affected dramatically, whereas TL-
2OOH and TL-OOH were less affected by temperature. TL-3OOH increased rapidly 
from 0°C to a maximum at 20 – 23°C (ambient temperature), an increase of 
approximately 2.5 times compared to 0°C, and then decreased significantly up to 
40°C (Figure 4.8). The optimum temperature for TL-3OOH and total product 




Figure 4.8: Effect of temperature (0 – 40°C) on the sfLOX-catalysed TL reaction under the 
conditions: 200 µL TL emulsion, 500 µL SBF suspension, 10 mL citrate buffer (50 mM, pH 5). The 
results from a single experiment represent temperature effect on product formation. 
3.1.6. Effect of antioxidant, BHT on product formation 
The sfLOX-catalysed TL reaction at the above conditions (200 µL TL emulsion, 
500 µL SBF suspension, 10 mL citrate buffer (50 mM, pH 5), 45 min reaction time, 
without oxygenation, and ambient temperature) was optimised in the presence of 
antioxidant, BHT (0 – 0.2 mg/mL ethanol). BHT (and some other antioxidants) are 
funtional as antioxidants at very low concentrations (≤ 0.01% w/w), but they may 
exhibit pro-oxidant behaviours such as oxidation initiation at higher concentrations 
[221, 222]. Pro-oxidation could promote non-specific oxygenation of substrates to 
form a range of undesirable products. However, BHT at optimised concentrations 
was reported to stimulate LOX reactions [223]. It is therefore of interest to 
investigate the effect of BHT effect on product formation in the sfLOX-catalysed TL 
reaction. 
In this work, TL-3OOH and TL-2OOH formation increased significantly with 
increasing BHT concentrations and reached maxima at 0.05 mg/mL (× 4.3) and 
0.025 mg/mL (× 2.0), respectively. TL-OOH formation was not affected by BHT 



















concentrations (> 0.05 mg/mL), whereas TL-2OOH stayed relatively constant after 
reaching the optimum at 0.025 mg/mL (Figure 4.9). BHT in the studied range did not 
show an inhibition effect on the reaction. 0.05 mg/mL was found to be the optimum 
BHT concentration for the maximum yield of sfLOX-catalysed TL reaction. 
For the following HPLC results (5 µL injection), a peak area of 16,000 corresponds 
to ~ 0.1 mg/mL or 0.1 mM TL-3OOH, and a peak area of 7,000 corresponds to ~ 0.1 
mg/mL or 0.11 mM TL in the 10 mL reaction. 
 
Figure 4.9: Effect of BHT concentration (0 – 0.2 mg/mL) on the sfLOX-catalysed TL reaction under 
the conditions: 200 µL TL emulsion, 500 µL SBF suspension, 10 mL citrate buffer (50 mM, pH 5). 
Due to the high concentrations of products, 5 µL injection was used for HPLC analysis instead of 
15 µL as normal. The results from a single experiment represent BHT effect on product formation. 
3.1.7. Final optimised conditions for maximum product formation 
The final optimised conditions were found to be: 500 µL SBF suspension, 200 µL 
TL emulsion, citrate buffer (50 mM, pH 5), BHT (0.05 mg/mL), ambient 
temperature, 45 min reaction time. Under the final optimised conditions, TL-3OOH 
and TL-2OOH yields were increased substantially (approximately 50 and 10 times 



















yields achieved under the initial conditions. The reproducibility of the optimised 
sfLOX-catalysed TL reaction was tested by repeating the reaction five times on the 
same day. The results were reproducible with relative standard deviation lower than 
5%.  
As it was previously observed, that the removal of oxygen from the reaction buffer 
did not affect product formation (Section 3.1.4 above), the final optimised reaction 
was also tested under nitrogen sparged buffer conditions. As was seen previously, 
there was no change in product formation regardless of changing oxygen 
concentration. Again, when TL substrate was prepared in solvent (instead of an 
emulsion), product formation was decreased under nitrogen sparged conditions (by 
approximately 50%) compared to atmospheric conditions (no gas sparging). This 
confirmed that the oxygen effect was diminished when TL in buffer was sonicated to 
make emulsion, whereas the oxygen effect remained when TL was prepared in 
solvent. 
3.2. Preparation for product characterisation 
The products obtained from the optimised sfLOX-catalysed TL reaction were 
derivatised to enable characterisation. TL hydroperoxides were reduced with sodium 
borohydride (NaBH4) into TL hydroxides and then hydrolysed to form hydroxy-
linoleic acid. This allowed the regio- and stereo-specificity of hydroxy groups on 
linoleate moieties to be identified. The chemical structures of purified TL-3OOH, 
TL-2OOH and TL-OOH were determined directly without derivatisation by NMR.  
3.2.1. Reducing TL hydroperoxides 
TL hydroperoxides formed in the LOX reaction were unable to be reduced directly in 
10 mL buffer with NaBH4, as was used for sfLOX-catalysed DHA reaction products 
(Chapter 3). TL hydroperoxides (after extraction) were reduced into TL hydroxides 
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by NaBH4 in the presence of methanol. The initial reducing conditions were 200 µL 
NaBH4 (1 M), extracted TL hydroperoxides, 1 mL methanol and 15 min reaction 
time. The reduced products (hydroxy TL) were less polar so they eluted after the 
corresponding TL hydroperoxides. Under the initial conditions, TL hydroperoxides 
were not completely converted into TL hydroxides. In addition, an unknown peak 
appeared at approximately 3 min and absorbed at λmax = 232 – 234 nm. This may be 
a product from an undesirable side reaction. The reaction was optimised with the 
following variables (extra water volume, NaBH4 preparation and reaction time) to 
maximise hydroxy TL and minimise the unknown compound. As TL-3OOH was the 
major product of the sfLOX-catalysed TL reaction, TL-3OOH and TL-3OH were 
reported in the reduction results below to represent TL hydroperoxides and TL 
hydroxides. 
Effect of water volume 
Different water volumes (200 – 800 µL) were added before initiating the reaction by 
adding 200 µL NaBH4 (1 M in water) into 1 mL methanol containing TL 
hydroperoxides. The major product formation fell dramatically when 200 µL water 
was added and continued to decline to zero when more water was used (Figure 4.10). 
The unknown product also decreased significantly to almost zero with increasing 
water volume. Adding water suppressed the conversion of TL hydroperoxides into 




Figure 4.10: Effect of extra water (200 – 800 µL) on reducing sfLOX-catalysed TL reaction products 
(n-2). 
Effect of NaBH4 preparation  
NaBH4 volume was optimised in the range below 200 µL, because higher water 
volumes decreased TL hydroxide formation (see above). A 1 M NaBH4 stock 
solution was used and 100 µL NaBH4 was the optimum value for TL hydroperoxide 
conversion into TL hydroxides. TL hydroxides were formed at a high amount; 
however, the unknown product was also present at a high amount (Figure 4.11). 
 







































The reducing reaction was optimised with different NaBH4 concentrations and 
volumes corresponding to the same NaBH4 amount in the reaction (~ 8 mg) (Table 
4.4). The conversion of TL hydroperoxides into TL hydroxides was maximised with 
50 µL NaBH4 4M. However, the unknown product appeared at all conditions (Figure 
4.12). 












Figure 4.12: Effect of NaBH4 volume and concentration on reducing sfLOX-catalysed TL reaction 
products (n-2). 
Effect of reaction time  
The time of the reducing reaction was optimised in the range 1 – 45 min. 
Surprisingly, the optimum TL hydroxide amount was obtained after 1 min (Figure 
4.13), which was opposite to the expected late full conversion. TL hydroxide yield 






















detected at 1 min. The unknown product kept increasing over time before being 
unchanged at 30 min (results not shown). The optimum reaction time for reducing 
sfLOX-catalysed TL products was identified to be at 1 min.  
 
Figure 4.13: Effect of reaction time (1 – 15 min) on the reduction of sfLOX-catalysed TL reaction 
products (n-2). 
Final optimised reduction conditions 
The final optimised conditions for the reduction of sfLOX-catalysed TL reaction 
products were found to be: 1 mL methanol, 200 µL NaBH4 (1 M), 1 min reaction 
time. Under the final optimised conditions, TL hydroperoxides were fully converted 
into TL hydroxides with only a minor trace of the previously mentioned side product 
(Figure 4.14). The reaction under optimised conditions was repeated in triplicate and 






















Figure 4.14: RP-HPLC chromatograms of final optimised sfLOX-catalysed TL reaction products: 
unreduced (TL-3OOH, in blue) and reduced (TL-3OH, in orange). 
 3.2.2. Hydrolysis of hydroxy TL 
Hydrolysis is needed before product characterisation by GC-MS and chiral HPLC as 
the free fatty acids are required for GC-MS analysis (after further derivatisation) and 
only free hydroxy fatty acids are available as standards for chiral HPLC. The reduced 
sfLOX-catalysed TL reaction products at the final optimised conditions were fully 
hydrolysed into hydroxy linoleic acid (HLA) with reproducible results (three 
replicates, %RSD < 5%) without detecting any remaining TL or TAGs from SBF. 
The product was analysed by RP-HPLC and was consistent with HLA produced 
from the sfLOX-catalysed LA reaction (0.1 mM LA, 50 µL SBF extract, 10 mL 
borate buffer (50 mM, pH 9), 15 min reaction time). Direct hydrolysis of TL 
hydroperoxides (without prior reduction into TL hydroxides) was also tested. The 
peak area of HLA after hydrolysis with or without reducing were quite similar ~ 2% 
difference (three replicates, %RSD < 5%). Going forward, hydrolysis without prior 




























3.3. Product characterisation 
3.3.1. Determination of hydroxy group positions on reaction products by GC-
MS 
The final optimised sfLOX-catalysed TL reaction products were completely reduced 
and hydrolysed into hydroxy linoleic acid (HLA) before fully hydrogenating and 
trimethylsilylating into derivatives for GC-MS analysis. The hydrogenated and 
trimethylsilylated (TMS) derivatives are more volatile and thermally stable, and 
therefore more suitable for GC analysis. The positions of the hydroxy groups on the 
LA moieties of TL were identified by interpretation of fragmentation patterns of their 
derivatives. Two fully resolved mono-HLAs (429 m/z precursor ion) eluted at 
approximately 20 min, and the important fragments of these compounds are reported 
in Table 4.5. Based on the fragmentation patterns, they were identified as fully 
hydrogenated, TMS derivatives of 13-HLA (Figure 4.15) and 9-HLA. The mono-
HLAs were comprised of 90% 13-HLA in percentage of peak area. The results 
confirmed the presence of 13-HLA as the major product of the reaction.  
Table 4.5: Important m/z fragments of 9-HLA and 13-HLA from sfLOX-catalysed TL reaction under 





Important m/z fragments 
20.88 9-HLA               73, 229, 317, 413, 429 




Figure 4.15: Structure showing assignment of important fragments from the mass spectrum of fully 
hydrogenated di-TMS-13-HLA. 
3.3.2. Determination of stereochemistry of reaction products by chiral HPLC 
The sfLOX-catalysed TL reaction products at the final optimised conditions were 
reduced and hydrolysed completely before analysing with chiral HPLC to determine 
the chirality of the hydroxy group on HLA. The reduced products from the sfLOX-
catalysed LA reaction at pH 9 (0.1 mM LA, 50 µL SBF extract), with 13S-HLA as 
the major product, were used as a standard for comparison. HLAs from the sfLOX-
catalysed TL reaction were stereo-specifically identified by matching their retention 
time with HLAs from sfLOX-catalysed LA reaction (Figure 4.16). The results 
showed that the products were approximately 90% 13-HLA and 10% 9-HLA which 
matched with the GC-MS results. Approximately 99% of 13-HLA was identified to 
be 13S-HLA and only ~ 1% was 13R-HLA (Figure 4.16). The chirality of 9-HLA 




































Figure 4.16: Chiral HPLC chromatogram of 13S-HLA from sfLOX-catalysed TL reaction (sfLOX-
TL) and sfLOX-catalysed LA reaction (sfLOX-LA). 
3.3.3. Chemical structure identification of reaction products by NMR 
spectroscopy 
1H NMR 
TL-3OOH, purified using preparative HPLC, was characterised and its chemical 
structure determined using both one and two dimensional NMR spectroscopy 
experiments (1D 1H-NMR and 2D 1H,1H-COSY NMR). Pure TL was used as a 
reference for comparison with TL-3OOH. As described below, the major differences 
were from the formation of hydroperoxy groups and changes in the double bond 
systems. This resulted in the presence of new peaks and the decrease or 
disappearance of several peaks. 1H-NMR data for both TL and TL-3OOH are 
































Table 4.6: 1H-NMR data for TL. 
 
Table 4.7: 1H-NMR data for TL-3OOH. 
a Multiplicity of proton at C2 in both TL and TL-3OOH appeared as offset triplets most likely due to 
separation of sn-1,3 and sn-2 positional signals. b Integration for the signal at 1.30 ppm (protons at C4-
7 and C16-17) in TL-3OOH was approximately 49H, which was higher than expected, probably due 
to difficulty in integrating this large number of hydrogens, although there may also be some overlap 
with solvent peaks.  
The 1H NMR spectrum of TL had signals in the region between 0.5 and 5.5 ppm. In 
comparison with the spectra of TL, TL-3OOH had a new signal at chemical shift 
~ 8.0 ppm due to the hydroperoxy group, -OOH. The olefinic proton signals (C9 – 
Carbon 1H (ppm) Multiplicity Integration J (Hz) 
1     
2 2.31 ma 6H 7.5/7.7 and 7.4/7.8 
3 1.61 m 6H  
4 – 7  1.30 m 24H  
8 2.04 q  6H 6.9 
9 - 10 5.28 – 5.42 m 6H  
11 2.76 t 6H 6.6 
12 - 13 5.28 – 5.42 m 6H  
14 2.04 q  6H 6.9 
15 – 17  1.30 m 18H  
18 0.88 t 9H 6.8/7.1 
Glycerol-CH 5.27 m 1H  
Glycerol-CH2 4.15 – 4.29 dd, dd 4H 6.0/11.9 and 4.3/11.9 
Carbon 1H (ppm) Multiplicity Integration J (Hz) 
1     
2 2.31 ma 6H 7.6/7.4 and 7.6 
3 1.61 m 6H  
4 – 7  1.30 m 24Hb  
8 2.18 m 6H  
9 5.46 – 5.51 dt 3H 7.8/10.6 
10 5.98 – 6.03 t 3H 11.0 
11 6.54 – 6.59 dd 3H 11.2/15.2 
12 5.53 – 5.58 dd 3H 8.4/15.2 
13 4.35 – 4.39 q 3H 5.4 
14 1.61 m 6H  
15 1.41 – 1.50 m 6H  
16 – 17  1.30 m 12Hb  
18 0.88 t 9H 6.8/7.1  
-OOH 8.02 s 3H  
Glycerol-CH 5.27 m 1H  
Glycerol-CH2 4.15 – 4.29 dd, dd 4H 6.0/11.9 and 4.3/11.9 
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C12) in TL-3OOH shifted downfield from ~ 5.3 ppm in TL to 5.4 – 7 ppm in TL-
3OOH (Figure 4.17). These chemical shift changes are consistent with the presence 
of both a hydroperoxy group and a new conjugated diene in each linoleate moiety of 
TL-3OOH. The C13 proton was shifted upfield significantly from ~ 5.3 in TL to 
4.4 ppm in TL-3OOH as C13 changed from an olefinic to an allylic proton (Figure 
4.17).   
 
Figure 4.17: Partial 1D 1H-NMR spectra of TL-3OOH (blue trace) and of TL (red trace) overlaid, 
measured in deuterated chloroform at 500 MHz (10°C) with chemical shift approximately from 4 to 
8 ppm. The full spectra are included in the Appendix. 
Diallylic methylene protons at C11 (-CH=CH-CH2-CH=CH-) and allylic methylene 
protons at C8 and 14 (=CH-CH2-) in the 1H NMR spectrum of TL are shifted 
significantly in the 1H NMR spectrum of TL-3OOH. Diallylic methylene protons at 
C11 (6H, peak at ~ 2.8 ppm) in TL are present as olefinic protons (3H, -CH=) at 
~ 6.6 ppm in the spectrum of TL-3OOH. The three remaining diallylic methylene 
protons in TL are present as hydroperoxy groups (–OOH) at ~ 8.0 ppm. The 
chemical shift of allylic methylene protons C8 and C14 (12H, peak at ~ 2 ppm) in TL 
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was shifted to 2.2 ppm (6H, C8) and 1.6 ppm (6H, C14) in TL-3OOH, respectively. 
Other changes are also consistent with the new structure (Tables 4.6 and 4.7). 
In TL-3OOH, the coupling constant of the C9,10 protons was ~ 11.0 Hz, whereas the 
C11,12 proton coupling constant was ~ 15.2 Hz. The values of less than 14.0 Hz 
showed olefinic protons at C9 and C10 were cis, whereas C11 and C12 olefinic 
protons were trans. The absence of chemical shift at ~ 6.2 ppm indicated the absence 
of an E,E conjugated diene in TL-3OOH (Table 4.7) [43]. These results indicate that 
the conjugated double bonds between C9 and C12 have a Z,E configuration, which is 
in agreement with the conjugated double bond system formed by LOX catalysis. The 
glycerol protons were unchanged in TL-3OOH, as compared to TL (Tables 4.6 and 
4.7), indicating that sfLOX-catalysed TL without fatty acid hydrolysis. The structure 
of TL-3OOH was identified to have a glycerol backbone with three linoleate 
moieties containing a hydroperoxy group at C13 and conjugated Z,E double bonds 
between C9 and C12 in each moiety. 2D 1H,1H-COSY NMR couplings between 
neighbouring proton signals were consistent with the assigned structure. These 
findings confirmed GC-MS results of selective oxygenation at C13. The structure of 
TL-2OOH and TL-OOH was also elucidated in the same manner with TL-3OOH. 
Shifting of signals and correlation of neighbouring protons in TL-2OOH and TL-
OOH were a combination between TL-3OOH and TL spectra. TL-OOH was 
confirmed to have a hydroperoxide group and a conjugated diene in one linoleate 
moiety. Two hydroperoxide groups and two conjugated dienes were determined in 
two linoleate moieties in TL-2OOH. The NMR spectra of these two compounds are 
included in the Appendix.  
13C-NMR 
The 13C-NMR signals for fatty acid carboxylate groups (in the region 170 – 
175 ppm) are characteristic for both the type of fatty acid and their positional 
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distribution at either the sn-1,3 or sn-2 within a TAG compound. The ratio between 
the signals of carboxylate carbons for a specific fatty acid at the sn-1,3 and sn-2 
positions in the 13C-NMR spectrum can be used to quantify the sn-1,3 to sn-2 ratio of 
the fatty acid. In TL, the sn-2 carboxylate carbon was at ~ 173.0 ppm while the sn-
1,3 carboxylate carbons were at ~ 173.5 ppm (Figure 4.18A). As expected, the sn-1,3 
to sn-2 ratio was identified to be approximately 2:1 based on integration. In the 
mixture of sfLOX-catalysed TL reaction products containing TL-OOH, TL-2OOH 
and TL-3OOH, the results showed that the chemical shifts of carboxylate carbons 
have moved downfield ~ 0.1 – 0.2 ppm and each carboxylate carbon peak (sn-1,3 
and sn-2) is split into 4 peaks, compared to one each in pure TL, illustrating the 
complexity of the mixture (Figure 4.18B).  
Purified TL-3OOH showed a single peak for sn-1,3 and another for sn-2 (sn-1,3 to 
sn-2 ratio = 2:1), consistent with each of the three fatty acids present having a 
peroxide present. However, carboxylate groups in TL-OOH and TL-2OOH spectra 
showed complex patterns with more than two signals, consistent with only some fatty 
acids being peroxylated, so that fatty acid carbonyl signals appear at different 
chemical shifts (see Appendix). As a result, for these two compounds the positions of 
hydroperoxy linoleate moieties on the glycerol backbone were not determined, so the 





                   
Figure 4.18: Partial 13C-NMR spectra measured in deuterated chloroform at 500 MHz (room 
temperature) of A) TL and B) mixture of sfLOX-catalysed TL reaction products, between 172 – 174 
ppm. 
3.4. Calculation of reaction yield using multiple analytical techniques 
Concurrent experiments using tuna oil (Chapter 5) demonstrated that the number of 
sonication pulses used in emulsion formation affected the properties of the emulsion, 
including stability and droplet size, which in turn affected the lipoxygenase-catalysed 
reactions. This resulted in emulsions being prepared with 20 sonication pulses 
(instead of 10 pulses) from this point forward, and in an approximate 30% increase in 
TL-3OOH and a corresponding 30% decrease in TL-OOH, from the sfLOX-
catalysed TL reaction. Further details are described in Chapter 5. Now using the new 
emulsion preparation, the reaction yield of the final optimised sfLOX-catalysed TL 
reaction was determined by a range of analytical techniques: RP-HPLC, GC-FID and 
iodometric titration.  
3.4.1. RP-HPLC 
TL-3OOH formation 
TL-3OOH was purified from the final optimised sfLOX-catalysed TL reaction 








1 mL mobile phase was used to establish a calibration curve using RP-HPLC (Figure 
4.21). Due to the limited amount of pure compound, the calibration curve was 
established by injecting increasing amounts (1 – 10 µL) of the purified TL-3OOH 
sample (0.98 mg/mL) which was equivalent to TL-3OOH concentrations from ~ 0.2 
to 2.0 mg/mL. The amount of TL-3OOH in the optimised reaction was determined to 
be 1.1 mg/mL from the calibration curve. From this result, at least 47% of the TL 
was determined to have been converted into TL-3OOH.  
 
Figure 4.21: Calibration for TL-3OOH using RP-HPLC. 
TL residues 
A TL calibration curve (Figure 4.22) was established from 0 to 2.0 mg/mL TL. From 
the calibration curve, the amount of TL remaining at the end of the reaction was 
determined to be at least 0.3 mg. This is equivalent to approximately 16% of the 
2 mg of TL starting material remaining unreacted. TL available in the SBF control 





















Figure 4.22: Calibration for TL using RP-HPLC. 
HLA after hydrolysis 
The final optimised sfLOX-catalysed TL reaction products from 200µL TL 
(10 mg/mL) for 10 mL reaction (2 mg, 0.23 mM TL as starting material) were 
hydrolysed and analysed by RP-HPLC. The HLA peak area was compared to the 
peak area of HLA produced from the sfLOX-catalysed LA reaction with 
approximately 100% yield under the following conditions: 0.1 mM LA, 50 µL SBF 
extract, 10 mL borate buffer pH 9 – 50 mM, 15 min reaction time, giving a final 
concentration of 0.1 mM HLA. If TL was converted completely into TL-3OOH, 
approximately 0.68 mM HLA would be present after hydrolysis.  
The HLA peak area from the sfLOX-catalysed TL reaction products after hydrolysis 
was roughly four times higher than the 0.1 mM LA-OH, produced from the sfLOX-
catalysed LA reaction. The formation of approximately 0.40 mM HLA from the 
hydrolysed sfLOX-catalysed TL reaction is equivalent to dioxygenation of at least 
59% of the available linoleic acid moieties in the TL. HLA formed in the SBF only 
reaction (no TL) was not included in the calculation of HLA from the hydrolysed 


















3.4.2. Iodometric titration  
An iodometric titration was performed to determine the total number of hydroperoxy 
groups present after the sfLOX-catalysed TL reaction. Compared to the theoretical 
maximum yield, where all TL is converted into TL-3OOH, it was determined that at 
least 85% of the linoleic acid moieties were dioxygenated. This result was higher 
than the result of HLA identified in the reaction after hydrolysis (~ 60%) but was 
consistent with unreacted TL in the reaction (~ 15%) determined by RP-HPLC.  
The results of 85% linoleic acid moieties in TL being dioxygenated were from using 
emulsions being prepared with 20 sonicator pulses. Emulsions being prepared with 
10 sonicator pulses were tested to compare and only ~ 70% of LA moieties in TL 
were dioxygenated for these emulsions. This seemed to match with the result of 
using TL emulsion being prepared with 20 pulses which showed an increase of ~ 
30% TL-3OOH and a corresponding decrease of ~ 30% TL-OOH. 
3.4.3. GC-FID  
The amount of unreacted LA moieties remaining after the reaction were also 
determined by GC-FID after conversion to methyl esters. Approximately 15% LA 
ME was identified to remain in the final optimised reaction (after subtracting LA ME 
in the blank SBF reaction), compared to the TL (2 mg) starting material. Therefore, 
at least 15% LA moieties in TL remained at the end of the reaction (some TL may 
have been lost during solvent extraction). This means approximately 85% LA 





Lipoxygenase-catalysed reaction optimisation 
The optimum pH of the sfLOX-catalysed DHA reaction at pH 8 was proposed to be a 
compromise between the maximum activities of the three sfLOX isozymes in SBF 
(Chapter 3). This is because all isozymes are able to catalyse free fatty acids. 
However, the optimised pH 5 in this sfLOX-catalysed TL reaction was significantly 
lower than the optimum pH of sfLOX-catalysed DHA reaction. This could result 
from the predominance of type-2 LOX activity as they can oxygenate EFAs more 
effectively than LOX-1 as shown in previous work from different plant LOXs [56, 
92, 184]. In soybean seeds, the optimum pH of type-2 LOX has been found to range 
from acidic to neutral pH with various EFA substrates [122, 131, 174, 175], 
suggesting type-2 LOX in SBF is active to EFAs at pH 5. In consistence with the 
current work, optimum pH between 5 and 7 was reported for the catalysis of SBF or 
SBM as a LOX source on EFAs such as TL, fatty acid esters and TAGs in a number 
of previous studies [61, 111, 131, 224, 225]. Moreover for free fatty acids, the 
optimum pH is high to deprotonate the carboxylic group to obtain the negatively 
charged substrate required for high LOX-1 activity [49]. sfLOX from SBF was also 
found to react with hydrolysed natural oils at high pH 8 – 10 [60, 118, 160]. In 
contrast, TL as an esterified fatty acid cannot be deprotonated, so TL was not 
oxygenated by sfLOX effectively at high pHs but instead had an optimum pH 5 in 
this work. Bild et al. showed that type-2 LOX favoured nonpolar or unionised 
substrates [174].  
As observed in the sfLOX-catalysed DHA reaction, product formation from the 
catalysis of TL by sfLOX initially increased with increasing SBF concentration. At 
high SBF concentration, there was no decrease in product formation in the reaction 
with TL as a substrate even though there was a decrease in the sfLOX-catalysed 
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DHA reaction. TL hydroperoxides may be more stable than DHA hydroperoxides in 
the reaction mixture with high amounts of SBF. In a study by Frei and co-workers, 
TL hydroperoxide was found to be more significantly stable than LA hydroperoxide 
when they were incubated separately in fresh human plasma at 37°C. LA 
hydroperoxide degraded by almost 90% after 45 min, whereas TL hydroperoxide 
was still stable up to 120 min [226]. 
At high TL amounts (> 2 mg), TL-3OOH levels unchanged, whereas TL-2OOH and 
TL-OOH formation remained increased. This could result from insufficient oxygen 
in the reaction to convert all TL to TL-3OOH. No anaerobic reaction products were 
detected at high substrate concentrations or at low oxygen concentrations, as were 
observed in the sfLOX-catalysed DHA reaction. It was also noted that TL 
hydroperoxide formation was not affected significantly when oxygen concentration 
changed. It is likely that oxygen was not limiting in the reaction, so increasing the 
oxygen concentration (buffer saturated with oxygen) did not increase product 
formation. However, at low oxygen concentration (buffer saturated with nitrogen), it 
is unclear why product formation did not decrease. One explanation is that oxygen 
may be trapped inside the substrate-emulsifier micelles in aqueous solution during 
sonication and could be released to be used in the reaction to form hydroxylated 
products. The micelles were possibly only formed in aqueous solution with 
sonication and could not be formed when TL was prepared in solvent, as the 
substrate was fully dissolved. However, this potentially trapped oxygen in the 
micelles was not measured by the dissolved oxygen meter, as the measured oxygen 
concentration of the emulsion and buffer solutions was not significantly different. No 
work has investigated the effect of oxygen deprivation on the type-2 LOX-catalysed 




All sfLOX-catalysed TL reaction products started forming quickly within 1 min, 
indicating there was a simultaneous conversion of TL into TL-OOH, TL-OOH into 
TL-2OOH and TL-2OOH into TL-3OOH. The complete conversion of TL into 
hydroperoxides (45 min) was longer than the DHA conversion into di-hydroxylated 
DHA (20 – 30 min). This could be because the higher concentration of available 
linoleate moieties in the TL reaction, requiring ~ 0.7 mM oxygen, was more than the 
available DHA, requiring 0.4 mM oxygen for maximum conversion, while similar 
concentrations of enzyme were used. TL-OOH formed quickly and then converted 
slowly into TL-2OOH and TL-3OOH. The formation of TL-OOH slowed down over 
time compared to the conversion of TL-OOH into TL-3OOH through TL-2OOH. 
The rate of TL-2OOH formation was lower over time than its conversion rate into 
TL-3OOH until TL-3OOH formation reached a maximum. There was also a decrease 
in products after the reaction reached optimum product formation, consistent with the 
sfLOX-catalysed DHA reaction. 
The dioxygenation of TL by sfLOX was affected by both low and high temperatures 
and had optimum activity at room temperature. The effect of temperature on the 
catalysis of sfLOX on TL to produce TL-3OOH showed the same pattern as the 
sfLOX-catalysed DHA reaction in making 10,17-diHDHA. However, there was no 
significant effect of temperature on TL-OOH and TL-2OOH product synthesis. The 
presence of BHT at low concentrations enhanced product formation significantly. It 
is interesting to note that BHT is an antioxidant, but did not inhibit the dioxygenation 
catalysed by LOX. Different effects of antioxidants have been reported on LOX-
catalysed reactions using various substrates. In one study, tocopherol inhibited 
peanut LOX activity on TL and LA, whereas BHT showed no effect on these 
substrates [206]. Mammalian 15-LOX was found to be stimulated by BHT in 
catalysing the dioxygenation of biomembranes [223]. Especially in soybean seeds, 
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BHT was previously found to increase LOX-2 + LOX-3 activity, whereas no effect 
on LOX-1 activity was observed with LA as a substrate [227]. These findings 
partially support that BHT enhanced type-2 LOX activity on the catalysis of TL in 
the current work. The enhancement may result from the increase of substrate 
accessibility to the enzyme, and the suppression of unspecific oxygenation products 
formed through free radicals [223]. BHT, a lipophilic antioxidant, could largely 
distribute into lipid phase of oil droplets and disturb surfactant interfacial membrane 
structure, so the enzyme may gain better access toward the substrate therefore 
increasing enzyme activity and/or product formation. Moreover, BHT can scavenge 
free radicals, potentially forming over time, which may otherwise degrade reaction 
products. However, the mechanism of BHT enhancement of LOX reactions is 
unknown with futher investigation included in Chapter 5.  
Product characterisation 
The LA moieties in TL were found to be primarily dioxygenated at the 13C position 
after the sfLOX-catalysed reaction. 13-HLA is the major product of the LOX-1 
catalysed LA reaction. Formation of this product is consistent with the mechanism of 
substrate insertion into the catalytic pocket, where the methyl end of the EFA enters 
the active site of the enzyme. This is expected as the large glycerol backbone of 
acylglycerol substrates is unable to enter the active site [49, 108]. Reaction chirality 
was highly stereospecific (~ 99%) as expected, due to enzymatic catalysis and had S 
chirality which is well-known for major compounds produced by soybean LOX 
catalysis. Consistent with the major 13S derivative found in this work, two LOX 
isozymes in soybean leaves were previously found to catalyse the oxidation of TL to 






The sfLOX-catalysed TL reaction was estimated to have a high yield. From the RP-
HPLC results, approximately 85% TL (~ 16% TL remained identified by RP-HPLC 
using standard plot) was consumed to potentially produce TL-OOH, TL-2OOH and 
TL-3OOH and approximately 45% TL was converted into TL-3OOH. Iodometric 
titration indicated that approximately 85% of LA moieties in TL were oxidised, 
which was consistent with GC-FID results showing approximately 15% of LA 
moieties remained unreacted. However, only ~ 60% LA-OH was identified after 
hydrolysis of TL hydroperoxides. Some product yield may have been lost during the 
extra steps of hydrolysis and solvent extraction compared to other methods. Overall, 
the reaction yield was identified to be approximately 60 – 85%.  
5. Conclusion 
This work has demonstrated that SBF is able to catalyse the dioxygenation of TL (as 
a model EFA substrate). The reaction shows the advantage of proceeding directly 
without prior hydrolysis of EFA substrates. The enzyme activity on EFAs has been 
attributed to the presence of stable type-2 LOX in the flour matrix, due to its 
preference for acting on EFAs but being unstable when purified. The preferred 
reaction products are TL hydroperoxides fully dioxygenated at all three linoleate 
moieties while small amounts of mono- and di-hydroperoxy TL are obtained. The 
reaction yield is high (60 – 85%) in the presence of antioxidant BHT which showed a 
significant effect on product formation. It is important that the reaction products 
show highly regio- and stereo-specificity at C13S as it can be useful for potential 
application to the synthesis of nutraceuticals and pharmaceuticals. There is potential 
to apply this method to other EFA substrates and natural oils and then isolate the 



























SOYBEAN FLOUR LIPOXYGENASE CATALYSIS OF 
TUNA OIL AS A COMPLEX LIPID MIXTURE 
1. Introduction 
The fatty acids (FAs) in fish oils, such as those sourced from tuna and anchovy, exist 
primarily as triacylglycerols (TAGs). The TAGs found in these oils contain a range 
of FA types, including saturated FAs (SFAs) and unsaturated FAs (both 
monounsaturated FAs, MUFAs, and polyunsaturated FAs, PUFAs) of varying chain 
lengths. Approximately 30 – 40 % of all FAs in tuna oil are PUFAs (primarily EPA 
and DHA), most of which are located at the sn-2 position in TAGs [31, 228]. This 
distribution of DHA is consistent with other fish oils, whereas the distribution of 
EPA is species dependent [228]. For example, in a study with natural 
anchovy/sardine fish oil, 61.7% of DHA was found predominantly at the sn-2 
position, while 80.9% of EPA was bound at the sn-1,3 positions [229]. The position 
of LC-PUFAs in TAGs at either sn-2 or sn-1,3 may affect dioxygenation catalysed 
by LOX but it is difficult to investigate this due to a lack of available pure substrates. 
PUFA distribution in tuna oil TAGs has been reported previously [230-233]. For 
palmitic acid (P; the major SFA), DHA and EPA (D and E, respectively) – DDP and 
EEP were found to be the predominant PUFA-containing TAG regioisomers, 
compared to DPD and EPE. PDP and PEP were slightly more abundant than, or 
equal to PPD and PPE [232, 233]. The composition of TAG molecular species in a 
mixture of tuna and sardine oil was estimated to consist of ~ 1% TAGs with three 
omega-3 long chain PUFAs (n-3 LC-PUFAs; primarily DHA and/or EPA), ~ 20% 
with two n-3 LC-PUFAs and ~ 35% containing one n-3 LC-PUFA [230]. Similar 
results in another study reported ~ 4% DDD, ~ 20% di-PUFA TAGs and ~ 30% 
mono-PUFA TAGs in tuna oil, with DHA and EPA being the major PUFAs [231]. 
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As a result, not all TAG molecules in tuna oil are able to be dioxygenated by LOX as 
only PUFA-containing TAG molecules are acceptable as substrates in LOX 
reactions. 
n-3 LC-PUFAs are beneficial for human health [27, 234] so it is useful to be able to 
separate them from the other FAs in natural oils, for subsequent use in 
pharmaceutical and nutritional applications. The remaining fraction, composed 
primarily of SFAs and MUFAs, can be used for other applications, such as biodiesel 
production [235, 236]. However, this separation process can be difficult. Current 
methods for making n-3 LC-PUFA concentrated fish oils are lengthy and complex. 
Fish oils rich in n-3 LC-PUFA-containing TAGs are first hydrolysed or ethanolysed 
(either enzymatically or chemically) to obtain free FAs or FA ethyl esters, 
respectively [237, 238]. Then the free n-3 LC-PUFAs (or n-3 LC-PUFA ethyl esters) 
are separated from SFAs and MUFAs by various methods, such as supercritical fluid 
extraction, freezing crystallisation and urea complexation [234, 238]. Finally, free 
n-3 LC-PUFAs (or n-3 LC-PUFA ethyl esters) are esterified or transesterified back 
onto a glycerol backbone to enrich the oil with n-3 LC PUFA, some of which can 
contain up to 90% DHA and EPA [31, 234, 239]. Alternatively, fish oils can be 
selectively hydrolysed by lipases with particular FA and/or positional selectivity to 
obtain n-3 LC-PUFA concentrates [216, 240]. n-3 LC-PUFAs can be concentrated in 
free FA (FFA), ethyl ester or TAG formats. However, it has been reported that n-3 
LC-PUFAs are absorbed most readily in the body as TAGs [241], therefore this form 
is preferred. Selective separation of n-3 LC-PUFAs containing TAGs from natural 
oils, by first adding functional hydro(pero)xy groups using LOX could be very useful 
and much simpler. 
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Type-2 LOX is known to react with esterified FAs more effectively than LOX-1 [88, 
90]. Due to the presence of a stable type-2 LOX in soybean flour, soybean flour LOX 
(sfLOX) can catalyse the dioxygenation of TAGs. The work in Chapter 4 
demonstrated that sfLOX could be used directly to obtain a relatively high reaction 
yield (approximately 60 – 85%) with pure trilinolein (TL) as a simple model TAG 
substrate. Therefore, the use of sfLOX provides a promising approach for catalysing 
the dioxygenation of complex lipid mixtures, such as fish oils, for the synthesis of 
resolvin analogues directly from EPA and DHA-rich TAGs in these oils. However, 
this could be challenging compared to TL as a substrate for a number of reasons, 
such as, varying FA composition, FA chain length and saturation. Therefore, in this 
Chapter, the sfLOX-catalysed reaction with tuna oil is not only optimised for 
maximum product formation as was done in Chapter 4, but also the enzyme activity 
is investigated through monitoring the initial reaction rate under various reaction 
conditions. 
By monitoring the reaction rate it is possible to observe the direct effect of different 
reaction variables on the catalytic ability of the enzyme, not just overall changes in 
reaction yield which may be influenced by a number of opposing factors. Using 
conditions where the catalytic activity of the enzyme is maximised should result in 
high product yield. One specific variable that is of particular importance in LOX 
catalysed reactions with esterified substrates is the preparation of the substrate. TAG 
substrates are commonly prepared as emulsions in the presence of a surfactant or 
emulsifier for LOX reactions [92, 182]. Correct preparation of the substrate ensures 
that it is available to the enzyme. Understanding the emulsion properties (the 
uniformity and droplet size) is of particular importance when employing complex 
lipid mixture such as tuna oil, as it can have a significant effect on the catalytic 
activity of the enzyme, reproducibility of the reaction, and overall reaction yield.  
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Emulsion droplet size has been investigated in a few studies on lipid oxidation and 
LOX reactions. Non-enzymatic oxidation was found to increase with decreasing 
droplet size due to the increase of surface area [242], and with decreasing surfactant 
concentration when having similar droplet size [243]. Activity of a commercial 
soybean LOX-1 was shown to generally increase with increasing surface area of 
emulsion droplets for both linoleic acid and methyl linoleate emulsion systems. In 
this study, droplet surface area was manipulated by changing surfactant 
concentration and through different emulsification processes such as hand mixing or 
rotor-stator blending [244].  
Only a few studies have used SBF LOX to catalyse reactions with natural oils such 
as soybean oil, sunflower oil and butterolein but no product characterisation or 
reaction rate investigations have been reported [56, 61, 111]. Fish oils such as tuna 
oil are a rich source of EPA and DHA-containing TAGs, and so are good potential 
LOX substrates for the synthesis of resolvin analogues in TAG form. In this chapter, 
sfLOX was used to catalyse the reaction with tuna oil to assess the synthesis of 
potential resolvin analogues in a complex TAG substrate. The initial reaction rate 
was investigated under various conditions by monitoring the formation of conjugated 
dienes using a UV-Vis spectrophotometer. Product formation of di- and mono-
hydroperoxy TAGs was then measured using RP-HPLC to optimise the reaction 
yield. The reaction products after hydrolysis were characterised with RP-HPLC and 
GC-MS to identify regio-specificity of the reaction on n-3 and n-6 LC-PUFA 
moieties in tuna oil TAGs. This is the first time soybean flour has been used as a 
crude LOX source for the direct oxidation of TAGs in tuna oil without prior 
hydrolysis. The expected reaction products would be mainly mono- and di-
hydroperoxy TAGs, because ~ 50% of TAGs in tuna oil contain one or two n-3 LC-
PUFAs [230, 231]. Tri-hydroperoxy TAGs are likely to be insignificant because only 
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~ 1 – 4% of TAGs containing three n-3 LC-PUFAs are present in tuna oil [230, 231]. 
This work has potential applications in the processing of PUFA-rich oils as, after 
dioxygenation, hydroxylated n-3 LC-PUFA-containing TAGs can be easily separated 
from the oil. It is also possible that the hydroperoxy-TAGs generated in this reaction 
may provide a more bioavailable and/or potent form of resolvin analogues compared 
to those in the FFA form.  
2. Materials and methods 
2.1. Materials 
Soybean flour (Kialla Pure Foods, certified organic) was purchased from Organic 
Wholefoods (Brunswick East, VIC, Australia). Tuna oil and anchovy oil were 
obtained from NuMega Ingredients Ltd (Altona North, VIC, Australia). Trilinolein 
and DHA TAG (Nu-Chek Prep) were obtained from Adelab Scientific (Thebarton, 
SA, Australia). Acetyl chloride (Fluka), butylated hydroxytoluene (BHT), citric acid, 
gum arabic, methyl tricosanoate, N,O-bis(trimethylsilyl)trifluoroacetamide (with 1% 
trimethylchlorosilane), potassium phosphate monobasic, potassium phosphate 
dibasic, platinum (IV) oxide, pyridine (>99%), sodium citrate dihydrate, Trizma® 
base and (trimethylsilyl)diazomethane (2 M in diethyl ether) were purchased from 
Sigma Aldrich (Castle Hill, NSW, Australia). Hydrochloric acid (32%) and sodium 
tetraborate were purchased from APS Chemicals Ltd (Seven Hills, NSW, Australia). 
Acetone, diethyl ether, ethanol, methanol, potassium bicarbonate and sodium 
chloride were purchased from Chem-Supply (Gilman, SA, Australia). Acetonitrile 
(Scharlau, Spain), acetic acid (BDH Lab Supplies, UK) and sodium hydroxide 
(Fisher Chemicals, UK) were purchased from Science Supply (Mitcham, VIC, 
Australia). Isopropanol was obtained from Fisher Scientific (Scoresby, VIC, 
Australia). Calcium chloride from Merck (Darmstadt, Germany) was purchased from 
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Merck Millipore (Bayswater, VIC, Australia). Triton X-100™ and toluene were 
purchased from Ajax Finechem (Taren Point, NSW, Australia). Hydrogen, nitrogen 
and oxygen gases were obtained from Coregas Pty Ltd (North Geelong, NSW, 
Australia).  
2.2. Fatty acid profiling by GC-FID 
FAs from tuna oil were transesterified into fatty acid methyl esters (FAMEs) and 
analysed by GC-FID [217]. Methyl tricosanoate internal standard (1 mg) was used 
for quantification. An Agilent Technologies 6890N Network GC system with flame 
ionisation detector and an SGE BPX70 column (30 m × 0.25 mm, 0.25 µm film 
thickness) was used. Samples containing approximately 5 mg of pure tuna oil were 
used for FAMEs analysis. Details on FAME conversion and GC-FID analysis are 
described in Chapter 4 (Section 2.5.4). 
2.3. UV-visible spectrophotometry for initial rate investigation 
To characterise the sfLOX-catalysed tuna oil reaction, UV-Vis spectrophotometry 
was used to measure the initial rate of the reaction by monitoring the formation of 
conjugated dienes through absorbance at 234 nm. The substrate (tuna oil) was 
prepared from a stock tuna oil solution (100 mg/mL), prepared in ethanol:acetone 
(1:1) and stored at 4ºC until required. To prepare a tuna oil emulsion (10 mg/mL), 
100 µL of the tuna oil stock solution was taken and the solvent evaporated under 
nitrogen flow. The tuna oil was added to 1 mL of filtered 50 mM Tris-HCl buffer, 
pH 7.5 containing 15% w/v gum arabic, in a 4.5 mL vial. The solution was sonicated 
using an ultrasonic processor Sonics Vibra cell (John Morris Scientific) (500 W, 20 
kHz, amplification 20%) to form the emulsion. Samples were sonicated with five 
pulses four times and the vial shaken after each repeat to minimise temperature 
increase. The emulsion was prepared fresh before use. Soybean flour (SBF) extract 
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was prepared by addition of 1 g SBF in 20 mL of water and stirred for 3 min. This 
was subsequently centrifuged for 5 min at 4,200 rpm (Allegra X-30 Centrifuge, 
Beckman Coulter) and the clarified supernatant retained. The supernatant was 
filtered through a 0.45 µm nylon syringe filter and then diluted in water to obtain the 
appropriate concentrations required for use in assays.  
An appropriate volume of buffer to bring the total volume of the assay reaction to 
3 mL was added to a quartz cuvette, with other components (20 µL, as required) 
added sequentially. The solution was then mixed by inversion of the cuvette. Next, 
20 µL of the tuna oil emulsion (10 mg/mL) was added without mixing. Finally, 
150 µL of SBF extract was added, the reaction mixture immediately mixed by 
inversion and the cuvette placed in the spectrophotometer to start the measurement 
immediately. The effect of different variables on the initial rate of the reaction were 
investigated, including pH (50 mM citrate buffer pH 4.5 – 6.0, 50 mM phosphate 
buffer pH 6.0 – 8.0, 50 mM borate buffer pH 8.0 – 9.0), butylated hydroxytoluene 
(BHT) concentration (1.67 – 13.33 µg/mL), and Triton X-100 concentration (0.0007 
– 0.0033% w/v). BHT (0.25 – 2 mg/mL) and Triton X-100 (0.1 – 0.5% w/v) stock 
solutions were prepared in ethanol and water, respectively. 
For tuna oil emulsions prepared with Triton X-100, a tuna oil working emulsion was 
prepared by mixing 400 µL of the tuna oil emulsion (10 mg/mL) and 56.6 mL of 
50 mM citrate buffer pH 5.0 (maintaining the ratio of tuna oil emulsion to buffer 
used in the 3 mL reactions). The working emulsion was continuously stirred to 
maintain its stability. An aliquot of SBF extract (150 µL) was transferred into the 
cuvette inside the UV-Vis spectrophotometer. The tuna oil working emulsion 
(2.85 mL) was then added and the change in absorbance was recorded immediately. 
The initial reaction rate was investigated with Triton X-100 prepared in the tuna oil 
170 
 
emulsion to obtain final concentrations of 0.0007 – 0.0033% w/v. The effects of 
other variables were also tested: oxygenation (nitrogen, none, air and oxygen 
sparging), temperature (0 – 40ºC) and calcium chloride (CaCl2) concentration (0.017 
– 0.067 mM).  
The initial reaction rate was measured at 234 nm for 1 min with a Cary 300 Bio UV-
visible spectrophotometer (Agilent Technologies) using a 1.0 cm path length quartz 
cuvette. The first 30 seconds were used to calculate the reaction rate. All sample 
analyses were conducted in triplicate unless otherwise stated. The values obtained for 
samples were presented as an average initial rate with error bars indicating one 
standard deviation. Tuna oil and SBF-only controls were subtracted from the initial 
rate readings. 
2.4. Zetasizer analysis for emulsion properties 
The droplet size and size distribution in tuna oil emulsions were measured using a 
Zetasizer Nano ZS (Malvern Instruments, Malvern, UK). The refractive indices were 
set at 1.45 and 1.33 for tuna oil and water, respectively. Samples were appropriately 
diluted prior to analysis to ensure accurate unobscured measurements were obtained. 
Data is represented as intensity Z-average, with all samples prepared in duplicate and 
measured in triplicate. These analyses were performed by Dr. Tim Nalder. 
2.5. TAG hydroperoxide enzymatic synthesis and optimisation for 
maximum product formation 
SBF extract was prepared as described in Section 2.3, except that 50 mM citrate 
buffer pH 5.0 was used in place of water and the SBF in buffer was stirred for 30 min 
instead of 3 min. Reactions (10 mL) used the optimal conditions determined by the 
UV-Vis spectroscopy method. The final conditions used were; 50 mM citrate buffer 
pH 5.0, saturated with oxygen, 0.05 mg/mL SBF extract concentration, 0.067 mg/mL 
tuna oil (emulsified) and 0.002% w/v Triton X-100. The tuna oil working emulsion 
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(95 mL) was prepared in a 250 mL Schott bottle by addition of 667 µL tuna oil 
emulsion (containing 0.3% w/v Triton X-100) and 94.33 mL 50 mM citrate buffer 
pH 5.0 (maintaining the ratio of tuna oil emulsion and buffer used in the 3 mL 
reactions), and the solution was stirred for at least 10 min. The solution was then 
saturated with oxygen by bubbling pure oxygen into the solution for 10 min. An 
aliquot (9.5 mL) of tuna oil working emulsion was added into a 20 mL vial and 
stirred, with 0.5 mL of SBF extract added to initiate the reaction. The reaction 
mixture was stirred for 15 min. Acetic acid (50 µL) was added at the end of the 
reaction. Reactions shorter than 15 min were stopped by adding the reaction mixture 
into 20 mL diethyl ether. Reaction products were extracted with 3 × 20 mL diethyl 
ether and the solvent removed under vacuum. The lipid fraction was then dissolved 
in 1 mL methanol:isopropanol (1:1) with 0.1% v/v acetic acid for RP-HPLC analysis.  
Reaction variables were evaluated for the formation of mono- and di-hydroperoxy 
TAGs. The variables were reaction time (0 – 90 min), SBF extract concentration 
(0.0125 – 12.5 mg/mL), BHT concentration (0, 0.0033 or 0.05 mg/mL) and tuna oil 
emulsion concentration (0.067 – 0.4 mg/mL). Different SBF stocks were prepared or 
diluted from the original stock (1 g SBF in 20 mL buffer) to obtain appropriate final 
SBF extract concentrations in the reaction, while maintaining the same SBF extract 
volume (0.5 mL). Each variable was investigated individually and then the optimal 
conditions were combined. Blank controls for the tuna oil emulsion and SBF extract 
were performed with the autoxidation products from the blank controls subtracted 
from the peak areas determined from the different reactions.  
For optimisation of individual reaction variables, experiments were repeated between 
1 and 3 times to ensure a clear trend and optimum was observed. Values from a 
single representative experiment are shown in the results section for each variable. 
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Results at different reaction conditions for each variable were considered to be 
different when the results varied by greater than ± 5%. The optimised reaction 
conditions were conducted in triplicate. 
2.6. Hydrolysis of TAG hydroperoxides 
The sfLOX-catalysed tuna oil reaction products (TAG hydroperoxides) needed to be 
hydrolysed prior to analysis by RP-HPLC and GC-MS. The method was performed 
as described in Chapter 4 (Section 2.4) with some modifications. In a 10 mL vial, 
samples were dissolved in 1 mL of ethanol and 1.5 mL 25% (w/v) NaOH in water 
was added. The reaction mixture was stirred at 65ºC for 15 or 60 min and water was 
subsequently added to a final volume of 10 mL (to dilute the sample before 
acidification, which may cause side reactions). The sample was acidified by the 
addition of 4 M HCl until the solution turned cloudy and the pH was checked (a pH 
of approximately 2.0 – 3.0 is required). The hydrolysis products were extracted by 
diethyl ether (2 × 20 mL), with the solvent subsequently removed by evaporation 
under vacuum. The final sample was diluted in 1 mL of methanol containing 
0.1% (v/v) acetic acid for RP-HPLC or GC-MS analysis. Reactions were performed 
in triplicate. 
2.7. Monitoring reaction product formation by RP-HPLC 
The sfLOX-catalysed tuna oil reaction products, including the major mono- and di-
hydroperoxy TAGs, were separated using the same HPLC system, column and 
procedure as described in Chapter 4 (Section 2.5), except that the injection volume 
was 30 µL. Reproducibility was confirmed by repeat injections. The composition of 
mobile phase was A: 0.1% (v/v) acetic acid in water and B: methanol with 0.1% 
(v/v) acetic acid. Hydrolysed reaction products were separated using the following 
gradient conditions; 50% (v/v) to 80% (v/v) B over 40 min, then to 100% (v/v) B 
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over 10 min and held at 100% B for another 10 min. The separation used a flow rate 
of 1 mL/min at 23ºC. The retention times were compared with resolvin analogue 
standards to identify product regio-specificity.  
2.8. Determination of hydroxy group positions on reaction products by 
GC-MS 
The hydrolysed sfLOX-catalysed tuna oil reaction products were fully hydrogenated 
and trimethylsilylated as described in Chapter 3, Section 2.3.2. Then derivatives were 
analysed with GC-MS as previously covered in the same section of Chapter 3. 
3. Results 
3.1. Tuna oil fatty acid profile 
The FA profile of tuna oil was determined by GC-FID analysis. This was done to 
determine the concentration of FAs containing 1,4-pentadiene units (PUFAs), which 
lipoxygenase is capable of reacting with. Only FAs that contributed > 1% of the total 
peak area were considered for the calculation of FA composition. The results were 
calculated from peak area relative to the concentration of internal standard 
(tricosanoate methyl ester, 1 mg) using theoretical relative FID response correction 
factors to correct the peak areas of the FAs. Approximately 30% of FAs in the tuna 
oil were found to be PUFAs, with DHA, EPA, AA, and LA being the four major 
species (Table 5.1). DHA and EPA accounted for approximately 70 and 20% of 
PUFAs, respectively, with AA and LA combined forming 10%.  
Table 5.1: PUFA content identified in tuna oil by GC-FID (n=3). 
PUFA FA content (%) (Mean ± SD) 
LA 1.17 ± 0.02 
AA 1.53 ± 0.02 
DHA 21.90 ± 0.34 
EPA 5.82 ± 0.09 
174 
 
3.2. Effect of emulsion droplet size on LOX product formation 
The final optimised sfLOX-catalysed reaction conditions with TL (Chapter 4) were 
applied to the sfLOX-catalysed tuna oil reaction with some modifications. 
Preliminary results from RP-HPLC analysis of reaction products showed that tuna oil 
emulsions (1 mL) prepared with 5 sonication pulses gave a good product yield, 
however the amount of products formed from these emulsions was inconsistent. To 
explore this, TL emulsions were prepared to investigate the droplet size and size 
distribution using a Zetasizer. Using this set up, it was possible to investigate how 
the number of sonication pulses (5 – 20 pulses in a 1 mL TL stock emulsion) affected 
both the size of the emulsion droplets and the reproducibility of their preparation. 
Further to this, the emulsion properties were compared with product formation in 
sfLOX-catalysed reactions, as determined by RP-HPLC, to investigate what effect 
emulsion size has on the reaction.  
The reproducibility of size distribution increased as the number of sonication pulses 
increased. All emulsions (prepared with 5, 10, 15 or 20 pulses) had monomodal 
droplet size distributions, however emulsions with 5 sonicator pulses showed poor 
reproducibility (Figure 5.1A). Emulsions generated with 5 or 10 pulses had poor 
polydispersity index (PdI) values (> 0.400), suggesting the emulsions had very broad 
size ranges, poor homogeneity and may not be suitable for analysis by Zetasizer. PdI 
is a dimensionless value generally ≤ 1 and is an indicator of the polydispersity of 
droplet size and the broadness of size distribution. In contrast, the size distribution of 
emulsions prepared with 20 pulses were well defined (Figure 5.1B), with PdI values 
< 0.250, suggesting a good level of emulsion homogeneity. The reproducibility of 
droplet size range also increased as the number of pulses increased from 5 to 20 
pulses. The average droplet size also tended to decrease when pulse number 
increased. The Z-average of the 6 analyses (duplicate samples analysed in triplicate) 
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was plotted against the number of pulses (Figure 5.1C), clearly showing the 
improvement in sample preparation reproducibility with respect to the average 




Figure 5.1: Effect of number of sonication pulses on the reproducibility of TL emulsion formation 
analysed by Zetasizer. A) Size distribution of TL emulsions with 5 sonication pulses, and B) size 
distribution of TL emulsions with 20 sonication pulses. C) Plots of TL emulsion Z-average values 
versus number of sonication pulses (5 – 20 pulses). Stock TL emulsions contain 10 mg/mL TL and 
15% w/v gum arabic in Tris-HCl buffer pH 7.5. Each experimental condition (pulse number) was 























The same emulsions, prepared using 5 to 20 pulses, were used as substrates in 
reactions with sfLOX under the final optimised conditions (TL 0.2 mg/mL, 0.3% w/v 
gum arabic, SBF extract 2.5 mg/mL, 10 mL 50 mM citrate buffer pH 5.0, 45 min 
reaction time) and product formation was monitored using RP-HPLC. For TL-3OOH 
and total product, reproducibility of product formation increased significantly with 
increasing number of sonication pulses used to form the emulsions. Reproducibility 
of TL-2OOH and TL-OOH formation was comparable between all conditions, except 
for TL-OOH where 20 pulses showed better reproducibility. Consistent with the 
Zetasizer results, emulsions formed with 5 pulses were not uniform, therefore the 
reproducibility of product formation from these emulsions was poorer. However, 
emulsions formed with 10 pulses gave reasonable reproducibly in the formation of 
reaction products from sfLOX-catalysed TL reactions, suggesting the results in 
Chapter 4 using a TL emulsion prepared with 10 sonication pulses were fit for 
purpose. 
TL-3OOH and total product formation increased, whereas TL-OOH decreased with 
increasing number of sonication pulses. TL-2OOH formation was constant regardless 
of the number of pulses (Figure 5.2). TL-3OOH formation from the sfLOX-catalysed 
reaction using the TL emulsion formed with 20 pulses was approximately 40% 
higher than when the TL emulsion was formed with 5 pulses. Emulsions formed with 
20 pulses produced the greatest amount of total products in all sfLOX-catalysed TL 
reactions. Therefore, 20 sonication pulses were applied to make tuna oil emulsions, 





Figure 5.2: Effect of number of sonication pulses (5 – 20) on the formation of products from sfLOX-
catalysed TL reactions. Measurement of reaction product absorbance at 234 nm A) TL-3OOH and 
total product, B) TL-2OOH and TL-OOH. Reaction of TL 0.2 mg/mL, 0.3% w/v gum arabic, SBF 
extract 2.5 mg/mL, 10 mL citrate buffer (50 mM, pH 5), 45 min reaction time. Error bar stands for ± 1 
standard deviation (n=4). 
3.3. Investigation of the initial rate of sfLOX-catalysed tuna oil reactions  
LOX activity is commonly measured through the formation of LA hydroperoxides 
containing a single conjugated diene, which can be monitored spectrophotometrically 
at 234 nm [56, 59, 145]. Preliminary results from RP-HPLC analysis showed that 
sfLOX-catalysed tuna oil products containing one or more single conjugated double 
bonds absorbed optimally at 234 nm after subtracting blank controls. The initial 









































Section 2.3, using a UV-Vis spectrophotometer at 234 nm to monitor the formation 
of all products.  
Before proceeding with the investigation, a standard curve was generated using a 
range of SBF extract concentrations (0.05 – 0.25 mg/mL) to determine the dynamic 
range of the assay, i.e. to ensure the reaction rate was not limited. The initial rate 
corresponded to the extract concentration in a linear fashion (Figure 5.3), ensuring 
the activity measured was relative to the enzyme concentration used in the assays. A 
concentration of 0.125 mg/mL SBF extract was chosen for use in further assays, as it 
fell approximately in the middle of the linear range. This assay was used to 
investigate the effects (positive or negative) of different variables (pH, BHT 
concentration, Triton X-100 concentration, oxygen, temperature, CaCl2 
concentration) on the reaction.  
 
Figure 5.3: Analysis of reaction rate as a function of SBF extract concentration (n=3). Reaction of 
SBF extract (0.05 – 0.25 mg/mL) with 0.067 mg/mL tuna oil emulsion in 3 mL citrate buffer (50 mM, 
pH 5.0). 
It was also necessary to check the stability of the sfLOX under these conditions over 
time. This was done by measuring the activity of the SBF extracts every 10 min over 























a period of 80 min. The sfLOX (1 in 20 dilution) was found to be relatively stable 
over 80 min (Figure 5.4) and all analyses measuring the initial reaction rate used the 
SBF solution within 80 min. 
 
Figure 5.4: Stability of sfLOX activity over time (0 – 80 min). Reaction of SBF extract 0.125 mg/mL 
with 0.067 mg/mL tuna oil emulsion in 3 mL citrate buffer (50 mM, pH 5.0). 
3.3.1. Effect of pH on the initial reaction rate 
The pH optimum of the sfLOX catalysis of tuna oil was determined using a number 
of different buffer systems (see Section 2.3) to cover the pH range 4.5 to 9.0. The 
assays used 0.067 mg/mL tuna oil emulsion and 0.125 mg/mL SBF extract. The 
sfLOX was found to be optimally active at pH 5.5, with the reaction slowing 
significantly at low (pH 4.5) and high pH (pH 9.0) (Figure 5.5). At pH 4.5 and 9.0, 
the activity was only 40% of that at pH 5.5. For consistency with the previous 
reaction of a pure TAG (TL), pH 5.0 was chosen for the sfLOX-catalysed tuna oil 
reaction, as this pH showed strong activity greater than 85% of that at pH 5.5. 






















Figure 5.5: Effect of pH on the sfLOX-catalysed tuna oil reaction (n=3). Reaction of SBF extract 
0.125 mg/mL with 0.067 mg/mL tuna oil emulsion in 3 mL of buffer. pH 4.5 – 6.0: 50 mM citrate 
buffer (blue); pH 6.0 – 8.0: 50 mM phosphate buffer (red); pH 8.0 – 9.0: 50 mM borate buffer (green). 
3.3.2. Effect of BHT concentration on the initial reaction rate 
The reaction products generated from the sfLOX-catalysed TL reaction increased 
significantly in the presence of BHT, as shown in Chapter 4 (Section 3.1.6). 
Therefore, the effect of BHT was investigated in the sfLOX-catalysed tuna oil 
reaction to observe if the effect was consistent. The effect was investigated over the 
range of 1.67 – 13.33 µg/mL; BHT in ethanol (20 µL) was used in the reaction. 
Control experiments showed that the addition of ethanol (up to 100 µL) did not affect 
the initial rate (data not shown). The initial rate increased approximately 25% in the 
presence of 3.33 – 6.67 µg/mL BHT compared to assays without BHT (Figure 5.6). 





















Figure 5.6: Effect of BHT concentration on the sfLOX-catalysed tuna oil reaction (n=3). Reaction of 
SBF extract 0.125 mg/mL with 0.067 mg/mL tuna oil emulsion in 3 mL citrate buffer (50 mM, pH 
5.0) with different concentrations of BHT (0 – 13.33 µg/mL). 
3.3.3. Effect of Triton X-100 concentration on the initial reaction rate 
Non-ionic surfactants such as Triton X-100 have previously been used to enhance 
LOX activity and thermal stability [117, 198]. In the concentration range (0.0007 – 
0.0033% w/v of Triton X-100) studied, the initial reaction rate increased 2.3 fold in 
the presence of 0.002% w/v Triton X-100, compared to reactions preformed without 
the surfactant (data not shown). Triton X-100 was then used as an emulsifier in the 
preparation of the tuna oil emulsion. The addition of Triton X-100 decreases the 
emulsion droplet size and could affect the enzyme activity. In the same concentration 
range as above, the initial reaction rate was shown to increase significantly (greater 
than 6-fold) with increasing Triton X-100 concentration. A similar effect on the 
initial reaction rate was observed with Triton X-100 prepared in tuna oil emulsion as 
was observed when Triton X-100 was used as an additive in the reaction, although a 
wider optimum range was obtained (0.0013 – 0.0027% w/v; Figure 5.7). A 
concentration of 0.002% w/v Triton X-100 (prepared in the tuna oil emulsion) was 






















Figure 5.7: Effect of Triton X-100 concentration on the sfLOX-catalysed tuna oil reaction (n=3). 
Reaction of SBF extract 0.05 mg/mL with 0.067 mg/mL tuna oil emulsion and Triton X-100 (0.0007 – 
0.0033% w/v) in 3 mL citrate buffer (50 mM, pH 5).  
3.3.4. Effect of oxygen on the initial reaction rate 
Oxygen is essential for a LOX-catalysed reaction to proceed. To investigate the 
effect of oxygen concentration on the sfLOX-catalysed tuna oil reaction, the reaction 
was performed with different concentrations of oxygen present in the solution. Tuna 
oil working emulsions were sparged with pure oxygen, air or nitrogen for 10 min, or 
left untreated before use, to alter the oxygen concentration from close to zero to a 
maximum of approximately 35 mg/L. The reaction rate increased significantly with 
increasing oxygen concentration, with the reaction rate increasing by approximately 
35% under oxygen-sparged conditions compared to the untreated reaction. Under 
nitrogen-sparged conditions, the reaction rate was observed to be approximately 80% 






















Figure 5.8: Effect of oxygen concentration on the sfLOX-catalysed tuna oil reaction (n=3). Reaction 
of SBF extract 0.125 mg/mL with 0.067 mg/mL tuna oil emulsion in the presence of 0.002% w/v 
Triton X-100 in 3 mL citrate buffer (50 mM, pH 5). 
3.3.5. Effect of temperature on the initial reaction rate 
Temperature is an important variable and can affect the initial rate significantly as it 
can alter the enzyme stability and oxygen concentration. The reaction was 
investigated with respect to temperature in the range 0 – 40°C. Tuna oil–buffer 
mixtures were incubated at the different temperatures and the initial rate of the 
sfLOX reaction determined: on ice (0ºC), ice water bath (10ºC), room temperature 
(~ 20ºC) or on a heating block at 30 and 40°C. The initial reaction rate was fastest 
between 10 and 30ºC, with an increase of approximately 20 – 25% compared to 0ºC 
and 40ºC (Figure 5.9). For convenience room temperature was chosen to perform 






















Figure 5.9: Effect of temperature (0 – 40ºC) on sfLOX-catalysed tuna oil reaction (n=3). Reaction of 
SBF extract 0.125 mg/mL with 0.067 mg/mL tuna oil emulsion in the presence of 0.002% w/v Triton 
X-100 in 3 mL citrate buffer (50 mM, pH 5). 
3.3.6. Effect of calcium chloride on the initial reaction rate 
Calcium ions have previously been found to remove substrate inhibition and activate 
enzyme activity in some plant LOX isozymes [186, 245]. The presence of calcium 
chloride (0.017 – 0.067 mM) in the reaction was investigated. Calcium chloride did 
not have a significant effect on the initial reaction rate (Figure 5.10), and was not 
studied further.  
 
Figure 5.10: Effect of calcium chloride on the sfLOX-catalysed tuna oil reaction. Conditions: 
0.067 mg/mL tuna oil emulsion, 0.05 mg/mL SBF extract, 0.002% w/v Triton X-100, 3 mL citrate 
buffer (pH 5, 50 mM). An aliquot (20 µL) of CaCl2 (0.017 – 0.067 mM) was added before initiating 







































3.3.7. Effect of variable combination on the initial reaction rate 
The combination of variables (Triton X-100, oxygen saturation and BHT) were 
tested to investigate any combined effects on the reaction. The following working 
tuna oil emulsions were used as substrates for comparison: 1) without Triton X-100, 
2) with Triton X-100, 3) with Triton X-100 and BHT, 4) with Triton X-100 and 
oxygen and 5) with Triton X-100 and BHT and oxygen. The initial rate for condition 
1 was close to zero, the addition of Triton X-100 (condition 2) as an emulsifier in the 
tuna oil emulsion substantially increased the initial rate to 0.126 Abs/min. Oxygen 
saturation in combination with Triton X-100 (condition 4) was found to increase the 
initial rate by ~ 40% compared to the reactions without oxygen sparging (conditions 
2 and 3, Figure 5.11). Under the reaction conditions with saturation of oxygen, the 
results showed that BHT decreased the initial rate ~ 10% compared to the control 
without BHT (conditions 4 and 5, Figure 5.11). Oxygen saturation did not increase 
the initial rate in the presence of both BHT and Triton X-100 (conditions 3 and 5, 
Figure 5.11). The reaction conditions in the presence of Triton X-100 and oxygen 
saturation showed the fastest initial reaction rate and were applied to scaled-up 
10 mL reactions for further optimisation using RP-HPLC to maximise reaction 
products (hydroperoxy TAGs). 
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Figure 5.11: Effect of combined variables on the sfLOX-catalysed tuna oil reaction (n=3). The 
reactions were conducted under the conditions: 0.067 mg/mL tuna oil emulsion, with or without 
0.002% w/v Triton X-100, 0.05 mg/mL SBF extract, without or with BHT (0.0033 mg/mL), with or 
without oxygen saturation, 3 mL citrate buffer (50 mM, pH 5). 
3.4. Effect of Triton X-100 concentration on emulsion properties 
The stock tuna oil emulsions (15% w/v gum arabic and 10 mg/mL tuna oil) 
containing different concentrations of Triton X-100 (0, 0.1, 0.3 and 0.5% w/v) were 
analysed by Zetasizer to investigate the effect of Triton X-100 concentration on the 
emulsion droplet size and size distribution. At all concentrations of Triton X-100 
tested, the emulsions were found to be mono-modal in their size distribution. 
Polydispersity index (PdI) values obtained were < 0.4 (Table 5.2) suggesting that the 
data were of reasonable quality and that the homogeneity of the emulsions was 


















Condition 1 2 3 4 5 
Triton X-100 (0.002% w/v) ✕ ✓ ✓ ✓ ✓ 
BHT (0.0033 mg/mL) ✕ ✕ ✓ ✕ ✓ 
O2 (~ 35 mg/L) ✕ ✕ ✕ ✓ ✓ 
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Table 5.2: Values determined by Zetasizer analysis of tuna oil emulsions prepared with different 
concentrations of Triton X-100, at 30°C (n=6). 
Triton X-100 % (w/v) in 
TO emulsion 
Z-average (d.nm) 
(Mean ± SD) PdI (Mean ± SD) 
0.0 388.4 ± 20.0 0.187 ± 0.021 
0.1 276.9 ± 5.3 0.207 ± 0.012 
0.3 205.1 ± 4.2 0.176 ± 0.008 
0.5 174.4 ± 2.6 0.180 ± 0.019 
 
Figure 5.12A shows examples of the size distribution curves determined for 
emulsions with different Triton X-100 concentrations, while Figure 5.12B shows the 
Z-average values obtained for emulsions prepared with the different concentrations 
of Triton X-100. As shown in Table 5.2 and Figure 5.12B, the Z-average of droplet 
diameter decreased significantly from 388.4 ± 20.0 nm to 174.4 ± 2.6 nm as the 
Triton X-100 concentration increased from 0 to 0.5% w/v. Tuna oil emulsions with 
higher concentrations of Triton X-100 (> 0.5% w/v) were not suitable for analysis by 
Zetasizer as they presented as bi-modal size distributions and the PdI values were > 
0.4 (data not shown). The appearance of a second micelle population is likely to have 
occurred due to Triton X-100 forming micelles predominantly composed of the 
surfactant itself. For this reason, emulsions containing high concentrations of Triton 





Figure 5.12: Effect of Triton X-100 concentration on tuna oil emulsion droplet size and size 
distribution. A) Size distribution of tuna oil emulsions prepared with 0.0 – 0.5% w/v Triton X-100 in 
the stock solution. B) Z-average values obtained for tuna oil emulsions prepared with 0.0 – 0.5% w/v 
Triton X-100 in the stock solution (n = 6). 
3.5. Optimisation of sfLOX-catalysed tuna oil reaction conditions by RP-
HPLC DAD 
The conditions identified by UV-Vis spectroscopy (0.067 mg/mL tuna oil emulsion, 
0.05 mg/mL SBF extract, 0.002% w/v Triton X-100, oxygen saturated buffer) to 
improve the reaction rate of product formation were applied to scaled-up 10 mL 






















by absorption at 234 nm and the substrate monitored at 210 nm. Because of the very 
low amount of tri-hydroperoxy TAGs produced, the formation of di- and mono-
hydroperoxy TAGs were the focus of this investigation. Di- and mono-hydroperoxy 
TAGs were separated by RP-HPLC due to differences in their polarity. Di-
hydroperoxy TAGs (TAG-2OOH) eluted earlier than mono-hydroperoxy TAGs 
(TAG-OOH) as they are more polar with two hydroperoxy groups (Figure 5.13).  
 
Figure 5.13: RP-HPLC chromatograms of sfLOX-catalysed tuna oil reaction products compared to 
blank tuna oil control. Reaction of 0.067 mg/mL tuna oil emulsion, 0.002% w/v Triton X-100 and 
0.25 mg/mL SBF extract, in 10 mL citrate buffer (50 mM, pH 5.0) saturated with oxygen, for 15 min 
(blue trace). Blank tuna oil control under the same above conditions without SBF (orange trace). 
3.5.1. Effect of reaction time on product formation 
To allow for the formation of the maximum amount of reaction products, reaction 
time was investigated from 1 to 90 min. A 100 mL reaction was initiated, then at 
different time points 10 mL aliquots were taken and added directly into 20 mL 
diethyl ether with 50 µL acetic acid to stop the reaction. The lipid fraction was 
extracted and the products analysed by RP-HPLC. TAG-OOH increased significantly 





























2OOH concentration was minimal at 1 min and did not increase over time (results 
not shown). Unreacted fish oil TAGs appeared to decrease with a small change over 
time (Figure 5.14). Under these conditions, the reaction had reached completion after 
15 min, although a large amount of substrate still remained. A 15 min reaction time 
was chosen for further experiments. 
 
Figure 5.14: Effect of reaction time on the formation of sfLOX-catalysed tuna oil reaction products 
and unreacted TAGs over time. Reactions contained 0.067 mg/mL tuna oil emulsion, 0.002% w/v 
Triton X-100, 0.05 mg/mL SBF extract, in 10 mL citrate buffer (50 mM, pH 5.0), saturated with 
oxygen. TAG-OOH measured at 234 nm (left axis), TAG measured at 210 nm (right axis). The results 
from a single experiment represent reaction time effect on product formation. 
3.5.2. Effect of SBF concentration on product formation 
The optimal enzyme concentration for the reaction needed to be determined, as at 
low concentrations the conversion is incomplete, and at high concentrations product 
formation may be inhibited. SBF extract concentration was optimised in the range 
0.0125 – 2.5 mg/mL, with the production of TAG-OOH and TAG-2OOH monitored. 
The formation of TAG-OOH increased substantially with increasing SBF extract 
from 0.0125 to 0.125 mg/mL, reaching a maximum between 0.05 and 0.125 mg/mL, 






































concentration of TAG-OOH remained relatively constant (Figure 5.15). At SBF 
concentrations < 0.25 mg/mL, TAG-2OOH formation was minimal. From 0.25 to 
1.25 mg/mL SBF extract, TAG-2OOH increased significantly, then stayed constant 
up to 2.5 mg/mL. The concentration of TAG decreased dramatically up to 
1.25 mg/mL SBF extract, then decreased slightly until 2.5 mg/mL (Figure 5.15). The 
amount of TAG remaining at the end of the reaction using 2.5 mg/mL SBF extract 
was approximately 5% of that remaining when 0.0125 mg/mL SBF extract was used. 
The reaction has gone to completion as the substrate was limiting from 1.25 mg/mL 
SBF extract onward. The peak area of substrate consumed did not account for the 
peak area of products formed in the reaction. However, there were no other products 
formed to compensate the significant decrease of TAG and small amount of TAG-
OOH and TAG-2OOH formation.  
  
Figure 5.15: Effect of SBF extract concentration on sfLOX-catalysed tuna oil reaction. Reaction of 
0.067 mg/mL tuna oil emulsion, 0.002% w/v Triton X-100, SBF extract (0.0125 – 2.5 mg/mL), in 
10 mL citrate buffer (50 mM, pH 5.0), saturated with oxygen, 15 min reaction time. Lines in graph are 
not joined due variation in results conducted on different days. TAG-2OOH and TAG-OOH measured 
at 234 nm (left axis), TAG measured at 210 nm (right axis). The results from a single experiment 







































3.5.3. Effect of SBF concentration in the presence of BHT on product formation 
BHT is an antioxidant or radical scavenger that is known to protect lipids from 
autoxidation. The SBF extract concentration was re-optimised in the presence of 
BHT (0.0033 mg/mL) to potentially recover the lost products at SBF concentrations 
above 0.05 mg/mL. The addition of BHT at 0.0033 mg/mL showed a 25% increase 
in the initial reaction rate (as determined by the UV-vis method), therefore this 
concentration was tested. TAG-2OOH formation was higher (approximately 2-fold) 
in the presence of BHT compared to without BHT (compare Figures 5.15 and 5.16). 
TAG-OOH formation was drastically increased at 0.05 mg/mL SBF extract 
concentration, roughly 2.5-fold higher than at any other SBF extract concentrations 
(Figure 5.16). TAG consumption in the reaction was observed to be similar in the 
presence and absence of BHT (Figures 5.15 and 5.16). Again, the reaction reached 
completion with minimal TAG remaining at 1.25 mg/mL SBF extract.  
  
Figure 5.16: Effect of SBF extract concentration on the sfLOX-catalysed tuna oil reaction in the 
presence of 0.0033 mg/mL BHT. Reaction of 0.067 mg/mL tuna oil emulsion, 0.002% w/v Triton X-
100, SBF extract (0.0125 – 2.5 mg/mL), in 10 mL citrate buffer (50 mM, pH 5.0), containing 
0.0033 mg/mL BHT, saturated with oxygen, 15 min reaction time. TAG-2OOH and TAG-OOH 
measured at 234 nm (left axis), TAG measured at 210 nm (right axis). The results from a single 








































In the sfLOX-catalysed TL reaction (Chapter 4, Section 3.1.6), product formation 
was found to increase significantly at a higher BHT concentration of 0.05 mg/mL. 
Therefore, this BHT concentration was tested, and the SBF extract concentration 
(0.0125 – 2.5 mg/mL) was re-optimised. As the SBF extract concentration increased 
the amount of TAG-OOH and TAG-2OOH detected increased substantially, while 
TAG decreased significantly (Figure 5.17). The SBF extract concentration for 
maximum yield of both TAG-OOH and TAG-2OOH was found to be 1.25 mg/mL. 
At higher SBF extract concentrations, there was no further conversion of TAG-OOH 
into TAG-2OOH. This is likely because no more unreacted PUFA were available in 
the TAG-OOH compounds to further convert into TAG-2OOH.  
 
Figure 5.17: Effect of SBF extract concentration on the sfLOX-catalysed tuna oil reaction in the 
presence of 0.05 mg/mL BHT. Reaction of 0.067 mg/mL tuna oil emulsion, 0.002% w/v Triton X-
100, SBF extract (0.0125 – 2.5 mg/mL), in 10 mL citrate buffer (50 mM, pH 5.0), containing 
0.05 mg/mL BHT, saturated with oxygen, 15 min reaction time. Reaction products (TAG-OOH and 
TAG-2OOH) measured at 234 nm (red and blue traces), TAG measured at 210 nm. The results from a 
single experiment represent the effect on product formation. 
3.5.4. Effect of tuna oil amount on product formation 
Using the conditions determined above (1.25 mg/mL SBF extract and 0.05 mg/mL 


















concentration was investigated. This was done because the concentration of TAG 
substrate used in the initial reactions was potentially limiting the reaction. Tuna oil 
concentrations ranging from 0.067 to 0.4 mg/mL were investigated by increasing the 
stock tuna oil emulsion volume from 66.7 to 400 µL, instead of increasing stock tuna 
oil concentrations and using the same volume in the reaction. This is because stock 
tuna oil emulsions cannot be formed in water at high concentrations of tuna oil. In 
this way, the concentrations of emulsifiers (gum arabic and Triton X-100) in the 
reaction were also increased. In the studied range, TAG-OOH increased steadily with 
concentrations from 0.067 to 0.2 mg/mL, before decreasing with concentrations 
greater than 0.2 mg/mL. TAG-2OOH formation was greatest with 0.133 mg/mL tuna 
oil, and decreased at higher concentrations (Figure 5.18). A tuna oil concentration of 
0.2 mg/mL was chosen for further optimisation because at this concentration TAG-
OOH was highest and a high amount of tuna oil still remained after the reaction 
ceased, showing that substrate was not limiting the reaction. 
 
Figure 5.18: Effect of tuna oil emulsion concentration on the sfLOX-catalysed tuna oil reaction. 
Reaction of tuna oil emulsion (0.067 – 0.4 mg/mL), SBF extract 1.25 mg/mL, BHT 0.05 mg/mL, 
10 mL citrate buffer (50 mM, pH 5) saturated with oxygen, 15 min reaction time. Reaction products 
(TAG-OOH and TAG-2OOH) were measured at 234 nm (orange and blue traces), and TAG was 
measured at 210 nm (grey trace). The results from a single experiment represent tuna oil emulsion 



















3.5.5. Reoptimisation of SBF concentration on product formation 
The addition of more SBF extract was tested to see whether more reaction products 
could be formed with the higher substrate concentration. The reaction with 
0.2 mg/mL tuna oil was re-assessed with higher SBF concentrations (1.25 – 
7.5 mg/mL). More TAG-OOH and TAG-2OOH were detected as SBF extract 
concentration increased up to 5 mg/mL. From 5 mg/mL of SBF extract 
concentration, the maximum amount of TAG-OOH and TAG-2OOH was obtained 
with minimal amount of TAGs remaining (Figure 5.19).  
 
Figure 5.19: Effect of SBF concentration on the sfLOX-catalysed reaction with 0.2 mg/mL tuna oil. 
Reaction of 0.006% w/v Triton X-100, SBF extract (1.25 – 7.5 mg/mL), 10 mL citrate buffer (50 mM, 
pH 5) saturated with oxygen, 15 min reaction time. Reaction products (TAG-OOH and TAG-2OOH) 
measured at 234 nm, TAG measured at 210 nm. The results from a single experiment represent the 
effect on product formation. 
As higher amounts of SBF could convert most of the remaining substrate from 
0.2 mg/mL tuna oil into TAG-OOH and TAG-2OOH, the reaction with 0.25 mg/mL 
tuna oil was also tested with higher SBF extract concentrations (1.25 – 12.5 mg/mL). 
As expected, both TAG-OOH and TAG-2OOH increased significantly from 1.25 to 


















concentrations TAG-2OOH slowly decreased whereas TAG-OOH and TAG 
remained stable (Figure 5.20).  
 
Figure 5.20: Effect of SBF concentration on the sfLOX-catalysed reaction with 0.25 mg/mL tuna oil. 
Reaction of 0.0075% w/v Triton X-100, SBF extract (1.25 – 12.5 mg/mL), 10 mL citrate buffer 
(50 mM, pH 5) saturated with oxygen, 15 min reaction time. Reaction products (TAG-OOH and 
TAG-2OOH) measured at 234 nm, TAG measured at 210 nm. The results from a single experiment 
represent the effect on product formation. 
The PUFA-containing TAGs in tuna oil at increasing concentrations (0.067, 0.2 and 
0.25 mg/mL) could be converted into TAG-OOH and TAG-2OOH effectively by 
using appropriate SBF concentrations (1.25, 5 and 7.5 mg/mL, respectively). These 
reactions were reproducible with relative standard deviation < 5%. The conversion 
efficiency relative to the amount of tuna oil used was calculated by dividing the peak 
areas by the amount of tuna oil in each 10 mL reaction. As shown in Table 5.3 
below, the total product formation efficiency of both TAG-OOH and TAG-2OOH 
was comparable between reactions using different tuna oil amounts (0.667 – 2.5 mg). 
There was no significant difference in the efficiency of TAG-OOH and TAG-2OOH 
conversion. However, TAG-OOH conversion tended to decrease whereas TAG-




















Table 5.3: Relative product formation efficiency for sfLOX-catalysed tuna oil reactions using 













0.667 16.7 18.0 34.7 
2 15.7 18.1 33.7 
2.5 14.0 19.7 33.7 
 
Although product formation efficiency was not much different between tuna oil 
amounts in the reaction, the maximum amount of reaction products was obtained 
with 2.5 mg tuna oil per 10 mL reaction. As a result, the final optimised reaction 
conditions were 0.25 mg/mL tuna oil emulsion, 0.0075% w/v Triton X-100, 
7.5 mg/mL SBF extract, 0.05 mg/mL BHT, 10 mL citrate buffer (50 mM, pH 5) 
saturated with oxygen, 15 min reaction time.  
3.6. Product characterisation 
Reaction products formed in the catalysis of tuna oil by sfLOX using the final 
optimised conditions were hydrolysed to enable characterisation of the different 
PUFA products. The hydrolysed reaction products from reactions using 0.067 and 
0.25 mg/mL tuna oil were compared. The RP-HPLC results for the conditions using 
the 0.25 mg/mL tuna oil emulsion showed that the yield of hydrolysed products was 
much lower than expected. Additionally unknown compounds absorbing at 270 nm 
were also formed in significant amounts. The hydrolysis conditions using 12.5 M 
NaOH for 90 min (Chapter 4, Section 2.4) may be too harsh for the n-3 LC-PUFAs 
found in tuna oil. To address this the reaction was trialled with different sodium 
hydroxide concentrations (2.1 – 12.5 M) and reaction times (1 – 90 min) to minimise 
the loss of the products. The optimum sodium hydroxide concentration was found to 
be 6.25 M. As for reaction time, the optimum conditions were inconclusive (either 15 
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or 60 min). At 15 min, higher amounts (20 – 30% more) of the products were 
released by hydrolysis and the reaction was more reproducible than at 60 min. 
However, an extra peak eluting at ~ 30 min was observed in the 15 min reaction that 
was absent in the 60 min hydrolysis.  As neither hydrolysis time was ideal, both were 
used.  
3.6.1. Determination of hydroxy fatty acid composition by RP-HPLC 
The hydrolysed sfLOX-catalysed tuna oil products were compared with standards of 
mono- and di-hydroxy analogues of DHA and EPA under the same RP-HPLC 
running conditions. The standards were previously synthesised and purified in-house 
using sfLOX. Retention times and absorbance spectra of sample peaks were matched 
to standards to confirm the presence of particular compounds in the samples. 
However, slight variation in retention times between runs made retention time 
matching difficult, so each standard and sample were co-injected to observe if co-
elution occurred. An example, showing the co-elution of the 17-HDHA standard with 
a peak in the 15 min hydrolysis sample is shown in Figure 5.21. 17-HDHA and 15-
HEPA were confirmed to be present in both hydrolysis samples. A peak eluting at 
23 min matched the retention time of 7,17-diHDHA, but their spectra were different. 
It has a maximum absorbance at 234 nm instead of two absorption maxima at 226 
and 246 nm. This compound and the extra peak in the 15 min hydrolysis sample 





Figure 5.21: Co-elution of the 17-HDHA standard and hydrolysed sfLOX-catalysed tuna oil products 
after 15 min hydrolysis with 6.25 M NaOH. 
3.6.2. Determination of hydroxy group positions on reaction products by GC-
MS 
After hydrolysis the reaction products were derivatised to fully hydrogenated and 
trimethylsilylated (TMS) compounds. This was done as the derivatives are more 
volatile and stable at high temperature, allowing for GC-MS analysis. The 
fragmentation patterns obtained for the derivatives were used to identify the positions 
of hydroxy groups on the different FA products. Two major mono-hydroxy products 
and a range of FAs with different chain lengths were detected. No significant 
difference was observed between the samples hydrolysed for 15 or 60 min. 
Two mono-hydroxy products that eluted between 24 and 27 min (Table 5.4) were 
identified based on fragmentation patterns (Figure 5.22). They were identified as 
fully hydrogenated TMS derivatives of 17-HDHA and 15-HEPA, confirming the 
presence of these two compounds that were also identified by RP-HPLC. Only trace 
amounts of di-hydroxy products were detected between 28 and 30 min, meaning the 
identification of the di-hydroxy products was not possible. Various FAs from C14 to 























Hydrolysed sfLOX-TO (15 min) + 17-HDHA 17-HDHA
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These saturated, TMS derivatives most likely originated from palmitic and steric 
acids (SFAs), and oleic acid (a MUFA) present in the tuna oil, which sfLOX is 
unable to catalyse, and from unreacted DHA, EPA, LA and AA (PUFAs) remaining 
after the reaction. 
Table 5.4: Important m/z fragments of the hydrogenated, trimethylsilyl derivatives of mono-hydroxy 







24.14 15-HEPA 73, 117, 173, 401, 457 
26.93 17-HDHA 73, 173, 373, 429, 485 
 
 
Figure 5.22: Mass spectrum of fully hydrogenated di-TMS-17-HDHA and structure showing 

































3.7. Applications of optimised sfLOX-TAG reaction conditions 
3.7.1. Using other complex lipids as substrates 
The conditions optimised with tuna oil were applied to tridocosahexaenoin (DHA 
TAG) and anchovy oils. Both were found to yield high concentrations of products 
absorbing at 234 nm when being catalysed by sfLOX (Figure 5.23). A small amount 
of substrate remained after the reactions, < 10% for both substrates. However, the 
remaining substrate concentration is not indicative of reaction yield, as both substrate 
and products can also be metabolised into other compounds that cannot be detected 
by the HPLC protocols in the current work. From the DHA TAG reaction (Figure 
5.23A) the two major peaks were expected to be tri- and di-hydroperoxy DHA 
TAGs, while the smaller peaks between 15 and 20 min were expected to be mono-
hydroperoxy DHA TAGs. These are consistent with the retention times of the 
sfLOX-catalysed TL reaction products. As for anchovy oil, two groups of potential 
di- and mono-hydroperoxy PUFA TAGs with the same retention time as those from 
the sfLOX-catalysed tuna oil reaction were obtained at high concentration (Figure 
5.23B). The results confirmed that sfLOX was able to catalyse anchovy oil and DHA 
TAGs effectively using the conditions optimised with tuna oil. However, sfLOX did 
not show any significant activity with DHA TAGs using the optimised conditions 





Figure 5.23: Chromatograms of A) sfLOX-catalysed DHA TAG reaction products, B) sfLOX-
catalysed anchovy oil reaction products produced using the conditions optimised with tuna oil. 
3.7.2. Using commercial 15-sLOX-1 as a LOX source 
The sfLOX preparation was shown to react effectively with different complex lipids, 
including tuna oil, anchovy oil and DHA TAGs. To determine if a commercial 
enzyme could react with esterified FA substrates, the optimised reaction conditions 
from the reactions with tuna oil and TL were tested with the commercial 15-sLOX-1. 
50% substrate amount was used in the reactions with the commercial enzyme, 



















































DHA (Chapter 3). In comparison with sfLOX, 15-sLOX-1 was only capable of 
oxygenating esterified FAs poorly, with minimal product formation observed. Taking 
into account the differences in substrate concentration, the formation of mono- and 
di-HPTAGs from the 15-sLOX-1-catalysed tuna oil reaction was approximately 4 
and 1.5%, respectively, of that from the sfLOX-catalysed reaction (Figure 5.24A). 
Approximately 85 and 10% unreacted tuna oil remained for 15-sLOX-1 and sfLOX-
catalysed reactions, respectively. The 15-sLOX-1 catalysis of TL as a substrate gave 
tri-, di- and mono-HPTL at approximately 0.5, 1.5 and 15%, respectively, of the 
amounts formed with sfLOX (Figure 5.24B) using the optimised conditions found 
for the sfLOX-catalysed reaction with TL. Approximately 75 and 30% of unreacted 
TL remained in the reactions with 15-sLOX-1 and sfLOX, respectively. These results 






Figure 5.24: Reactions catalysed by 15-sLOX-1 and sfLOX with different esterified FA substrates. A) 
Tuna oil and B) TL, under the optimum conditions found for sfLOX. Amount produced per milligram 
substrate, error bars indicate (±) one standard deviation (n=3). 
4. Discussion 
Increasing the number of sonication pulses increased the homogeneity of TL 
emulsions, and therefore led to more reproducible product formation from sfLOX-
catalysed reactions. Micelle droplet size decreased significantly with the increasing 
number of pulses. Reaction product profiles showed an overall decrease in TL-OOH 






































overall increase in dioxygenation. Smaller droplets have previously been found to be 
more sensitive to lipid oxygenation than larger droplets due to the increase in total 
surface area [242]. Similarly, the interaction between substrate and enzyme at the 
buffer-droplet interface is likely to be enhanced by the increase in total surface area, 
resulting in increased enzyme activity.  
Some studies have shown that both LOX-1 and type-2 LOX (LOX-2 and LOX-3) 
were able to metabolise esterified FA substrates, but type-2 LOX was found to have 
significantly higher activity than LOX-1 from soybean [122, 131] and barley [92, 
179]. The current study showed that the sfLOX-catalysed reaction significantly 
increased product formation with esterified FAs (TL and tuna oil) compared to the 
commercial type-1 LOX reactions. In agreement with this observation, sfLOX has 
previously been found to possess much higher activity with TL compared to a 
commercial LOX-1 [56, 61]. In this thesis, multiple LOX isozymes (LOX-1, LOX-2 
and LOX-3) were found to be active in both sfLOX and the commercial LOX, 
although the commercial LOX may contain a lower concentration of LOX-2. Or it 
may be less active compared to that found in sfLOX, as indicated by the colorimetric 
tests (Chapter 3). LOX-1 and LOX-3 may contribute to esterified FA dioxygenation, 
but at a considerably slower rate compared to LOX-2.  
The optimum pH found for the sfLOX-catalysed reaction with tuna oil of pH 5.5 is 
likely to be due to the activity of LOX-2 or LOX-2 and LOX-3 combined. In support 
of this proposal, purified type-2 LOX was also found to have higher activity with TL 
at pH 5.5 (compared to pH 6.5 and 8.3) in a previous study [131]. Using LA as a 
substrate, Christopher and co-workers showed that purified LOX-3 had a broad 
optimum pH range from 5.5 to 8.0 and the activity was significantly reduced at pH 
4.5 and 9 [214].  
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Through investigating the initial reaction rate using UV-vis spectrophotometry the 
sfLOX-catalysed tuna oil reaction was found to be pH dependent and have a low 
optimum pH of 5.5, similar to that determined with the TL reaction (see Section 
3.1.1, Chapter 4). The initial reaction rate was significantly less at low pH (4.5) and 
high pH (9). In agreement with the observations from this work, several previous 
studies also used acidic and neutral pH for the sfLOX-catalysed dioxygenation of 
various esterified FAs and natural oils such as TL, dilinolein, methyl linoleate, 
soybean oil and butterolein at pH 6 – 7 [61, 111, 224, 225]. Cai and co-workers also 
found a similar pH optimum for sfLOX using soybean oil as a substrate in the pH 
range of pH 5 – 9, with a slight decrease in the reaction yield from pH 5 to 8 and a 
significant decrease in the reaction yield at pH 9 [111]. However, in a study by 
Kohlen and co-workers, sfLOX was shown to have a sharp optimum activity with TL 
at pH 7 and significant decreases towards both low and high pH in the studied range 
of pH 5 to 10 [61]. Moreover, Koch and colleagues found that a crude soybean meal 
extract catalysed reaction with TL had two optima, at pH 5.5 and pH 8.3, but the 
activity at pH 8.3 was less than at pH 5.5 [131], consistent with the observations in 
the sfLOX-catalysed tuna oil reaction.  
The effect of surfactants on soybean LOX-catalysed esterified FA reactions has been 
found to be inconsistent between studies [169, 172, 206]. Dillard and co-workers 
showed that soybean LOX activity was inhibited by the presence of Triton X-100 
and Tween 40 in the reaction with TL [206]. Piazza and colleagues found that Tween 
20 did not affect the oxidation rate of 1,3-dilinolein by soybean LOX-1, but a 
significant increase in the oxidation rate with 1-monolinolein in the presence of 
Tween 20 was observed [169]. Fukuzawa et al. reported that soybean LOX-1 activity 
increased substantially in oxygenated egg yolk phosphatidyl choline in the presence 
Triton X-100, due to the increase of substrate availability by disturbing the 
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membrane structure of vesicles [172]. In agreement with some of these findings, the 
initial rate of the sfLOX-catalysed tuna oil reaction observed here was found to 
increase greatly in the presence of Triton X-100. The optimum Triton X-100 
concentration was very low, at approximately 0.002% w/v (0.031 mM), compared to 
its critical micelle concentration at 0.24 mM [246]. When Triton X-100 was used as 
an emulsifier combined with gum arabic in the tuna oil emulsion (instead of being 
added directly to the reaction buffer), the decrease in the size of tuna oil emulsion 
droplets with increasing Triton X-100 concentration was expected, as surfactant has 
been used to decrease the oil in water droplet size in several studies previously [247, 
248]. Under this condition, the initial reaction rate increased to a higher extent than 
the same Triton X-100 concentration directly added into the reaction mixture. This 
suggested that the effect of decreasing emulsion droplet size was much stronger than 
that of Triton X-100 on the enzyme activity. Further investigations using different 
reagents to reduce droplet size were not performed. 
In this work, the smallest tuna oil droplet size prepared in the 50 mM Tris-HCl buffer 
pH 7.5 (15% w/v gum arabic and 10 mg/mL (1% w/v) tuna oil) with 0.5% w/v Triton 
X-100 was 174.4 ± 2.6 nm. Similarly, previous work by Kentish et al. using 15% v/v 
flaxseed oil in water with Tween 40, demonstrated that droplet size decreased with 
increasing concentrations of surfactant before reaching the lowest droplet size of 
135 ± 5 nm at 5.6% v/v [247]. The initial rate increased significantly with decreasing 
droplet size by increasing Triton X-100 from 0 to 0.3% w/v in the stock tuna oil 
emulsion. As mentioned previously, smaller droplets are more susceptible to lipid 
oxidation as the total surface area is higher than that of larger droplets [242]. 
Increasing the surface area may also result in increased interaction between the 
enzyme (sfLOX) and the substrate (tuna oil) at the oil-water interface. This likely 
improves the substrate accessibility to the enzyme’s active site and increases the 
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initial rate significantly. In agreement with this, the activity of a commercial soybean 
LOX-1 was found to increase with increasing surface area of methyl linoleate 
emulsion droplets, which was induced by the increase of surfactant concentration 
[244]. However, the rate decreased when the emulsion contained greater than 0.3% 
w/v Triton X-100, although the droplet size still tended to decrease. It is possible that 
at higher surfactant concentrations, multilayers of surfactant surround the oil droplets 
at the oil-water interface and protect oil from oxidation [249]. This was demonstrated 
in a study by Fomuso et al. where a 10% fish oil-caprylic acid structured emulsion 
containing 0.25% Tween 20 had a higher level of oxidation over a 48-day period 
than an emulsion prepared with 1% Tween 20 [243]. Although gum arabic was not 
added to make the emulsion in the study by Fomuso et al., they used a much higher 
fish oil concentration (10%) than was used in this work (1%). As a result, it is 
postulated that Triton X-100 at concentrations higher than 0.3% w/v may be acting to 
shield the tuna oil interface, which interferes with the access of sfLOX to the 
substrate.   
Oxygen is necessary for LOX-catalysed reactions with PUFAs. As expected for a 
typical LOX reaction, the reaction rate increased when the oxygen concentration was 
increased. Under oxygen saturated conditions, the initial rate increased ~ 35% 
compared to conditions without oxygen sparging. This was similar to the ~ 35% 
increase in product formation with oxygen saturation compared to without oxygen 
sparging found in the sfLOX-catalysed DHA reaction (see Section 3.1.5, Chapter 3). 
At low oxygen concentrations (nitrogen sparging), the reaction rate only decreased 
~ 20% compared to the untreated condition. This was in agreement with no 
significant change in product formation from sfLOX-catalysed TL reaction between 
nitrogen-sparged and un-sparged conditions. For reaction temperature, the initial 
reaction rate optimum was found between 10 and 30°C, which was a broad 
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temperature range compared to the sharp optimum at room temperature for product 
formation in sfLOX-catalysed reactions of DHA and TL (see HPLC results, Chapters 
3 and 4 respectively). This suggests that the sfLOX-catalysed reaction with natural 
oils, such as tuna oil, may be less affected by temperature than the reactions found 
with pure substrates (DHA and TL). The initial reaction rate was lower at 0°C and 
40°C, which is typically for LOX activity. This is the result of a compromise 
between enzyme denaturation, oxygen concentration and substrate solubility in the 
reaction medium, as discussed in Chapter 3.  
CaCl2 did not show any effect on the sfLOX-catalysed tuna oil reaction in the 
presence of Triton X-100. LOX-2 and LOX-3, or LOX-2 only are thought to be the 
key LOX isozyme(s) catalysing reactions with esterified FAs, such as tuna oil. 
However, Zimmerman and Snyder found that CaCl2 inhibited purified LOX-2 in the 
presence of Tween 20 using LA as a substrate [250]. Another study’s findings were 
similar to the current results, where it was reported that LOX-2 was stimulated, but 
LOX-3 was inhibited by CaCl2 using LA as a substrate [214]. Previous investigations 
have also demonstrated that purified LOX-2 [250] and crude SB extract [251] are not 
activated by CaCl2 when methyl linoleate and TL were used as substrates, 
respectively.  
The optimisation of the tuna oil reaction using RP-HPLC showed that the reaction 
time for optimal product formation was 15 min, which was shorter than that for the 
sfLOX-catalysed DHA (30 min, Chapter 3) and sfLOX-catalysed TL reactions (45 
min, Chapter 4). This could be because the formation of di-hydroxy PUFA products 
(two hydroxy groups in one fatty acid molecule) is significantly slower than that of 
mono-hydroxy PUFA products [43, 125], as observed with the sfLOX-catalysed 
reactions of DHA and tuna oil as a substrate respectively. TL-3OOH (three 
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hydroperoxy groups with one on each fatty acid moiety) may also require longer 
reaction times compared to up to two hydroperoxy addition into PUFA-containing 
TAGs in tuna oil. Moreover, the ratio of enzyme to substrate in the tuna oil reaction 
is much higher than that in DHA and TL reaction, which likely contributes to the 
shorter reaction time for tuna oil. 
Longer reaction times did not affect sfLOX-catalysed tuna oil reaction product 
formation. This differed to the work in Chapter 3 and 4, where product formation 
from sfLOX-catalysed reactions with DHA and TL tended to decrease after reaching 
the optimum reaction time. In previous studies, hydroperoxide yields have also been 
reported to degrade after the optimum reaction time was reached [162, 212]. 
Different enzyme sources and substrates were used in these studies. Haefliger and 
Sulzer used SBF as a LOX source to catalyse the dioxygenation of LNA [162]. 
Therond et al. used various phosphatidylcholines as substrates in reactions catalysed 
by soybean LOX-1, and demonstrated a more dramatic degradation of product 
formation with C18/AA-PC compared to the other substrates [212].  
The optimisation of SBF extract concentration using 0.067 mg/mL tuna oil, 
increasing SBF extract concentration from 0.0125 to 0.05 mg/mL led to increased 
product formation. However, for SBF extract concentrations of 0.05 – 0.5 mg/mL, 
the substrate was consumed significantly but product formation decreased. At SBF 
extract concentrations > 0.05 mg/mL, products and substrate may be metabolised or 
degraded as a result of other enzymes in SBF and/or free radicals.  
In the presence of BHT (0.0033 – 0.0067 mg/mL), the initial rate was found to 
increase approximately 25% compared to conditions without BHT. The optimum 
BHT concentration (0.0033 mg/mL) and the resulting change in LOX activity was 
much lower compared to findings from the sfLOX-catalysed TL reaction (0.05 
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mg/mL BHT and 2 – 4.3 fold increase of product formation, see Section 3.1.6, 
Chapter 4). The optimum SBF extract concentration was the same at 0.05 mg/mL 
with or without BHT but overall product yield was significantly higher with BHT. 
However, at higher SBF extract concentrations (> 0.05 mg/mL) both mono-HPTAGs 
and TAGs still decreased substantially as observed in the conditions without BHT.  
At a higher BHT concentration of 0.05 mg/mL, product formation increased 
significantly with increasing SBF extract concentrations compared to conditions 
without BHT, as seen with the sfLOX-catalysed TL reaction (see Section 3.1.6, 
Chapter 4). The increase continued at SBF extract concentrations greater than 
0.05 mg/mL which was not observed in the presence of BHT at 0.0033 mg/mL. The 
decrease in TAG concentration was the same with both 0.0033 and 0.05 mg/mL 
BHT. This suggested that BHT at 0.05 mg/mL could be enough to protect TAG 
hydroperoxides and substrate from degradation, possibly from the attack of free 
radicals, therefore product formation increased with the increasing SBF extract 
concentration. This is because for 0.067 mg/mL tuna oil, the molar concentration of 
BHT at 0.05 mg/mL is roughly three times higher than that of tuna oil, whereas 
0.0033 mg/mL BHT only contains approximately 0.2 molar equivalents.  
Decomposition of lipid hydroperoxides can occur by either enzymatic or non-
enzymatic reactions. The most common non-enzymatic decomposition pathway is 
through free-radical mechanisms and involves the homolytic cleavage of 
hydroperoxides into peroxyl and alkoxyl radicals. The process is catalysed by 
transition metal ions and metalloproteins [252]. These radicals are further degraded 
to form various epoxy and oxo compounds, shorter chain compounds (such as 
alcohols and alkanes) and volatile compounds (aldehydes) through β-scission 
(breaking the molecules at covalent bonds adjacent to carbon-oxygen bond), 
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epoxidation and oxidation mechanisms [253, 254]. Antioxidants such as BHT can be 
used as free radical scavengers that act by donating a hydrogen. The presence of 
BHT in the reactions is likely protecting the TAG hydroperoxides, formed by sfLOX 
catalysis, from free-radicals in solution, resulting in the significant increase in the 
TAG hydroperoxide yield. This is not due to the increase of enzyme activity as the 
initial rate (UV-vis results) increased as a much smaller ratio compared to product 
formation (RP-HPLC results). Reducing the rate of breakdown could account for this 
increase of product formation. However, using HPLC-DAD and GC-MS no 
aldehydes or other oxidative compounds were detected in either sfLOX-catalysed 
reactions with TL or tuna oil in the absence of BHT. 
LOX-2 and LOX-3 have been found to form radical intermediates more readily in 
comparison to LOX-1. LOX-2 and LOX-3 were reported to bleach β-carotene in the 
presence of LA at pH 6.5 more efficiently than LOX-1 at pH 9, due to their ability to 
form active peroxyl radicals that facilitate the co-oxidation of β-carotene [156]. The 
formation of radical intermediates by LOX-3 is independent of oxygen 
concentration, whereas LOX-1 only produces radical intermediates at low oxygen 
concentrations [255]. This further supports the sfLOX-catalysis of esterified FAs, 
which involves mainly type-2 LOX, requirement for BHT to protect TAG 
hydroperoxides from free-radical degradation. Similarly, BHT was previously found 
to increase LOX-2 and LOX-3 activity more significantly than LOX-1 activity [227]. 
In the presence of BHT, more sfLOX-catalysed tuna oil reaction products can be 
generated by adding extra tuna oil and SBF without a drop in reaction efficiency. The 
10 mL sfLOX reaction with 0.667 mg tuna oil was effectively catalysed with 
minimum amount of tuna oil remaining (< 10%). Tuna oil amounts of 2.0 and 2.5 mg 
can be efficiently converted into products by adding more enzyme. However, at high 
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tuna oil amounts (≥ 3 mg) product formation decreased significantly, which may be 
due to inhibition by oxygen depletion, the decrease of mass transfer and/or the 
increase of emulsifier concentration (Triton X-100 and gum arabic). No further work 
testing the effects of the concentration emulsifier components on the reaction was 
conducted.  
Using the conditions optimised with the sfLOX-catalysed tuna oil reaction, DHA 
TAG, tuna oil and anchovy oil were effectively converted into TAG hydroperoxides 
with less than 10% of unreacted TAG remaining. It is possible that approximately 
90% DHA TAG was consumed in the sfLOX-catalysed reaction. However, tuna oil 
and anchovy oil reactions have less than 50% TAGs containing one, two or three 
PUFAs, but only < 10% TAGs (by total HPLC peak area at 210 nm) in these oils 
were available after the reactions. This could be due to the differences in molar 
extinction coefficients of various TAGs in oils. TAGs containing PUFAs were 
shown to have more significant peak area than TAGs without PUFAs at the same 
concentration [256]. The minimal peak area detected could be mainly from TAGs 
lacking PUFAs. 
Mono- and di-hydroperoxy TAGs were formed in the sfLOX-catalysed tuna oil 
reaction and only mono-hydroperoxy PUFA moieties in TAGs were observed. The 
major mono-hydroxy products were identified by RP-HPLC and GC-MS as 17-
HDHA and 15-HEPA moieties in TAG form, which corresponds to the major mono-
hydroxy products from DHA and EPA reactions catalysed by sfLOX (Chapter 3) and 
soybean LOX-1 [43]. The formation of only mono-hydroxy PUFA products is in 
agreement with previous studies where esterified FAs have been shown to react with 
LOX by inserting only at the methyl end in the active site [211, 257]. Whereas the 
carboxyl groups required for the formation of di-hydroxy PUFA products (containing 
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double conjugated dienes and a conjugated triene) are unavailable in esterified FA. 
The optimised sfLOX-catalysed tuna oil reaction conditions were confirmed to be 
effective conditions for other complex lipid substrates such as DHA TAGs and 
anchovy oil. This study has shown that 15-sLOX-1 was unable to react effectively 
with esterified FAs (tuna oil and TL) under the optimum conditions of sfLOX. 
5. Conclusion 
LOX from soybean flour has been demonstrated to catalyse the dioxygenation of 
tuna oil (a complex lipid mixture), whereas 15-sLOX-1 was unable to catalyse 
esterified FAs (tuna oil and TL) effectively. Prior hydrolysis is not required to 
oxygenate PUFA-containing TAGs using this method. Soybean flour contains both 
LOX-2 and LOX-3, which is advantageous compared to many purified LOX 
preparations available commercially. LOX-2 or its combination with LOX-3 in 
soybean flour are thought to be responsible for the activity of sfLOX in catalysing 
esterified FA substrates. In contrast to the results in Chapter 4, surfactant Triton X-
100 as a second emulsifier in the tuna oil-gum arabic emulsion was found to increase 
the reaction rate significantly with an optimum concentration of 0.3% w/v in the 
emulsion system partly due to the decrease of emulsion droplet size. The optimised 
sfLOX-catalysed tuna oil reaction conditions can be applied to other TAG substrates, 
such as DHA TAG and anchovy oil. The antioxidant BHT appears to protect against 
the degradation of TAG hydroperoxides without interference in sfLOX catalysis, and 




































BIOSSAYS OF POTENTIAL ANTI-INFLAMMATORY 
LIPID MEDIATORS FROM n-3 AND n-6 LC-PUFA 
ENZYMATICALLY SYNTHESISED BY SOYBEAN 
FLOUR LIPOXYGENASE 
1. Introduction 
PUFAs are long known to have many health benefits and the dietary 
omega-6/omega-3 ratio is important in maintaining good health and reducing risk of 
a wide range of diseases. In particular, DHA is found predominantly in the brain as a 
major component of neural membranes, and in cortical grey matter as the most 
abundant FA. Therefore, DHA has crucial structural and functional roles in brain 
health [189]. However, the mechanism for PUFA benefits is not fully understood. 
PUFAs are endogenously metabolised into specialised pro-resolving mediators 
(SPMs) by different types of enzymes including lipoxygenases and cyclooxygenases. 
SPMs are a group of structurally related, bioactive lipid compounds, which have 
been demonstrated to actively induce the resolution of inflammation [17, 19, 66]. 
They are hydroxylated compounds derived from omega-3 and omega-6 PUFAs and 
divided into four groups: lipoxins, resolvins, protectins and maresins. These 
compounds with highly stereo-specific hydroxy groups and characteristic conjugated 
double bond systems have shown high anti-inflammatory and pro-resolving 
bioactivity at low concentrations both in vitro and in vivo [6]. SPMs and potential 
analogues are promising in the treatment and prevention of inflammatory diseases as 
new anti-inflammatory drugs, and may in part explain the health benefits of PUFAs 
in the body. 
Inflammation is a protective response of the host which attempts to remove harmful 
stimuli and heal damaged tissue. Inflammation is induced by the attack of invading 
pathogens, from tissue injury and infection, leading to the release of pro-
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inflammatory lipid mediators such as leukotrienes and prostaglandins and other 
chemical mediators such as cytokines and chemokines to initiate and coordinate the 
inflammatory response. This is followed by the recruitment of white blood cells 
(leukocytes or PMN), especially neutrophils, to the injured area to target and destroy 
invading pathogens by secreting reactive oxygen species [8, 10, 11]. Platelets are 
also involved in inflammation. They are blood cells and have an important role in 
blood clotting. They gather at the damaged site and release adhesive molecules to 
recruit and aggregate with white blood cells. The platelet-granulocyte aggregates 
amplify inflammation by further secretion of immune modulators to recruit 
neutrophils, monocytes and lymphocytes [258]. Self-limited inflammation is 
essential for survival of the host from foreign invaders. However, uncontrolled 
inflammation is associated with a range of diseases such as cardiovascular diseases, 
diabetes and Alzheimer’s disease. Anti-inflammatory drugs targeting the treatment 
and prevention of these diseases are in demand. Anti-inflammatory activity is 
expressed through the ability to inhibit the inflammatory pathways such as pro-
inflammatory mediator generation and leukocyte recruitment and others, or by 
stimulating the anti-inflammatory pathway such as generation of anti-inflammatory 
cytokines.  
The anti-inflammatory activity of SPMs and related analogues has been measured in 
a number of studies using many different approaches, including: 1) a decrease in the 
concentration of pro-inflammatory lipid mediators such as LTB4 and PGE2 [259, 
260] or a decrease in the enzyme activity (such as 5-LOX) involved in their synthesis 
[261, 262]; 2) a reduction in the concentration of pro-inflammatory cytokine and 
chemokine secretion such as IL-1β, TNF-α, IL-6 and MCP-1 [75, 260, 263-269] 
and/or an increase in anti-inflammatory cytokines such as IL-10 and TGF-β [260]; 3) 
an inhibition of mRNA expression of pro-inflammatory factors such as IL-1β, IL-6, 
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inducible nitric oxide synthase (iNOS) and COX-2 [22, 270, 271]; 4) a decrease in 
platelet aggregation [70]; 5) PMN inhibition or a decrease in PMN migration [272], 
leukocyte cell number [22, 67, 260, 273], neutrophil count [266], or pathology score 
based on inflammation levels (white blood cell count from none (0) to severe (3)) 
[274]; 6) lower production of reactive oxygen species by neutrophil enzymes such as 
myeloperoxidase and iNOS [259] or a decrease in their enzyme activity [259, 275]; 
and 7) activation of receptors inducing anti-inflammatory activity [188, 275].  
Cytokine secretion is a common way to detect and quantify inflammation. 
Interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α) are major pro-
inflammatory cytokines involved in the process of inflammation and are produced 
mainly by activated macrophages. They are involved in the inflammatory response to 
various stimuli including infectious agents and pathological pain [276]. IL-1β, TNF-
α and other cytokines have been measured as markers of inflammation in various 
diseases such as cardiovascular diseases and chronic obstructive pulmonary disease 
[277, 278]. Secretion of IL-1β and TNF-α from cultured cells such as macrophages 
are also commonly used to evaluate the anti-inflammatory activities of specific 
compounds. IL-1β and TNF-α are pro-inflammatory cytokines, whereas some of 
other cytokines such as IL-6 and interferon-γ (IFN-γ) can be either pro-inflammatory 
or anti-inflammatory agents in various cases [276, 279], which may interfere with the 
interpretation of results in such assays.  
The mouse microglial cell line (C8-B4) [280] and the human monocytic cell line 
(THP-1) are inflammatory cells, macrophages and monocytes, involved in the 
inflammatory process. They can respond to inflammatory stimuli and secrete 
cytokines such as IL-1β and TNF-α in response, therefore allowing the assessment of 
anti-inflammatory activity of a compound of interest. Moreover, the C8-B4 cell line 
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is derived from mouse brain cells and DHA is rich in brain so the bioactivity of its 
metabolites may elucidate the neuroprotective function of DHA through anti-
inflammatory activity. Lipopolysaccharide (LPS) is a common stimulus used in 
inflammatory assays of C8-B4 and THP-1 cell lines as LPS can polarise monocytes 
into macrophages and also activate macrophages for cytokine secretion. 
17S-monohydroxy DHA (17-HDHA), 7S,17S-dihydroxy DHA (17,17-diHDHA or 
resolvin D5) and 10S,17S-dihydroxy DHA (10,17-diHDHA or protectin DX) were 
enzymatically synthesised from DHA using soybean flour as an inexpensive LOX 
source alternative to commercial LOX (Chapter 3). Other biologically important LC-
PUFAs (EPA, AA, DPAn-3 and DPAn-6) having different chain lengths and number 
of double bonds were also used to form analogues of the compounds synthesised 
from DHA. These compounds are of interest to assess anti-inflammatory activity as 
they are analogues of highly bioactive resolvins and protectins belonging to the SPM 
superfamily. As shown in previous work, resolvin D5 from DHA and DPAn-3 
(RvD5DHA and RvD5DPAn-3) and protectin DX from DHA and DPAn-6 (PDXDHA and 
PDXDPAn-6) are known members of the SPM superfamily, and their anti-
inflammatory bioactivities have been examined and confirmed in a number of studies 
[67, 70, 75, 259, 263-268, 270, 272, 274]. Mono-hydroxy PUFAs (17-HDHA, 17-
HDPAn-6, 15-HETE and 15-HEPA) have also shown anti-inflammatory activity in 
several studies [67, 261, 262, 270]. However, other di-hydroxylated compounds of 
resolvin D5 and protectin DX analogues from other biologically important PUFAs 
(EPA, ETE and DPAn-6) have not been investigated for anti-inflammatory activity. 
The anti-inflammatory activity of all these resolvin D5 and protectin DX analogues 




In this chapter, the anti-inflammatory activity of a range of resolvin and protectin 
analogues was tested in inflammatory bioassays. The mono- and di-hydroxy PUFAs 
were synthesised in milligram scale from a range of n-3 and n-6 LC-PUFAs (DHA, 
EPA, ETE, DPAn-3 and DPAn-6) using soybean flour lipoxygenase as a biocatalyst. 
For each PUFA, one mono- and two di-hydroxy compounds were synthesised and 
tested. The 15 purified mono- and di-hydroxy PUFA compounds with their PUFA 
precursors (PUFAs and resolvin analogues) were all tested for the first time on LPS-
induced inflammation models using human monocytic cells (THP-1) and mouse 
brain cells (C8-B4). IL-1β and TNF-α were measured to assess their anti-
inflammatory properties in vitro. For the first time, the bioactivities of resolvin D5 
and protectin DX-structured compounds and their precursor mono-hydroxy PUFAs 
in each PUFA group were systematically compared as a function of structure, and 
structure-activity relationships are discussed. 
2. Materials and methods 
2.1. Materials 
Soybean flour (Kialla Pure Foods, certified organic) was purchased from Organic 
Wholefoods (Brunswick East, VIC, Australia). The fatty acids DHA, EPA, ARA, 
DPAn-3 and DPAn-6 (Nu-Chek Prep) were obtained from Adelab Scientific 
(Thebarton, SA, Australia). 2,2-dimethoxypropane (Fluka), potassium phosphate 
monobasic, potassium phosphate dibasic, sodium borohydride and tris(2-
carboxyethyl)phosphine hydrochloride (TCEP) were purchased from Sigma Aldrich 
(Castle Hill, NSW, Australia). Heptane (99 %, 0.2 micron filtered), chloroform and 
isopropanol were obtained from Fisher Scientific (Scoresby, VIC, Australia). Acetic 
acid (BDH Lab Supplies, UK) was purchased from Science Supply (Mitcham, VIC, 
Australia). Triton X-100 was obtained from Ajax Chemicals (Sydney, NSW, 
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Australia). Oxygen gas was obtained from Coregas Pty Ltd (Yennora, NSW, 
Australia).  
2.2. Resolvin analogue synthesis 
The optimised 10 mL soybean flour LOX (sfLOX) catalysed DHA reaction 
conditions (Chapter 3) was scaled up 20 times and applied to the large-scale 
synthesis of di-hydroxy resolvin analogues from LC-PUFAs: 200 mL phosphate 
buffer (pH 8, 50 mM), oxygen saturation, 0.2 mM LC-PUFAs (from 20 mM stock in 
ethanol), 1 mL Triton X-100 solution in water 1% w/v, 16 mL SBF extract (5 g/100 
mL water), ambient temperature, 30 min reaction time. For the synthesis of di-
hydroxy DPAn-6 products used in the C8-B4 bioassays, TCEP (0.6 mM) was added 
in the sfLOX- catalysed DPAn-6 reaction before adding SBF to increase the 7,17-
diHDPAn-6 yield (details shown in Chapter 3, Section 3.3). The reactions were 
stopped after 30 min by adding 4 mL sodium borohydride (1 M) in water with 
stirring for 15 min. The reaction mixture was acidified with 1 mL acetic acid and 
stirred for 30 min. When TCEP was included as an additive, the reaction mixture was 
acidified directly without prior reduction with sodium borohydride. Then the reaction 
mixture was adjusted to pH 3 with hydrochloric acid solution (4 M) and reaction 
products were extracted by solvent extraction in a separating funnel with 3 × 200 mL 
chloroform. Emulsion formation was possible after shaking in the separating funnel, 
and required sitting without disturbance, or centrifugation to separate the two phases. 
For ease of handling, the total extract volume (600 mL) was divided into 2 parts (300 
mL each) and each washed with 100 mL water, then dried over sodium sulphate. The 
recombined extract (~ 600 mL) was concentrated under vacuum until approximately 
20 – 50 mL remained, which was filtered through a 0.45 µm nylon filter. The 
remaining solvent was evaporated under vacuum until only a few milliliters 
remained, which was transferred into a 2 mL HPLC vial before evaporation of the 
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remaining solvent under nitrogen. After evaporation, dark brown impurities were 
observed in the sample, which were likely from SBF. The impurities were removed 
by adding 3 × 1 mL mobile phase (90% heptane and 10% isopropanol with both 
containing 0.1% v/v acetic acid) as the impurities were not soluble in this solution. 
The collected solvent was evaporated under nitrogen gas, and redissolved in 1 mL 
mobile phase. This sample was then purified by semi-preparative HPLC. To achieve 
a high recovery of products during purification steps, chloroform was used for 
rinsing, after sample drying, filtering and transferring to ensure minimal loss of 
products. 
The optimised 10 mL sfLOX-catalysed DHA reaction (Chapter 3) was modified and 
applied to the large-scale synthesis of mono-hydroxy DHA compounds and 
analogues from LC-PUFAs under the following conditions (10 times scale up): 
100 mL borate buffer (pH 9, 50 mM), 0.2 mM LC-PUFAs (from 20 mM stock in 
ethanol), 500 µL SBF extract (1 g/20 mL water), ambient temperature, 15 min 
reaction time. The reaction was stopped after 15 min by adding 2 mL sodium 
borohydride 1 M in water with stirring for 15 min. The reaction mixture was 
acidified by adding 500 µL acetic acid and stirred for 30 min. Solvent extraction (3 × 
100 mL chloroform) was used to isolate the products from the reaction mixtures. 
Further steps from washing to evaporation were performed in the same way as above 
for the di-hydroxy compound synthesis. As less SBF was used, only insignificant 
amounts of the impurities were extracted with the mono-hydroxy products. The 
optimised 10 mL 15-sLOX-1 and DHA reaction in a previous study by Dobson et al. 
[43] was also used to scale up (15 times) for the large-scale synthesis of 17-HDHA 
using 15-sLOX-1.  
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2.3. Resolvin analogue purification by NP-HPLC 
Mono- and di-hydroxy resolvin and protectin analogues were purified with a NP-
HPLC system, an Agilent Technologies 1200 series HPLC, including a solvent 
degasser, quaternary pump, autosampler and diode array detector (DAD). A semi-
preparative diol-120-NP column (YMC-Pack, 250 × 10 mm, 5 µm particle size) was 
used. The mobile phase composition was 90% v/v solvent A (heptane with 0.1% v/v 
acetic acid, 0.1% v/v 2,2-dimethoxypropane) and 10% v/v solvent B (isopropanol). 
Samples were separated under isocratic conditions within 60 min at 10°C with a flow 
rate of 2.5 mL/min. Initially, 2 µL of each sample was injected to confirm the 
presence and retention time of the appropriate hydroxylated compounds. To purify 
products, samples were injected in increasing volume from 20 – 100 µL if the 
column pressure did not exceed 200 bar, until 1 mL of each sample was purified. 
Each hydroxylated product was collected manually from a short tube after the UV-
Vis detector when the peak response was detected on the chromatogram. The solvent 
from the total collected sample for each compound was evaporated under vacuum 
until approximately two millilitres remained. This volume was transferred to a pre-
weighed 2 mL HPLC vial. The remaining solvent was evaporated under a stream of 
nitrogen gas until sample was completely dry. The vial and sample were weighed to 
determine the amount of purified compound that had been collected. Generally, less 
than 10 mg of products was collected.  
For bioassays using human monocytic cells THP-1, the purified products were 
dissolved in 1 mL mobile phase and analysed with NP-HPLC using the same 
conditions as above to confirm the purity. Then the solvent was evaporated and the 
samples were re-dissolved in DMSO at a concentration of 60 mg/mL. For the mouse 
brain cell (C8-B4) assay, purified products were dissolved in DMSO at a 
concentration of 50 mM. To confirm compound purity, 4 µL of each compound in 
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DMSO was taken, solvent evaporated and re-dissolved in 200 µL mobile phase, 
followed by analysis with NP-HPLC. All samples were stored at -80°C when not in 
use. The fatty acid precursors were prepared at the same concentration as the resolvin 
analogues in DMSO and purified following the same procedure if high amounts of 
autooxidation products were detected.   
2.4. Bioassays 
2.4.1. Human monocytic cells (THP-1)  
PUFAs and resolvin analogues (60 mg/mL in DMSO) were sent to Dr Celine 
Deffrasnes (CSIRO) for bioassay testing with human monocytic cells (THP-1). The 
bioassays were conducted under the following experimental conditions: THP-1 
monocytes were stimulated with 1 µg/mL LPS and co-incubated with precursor 
PUFAs (DHA, EPA, ETE, DPAn-3 and DPAn-6) or their resolvin analogues at a 
concentration of 50 µg/mL for 24h. For cell viability tests, alamar blue was added to 
the cells and the cells were incubated for 4h, then the absorbance (optical density 
(OD)) was measured at 570 nm and fluorescence intensity was measured with 
excitation at 530 – 560 nm and emission at 590 nm. Cells were also counted using a 
hemocytometer. For IL-1β and TNF-α expression bioassays, supernatants were 
collected and both cytokines were measured by ELISA (Elisakit.com). For 17-
HDHA synthesised using 15-sLOX-1 (without purification), PUFAs and di-hydroxy 
resolvin analogues, assays were performed twice (IL-1β) or three times (TNF-α, high 
variability). IL-1β and TNF-α levels were measured twice with the mono-hydroxy 
resolvin analogues. All assays were performed in triplicate and compared to DMSO 
as the control. Prism from GraphPad was used to calculate p values for statistical 
analysis with a one-way anova Tukey post-test, and independent samples t-tests. 
Results were considered to be significantly different from the control if p < 0.05.  
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2.4.2. Mouse brain cells (C8-B4)  
PUFAs and resolvin analogues (50 mM in DMSO) were sent to Dr Chiara Bortolasci 
(Metabolic Research Unit, Deakin University) for bioassay testing on mouse brain 
cells (C8-B4). The bioassays were performed under the following experimental 
conditions. PUFAs and resolvin analogues were conjugated with 10% (w/v) fatty 
acid free bovine serum albumin, filtered into sterile glass vials and stored at -80ºC 
prior to the treatment of the cells. C8-B4 microglial cells (ATCC®CRL-2540™) 
were cultured in Dulbecco Modified Eagle Medium – DMEM (Life Technologies) 
with 10% Fetal Bovine Serum – FBS (Life Technologies) and seeded onto 48-well 
plates at 3.3×104 cells/well for the measurement of TNF-α release. All cells were 
treated with LPS at a dose of 1 ng/mL, and with PUFAs and resolvin analogues at 
doses of 50, 100 or 200 µM (n = 3 – 6 replicates per treatment group), and incubated 
at 37°C for 24 hours. After 24 hours, supernatant was collected and stored at -80°C. 
Levels of TNF-α in the media were measured using ELISA (Mouse TNF-α 
Quantikine ELISA Kit, R&D Systems, Cat. No MTA00B) according to the 
manufacturer’s instructions. Data were checked for normality using a Kolmogorov-
Smirnov test. Mean differences between treatment groups were assessed using 
independent samples t-tests. SPSS Statistics 25.0 was used to calculate p value. Data 
were considered to be significantly different if p < 0.05. 
3. Results 
3.1. Purity of purified compounds 
In total, 20 different PUFAs and resolvin analogues were tested in bioassays. The 
names of the precursors and their resolvin analogues with abbreviations are given in 
Table 6.1. The purity of each of the prepared compounds was estimated by peak area 
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of the compound compared to the total peak area including other impurities using 
NP-HPLC.  
Table 6.1: Full names and abbreviations of PUFA precursors and their resolvin analogues. 
Number Compound Name Abbreviation 
1 All cis-5,8,11,14-eicosatetraenoic acid ETE (AA) 
2 15-hydroxyeicosatetra-5Z,8Z,11Z,13E-enoic acid 15-HETE 
3 5,15-dihydroxyeicosatetra-6E,8Z,11Z,13E-enoic acid 5,15-diHETE 
4 8,15-dihydroxyeicosatetra-5Z,9E,11Z,13E-enoic acid 8,15-diHETE 
5 All cis-5,8,11,14,17-eicosapentaenoic acid EPA 







9 All cis-4,7,10,13,16-docosapentaenoic acid DPAn-6 











13 All cis-7,10,13,16,19-docosapentaenoic acid DPAn-3 



























3.1.1. Human monocytic cells (THP-1) 
After purification, most compounds had high purity (> 95%) except for 5,15-
diHETE, 7,17-diHDHA and 7,17-diHDPAn-6 (batch 1) with purity of approximately 
85% as shown in Table 6.2. 
Table 6.2: Purity of PUFAs and synthesised resolvin analogues for bioassays on THP-1 cells. Where 
multiple batches of a single compound were prepared, the batch number is given after the abbreviated 
compound name (eg. 5,15-diHEPA_1). 




(mg/mL) Purity (%) 
ETE (AA) 5.5 90 61.1 99 
15-HETE 4.91 82 59.9 99 
5,15-diHETE 2.2 35 62.9 87 
8,15-diHETE 3.1 50 62.0 >99 
EPA 6.6 110 60.0 99 
15-HEPA 5.77 96 60.1 >99 
5,15-diHEPA_1 1.5 25 60.0 99 
5,15-diHEPA_2 3.51 60 58.5 97 
8,15-diHEPA_1 0.6 10 60.0 >99 
8,15-diHEPA_2 1.52 25 60.8 >99 
DPAn-6 7.7 130 59.2 99 
17-HDPAn-6 6.18 103 60.0 >99 
7,17-diHDPAn-6_1 0.8 15 53.3 84 
7,17-diHDPAn-6_2 1.55 25 62.0 99 
10,17-diHDPAn-6_1 1.3 20 65.0 >99 
10,17-diHDPAn-6_2 5.23 85 61.5 >99 
DPAn-3 6.1 100 61.0 99 
17-HDPAn-3 5.25 87.5 60.0 99 
7,17-diHDPAn-3 3.5 60 58.3 >99 
10,17-diHDPAn-3 2.0 35 57.1 >99 
DHA 11 185 59.5 99 
17-HDHA_1a 8.2 130 63.1 >99 
17-HDHA_2a 5.79 96.5 60.0 >99 
7,17-diHDHA 2.3 40 58.3 86 
10,17-diHDHA 1.1 20 57.1 99 
a 17-HDHA_1 was prepared using commercial 15-sLOX-1, with no HPLC purification after synthesis 
and solvent extraction. 17-HDHA_2 was prepared approximately 10 months after 17-HDHA_1, using 
sfLOX and was purified by HPLC after synthesis.  
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3.1.2. Mouse brain cells (C8-B4) 
All of the synthesised compounds had a purity of at least 95%, except 10,17-
diHDPAn-3 (86%) as shown in Table 6.3. Some compounds (5,15-diHETE and 
10,17-diHDPAn-3) were obtained in smaller amounts (< 3 mg).  







(mM) Purity (%) 
ETE (AA) 9.38 616 50.0 >99 
15-HETE 5.34 334 49.9 >99 
5,15-diHETE 2.87 170.6 50.0 96 
8,15-diHETE 5.37 320 49.9 >99 
EPA 9.23 610 50.0 >99 
15-HEPA 6.47 406 50.0 98 
5,15-diHEPA 4.38 262 50.0 97 
8,15-diHEPA 3.57 214 49.9 >99 
DPAn-6 8.92 540 50.0 97 
17-HDPAn-6 7.87 454 50.0 >99 
7,17-diHDPAn-6 4.42 244 50.0 95 
10,17-diHDPAn-6 6.44 356 49.9 >99 
DPAn-3 9.31 564 49.9 98 
17-HDPAn-3 7.26 420 49.9 96 
7,17-diHDPAn-3 8.02 442 50.1 >99 
10,17-diHDPAn-3 1.20 66.2 50.0 86 
DHA 9.45 576 49.9 98 
17-HDHA 6.75 392 50.0 >99 
7,17-diHDHA 3.41 190 49.8 >99 
10,17-diHDHA 6.93 384 50.1 97 
 
3.2. Bioassays 
3.2.1. Human monocytic cells (THP-1)   
Cell viability 
When determining the bioactivity of compounds, it is important to first measure the 
impact of the chemical compounds on cell function including metabolic activity, cell 
proliferation, and cell death. The alamar blue assay uses a redox indicator dye 
(resazurin) that changes colour in response to cellular metabolic activity. The 
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absorbance and fluorescence intensity of the reagent are directly proportional to the 
number of living cells present. Cells were treated with the PUFAs and mono- and di-
hydroxy resolvin analogues under investigation, and the cell viability was measured 
using the alamar blue assay. Total cell number (cell count) can also give an 
indication of cell survival following treatment with a compound of interest. This was 
also performed after treatment of the cells with the compounds of interest.  
Di-hydroxy resolvin analogues and precursor PUFAs 
Initially, the impact of the precursor fatty acids and the di-hydroxy resolvin 
analogues on cell viability were tested (as well as 17-HDHA). Most compounds had 
little or no adverse effect on cell function (Figure 6.1). When metabolic activity was 
evaluated by the alamar blue assay, only 7,17-diHDHA, 17-HDHA and 7,17-
diHDPAn-6 showed a reduction in absorbance compared to DMSO, indicating a 
decrease in cellular activity (Figure 6.1A). Interestingly, 2 compounds showed an 
increase in absorbance values suggesting an increase in metabolic activity in cells 
treated with 8,15-diHEPA and 8,15-diHETE (Figure 6.1A). On the other hand, when 
cell viability was evaluated by changes in alamar blue fluorescence intensity, only 
5,15-diHETE showed a reduction in fluorescence intensity (Figure 6.1B), suggesting 
that this compound may adversely affect cell function. A second measure of cell 
viability is cell number. Only 2 compounds resulted in a decrease in cell counts, 17-
HDHA and 5,15-diHETE (Figure 6.1C). Overall, although there is some variability 
between the assays, most of the tested compounds showed no effect on cell viability. 
The compounds that impacted cell function were 5,15-diHETE (by alamar blue 
fluorescence measurement, Figure 6.1B and cell count, Figure 6.1C), 17-HDHA (by 
alamar blue OD, Figure 6.2A and cell count, Figure 6.2C) and to a lesser extent, 
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Figure 6.1: Cell viability of LPS-stimulated THP-1 monocytes co-incubated with PUFAs, di-hydroxy 
resolvins analogues and 17-HDHA_1 for 24 h, as measured by A) alamar blue absorbance (OD), B) 
alamar blue fluorescence intensity, C) cell counts. ***: p < 0.001, **: p < 0.01, *: p < 0.05, no 
indicator: not significant. Indicators in brackets: samples are significantly different from the controls 
but behave differently compared to other samples. Average results presented and error bars indicate + 








Mono-hydroxy resolvin analogues 
The effects of the mono-hydroxy resolvin analogues on cell viability were tested 
following the same methodology. None of the mono-hydroxy resolvin analogues 
adversely impacted cell function as shown by alamar blue OD, fluorescence intensity 
and cell count measurements (Figure 6.2). There were some differences observed in 
cell viability between 17-HDHA_1 and 17-HDHA_2 (Figure 6.2), although these 
two compounds should have been chemically identical. 17-HDHA_1 caused a 
decrease in alamar blue absorbance and cell count compared to 17-HDHA_2. 17-
HDHA_1 was prepared approximately 10 months before preparing 17-HDHA_2. It 
is possible that long term storage of this compound may have increased its impact on 
cell viability (potentially through the formation of breakdown products) and may 
have also affected its bioactivity. The alamar blue OD and cell count data obtained 
here for 17-HDHA_1 (Figures 6.2A and 6.2C) showed a reduction, but it was not 
statistically significant compared to the control. This could be because this assay was 
less reproducible with larger error bar than the previous one, therefore the results 
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Figure 6.2: Cell viability of LPS-stimulated THP-1 monocytes co-incubated with mono-hydroxy 
resolvin analogues, as measured by A) alamar blue absorbance, B) alamar blue fluorescence intensity, 
and C) cell counts. No significant differences between results were observed. Average results 







In the assay, LPS was used to stimulate an inflammatory response in human 
monocytic cells (THP-1). The inflammatory response can be monitored by 
measuring the secretion of inflammatory cytokines, such as IL-1β and TNF-α. All of 
the tested PUFAs and mono- and di-hydroxy resolvin analogues significantly 
reduced IL-1β secretion compared to the DMSO control in two separate assays, 
except for 10,17-diHDPAn-3, which did not result in a reduction in IL-1β levels in 
one of the two assays (Figure 6.3). Furthermore, the degree of IL-1β reduction was 
different between the compounds and there were some variations between the two 
assays (Figure 6.3). Overall, the results suggest that all the PUFAs and resolvin 
analogues (possibly except 10,17-diHDPAn-3) showed potential anti-inflammatory 












































































































































































































































































































                 

















































                 
Figure 6.3: IL-1β secretion in LPS-stimulated THP-1 monocytes co-incubated with precursor PUFAs, 
17-HDHA_1 and di-hydroxy resolvin analogues in A) the first and B) second assay, and mono-
hydroxy resolvin analogues in C) the first and D) second assay. ***: p < 0.001, **: p < 0.01, *: p < 








The inflammatory cytokine, TNF-α, was also monitored in the LPS-stimulated THP-
1 monocytes. There was significant variation in the results from three repeat assays 
of PUFAs, 17-HDHA and di-hydroxy resolvin analogues. The results of these three 
assays were combined after normalisation to DMSO, and are shown in Figure 6.4. In 
this graph, significant decreases in TNF-α secretion after treatment with 17-HDHA, 
7,17-diHDPAn-6 and 5,15-diHETE are only indicative not representative, and the 
conditions for this specific assay need to be optimised further before conclusions can 
be drawn. However, two compounds, 7,17-diHDPAn-6 and 5,15-diHETE, resulted in 
reductions in TNF-α secretion consistently and significantly throughout the three 



































































































































Figure 6.4: TNF-α secretion in LPS-stimulated THP-1 monocytes co-incubated with precursor 
PUFAs, 17-HDHA_1 and di-hydroxy resolvin analogues. Three separate assays are combined after 
normalisation to DMSO. ****: p < 0.0001, ns: not significant. Average results presented and error 
bars indicate + one standard error (n=10). 
As for the mono-hydroxy resolvin compounds, a strong reduction of TNF-α secretion 
was observed with 17-HDHA_1 and 17-HDHA_2, 17-HDPAn-3 and 17-HDPAn-6, 
but the results were inconsistent between the 2 assays for 15-HETE and 15-HEPA 
(Figure 6.5). This suggests that 17-HDHA, 17-HDPAn-3 and 17-HDPAn-6 may 
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possess anti-inflammatory properties through their ability to suppress TNF-α 
secretion. A larger extent of TNF-α reduction was observed with old 17-HDHA 
compared to the new one. 
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Figure 6.5: TNF-α secretion in LPS-stimulated THP-1 monocytes incubated with mono-hydroxy 
resolvin analogues. Two separate assays are shown. ***: p < 0.001, **: p < 0.01, *: p < 0.05, ns: not 
significant. Average results presented and error bars indicate + one standard error (n=1-3). 
3.2.2. Mouse brain cells (C8-B4)  
PUFAs and their resolvin analogues were also used to treat LPS-stimulated mouse 
brain cells (C8-B4). The levels of the inflammatory cytokines, IL-1β and TNF-α, 
were measured in the cells, however, no IL-1β secretion was detected in either 
treated or untreated cells (for unknown reasons), so only results for TNF-α secretion 
are reported. All PUFAs and resolvin analogues were tested at three concentrations 
(50, 100 and 200 µM). Testing with multiple doses can show a dose-dependent 
response, which is additional evidence of activity. For the data analysis, resolvins 
were grouped with their precursor PUFA; all compounds were compared with the 
vehicle, the mono-hydroxy molecule was compared with the precursor PUFA, and 
the two di-hydroxy molecules were compared with the corresponding mono-hydroxy 
compound. These comparisons were used to identify possible structure-activity 




As compared to vehicle, DHA and 17-HDHA did not impact TNF-α secretion except 
for a non-significant decrease in the TNF-α level at 100 µM DHA (p = 0.071) 
(Figure 6.6A). The two di-hydroxy DHA compounds decreased TNF-α levels 
significantly at certain concentrations. 7,17-diHDHA reduced TNF-α secretion at 
50 µM (p = 0.048) and 200 µM (p = 0.024), whilst 100 µM and 200 µM doses  of 
10,17-diHDHA were both shown to decrease TNF-α levels (p = 0.024 for both) 
(Figure 6.6B). 17-HDHA also did not affect TNF-α secretion at any dose compared 
to the precursor DHA (Figure 6.6C). Both di-hydroxy DHA compounds (7,17-
diHDHA and 10,17-diHDHA) were shown to decrease TNF-α secretion at certain 
concentrations compared to 17-HDHA. Similarly, 7,17-diHDHA reduced TNF-a 
levels significantly at low and high doses of 50 and 200 µM (p = 0.002 for both), 
whereas 10,17-diHDHA suppressed TNF-α secretion significantly at the higher doses 
of 100 and 200 µM (p = 0.004 and 0.002, respectively), and also tended to reduce 
TNF-α secretion at the low dose of 50 µM (p = 0.093) (Figure 6.6D). These results 
suggest that the two di-hydroxy DHA compounds possess anti-inflammatory 
properties, and the chemical modification of DHA to produce both di-hydroxy DHA 





   
Figure 6.6: TNF-α levels in C8-B4 treated cells with A) DHA and 17-HDHA in comparison with 
vehicle, B) 7,17-diHDHA and 10,17-diHDHA compared to vehicle, C) 17-HDHA compared to DHA, 
D) 7,17-diHDHA and 10,17-diHDHA compared to 17-HDHA at different doses of 50, 100 and 
200 µM. **: p < 0.01, *: p < 0.05, no indicator: not significant. Average results presented and error 
bars indicate + one standard error (n=3-6). 
DPAn-3 group 
In comparison to the vehicle, all DPAn-3 compounds affected TNF-α secretion at 
different levels. 17-HDPAn-3 decreased TNF-α secretion significantly at all 
concentrations (p = 0.024 for 50 and 200 µM, p = 0.036 for 100 µM), whereas TNF-
α concentration tended to decrease with DPAn-3 only at 200 µM (p = 0.095) (Figure 
6.7A). 10,17-diHDPAn-3 decreased TNF-α secretion significantly at 100 and 200 
µM (p = 0.024 for both), whereas 7,17-diHDPAn-3 slightly decreased TNF-α levels 
only at 200 µM (p = 0.095) but the result was not significant (Figure 6.7B). As a 
result, 17-HDPAn-3 possesses anti-inflammatory property at all doses, whereas the 







































































































Figure 6.7: TNF-α levels in C8-B4 treated cells with A) DPAn-3 and 17-HDPAn-3 in comparison 
with vehicle, B) 7,17-diHDPAn-3 and 10,17-diHDPAn-3 compared to vehicle, C) 17-HDPAn-3 
compared to DPAn-3, D) 7,17-diHDPAn-3 and 10,17-diHDPAn-3 compared to 17-HDPAn-3 at 
different doses of 50, 100 and 200 µM. **: 0.001 < p < 0.01, *: 0.01 < p < 0.05, no indicator: not 
significant. Average results presented and error bars indicate + one standard error (n=3-6). 
17-HDPAn-3 at the concentration of 200 µM (p = 0.002) was found to decrease 
TNF-α levels and at the concentration of 100 µM (p = 0.056) tended to decrease 
TNF-α levels compared to the precursor DPAn-3, which suggests that 17-HDPAn-3 
has higher anti-inflammatory activity than DPAn-3 (Figure 6.7C). In comparison 
with 17-HDPAn-3, 7,17-diHDPAn-3 showed less anti-inflammatory activity at all 
doses of 50, 100 and 200 µM (p = 0.065, 0.004 and 0.002 respectively) by increasing 
TNF-α levels, although the result at 50 µM was not statistically significant, whereas 
10,17-diHDPAn-3 showed more anti-inflammatory activity by decreasing TNF-α 
secretion at the highest dose of 200 µM (p = 0.026), but showed a trend towards less 
anti-inflammatory activity by increasing TNF-α levels at the lowest concentration of 




































































































different anti-inflammatory levels compared to 17-HDPAn-3, in which 7,17-
diHDPAn-3 was less anti-inflammatory than 17-HDPAn-3, whereas 10,17-
diHDPAn-3 generally seemed to be more anti-inflammatory than 17-HDPAn-3. The 
results suggest that adding a hydroxy group at position C17 improves the anti-
inflammatory properties of DPAn-3 at all doses. However, adding a second hydroxy 
group to form di-hydroxy DPAn-3 tends to decrease the anti-inflammatory 
properties.  
ETE group 
When compared with vehicle, none of the compounds in the ETE group changed 
TNF-α levels significantly, at any dose, indicating they may not have anti-
inflammatory activity (Figures 6.8A and B). 15-HETE did not change TNF-α levels 
at any dose when compared with ETE (Figure 6.8C). Neither of the di-hydroxy 
compounds, 5,15-diHETE or 8,15-diHETE, affected TNF-α secretion significantly 
compared to 15-HETE, although 5,15-diHETE seemed to decrease TNF-α levels 
slightly at all doses (Figure 6.8D). Overall these results do not show significant anti-
inflammatory activity from the ETE derived compounds. Furthermore, some of the 
responses from these compounds show higher levels of TNF-α secretion compared to 
the vehicle, although the results are not significant. Adding one hydroxy group at 
C15 appeared to slightly increase anti-inflammatory activity, and adding a second 






Figure 6.8: TNF-α levels in C8-B4 treated cells with A) ETE and 15-HETE in comparison with 
vehicle, B) 5,15-diHETE and 8,15-diHETE compared to vehicle, C) 15-HETE compared to ETE, D) 
5,15-diHETE and 8,15-diHETE compared to 15-HETE at different doses of 50, 100 and 200 µM. No 
significant differences between results were observed. Average results presented and error bars 
indicate + one standard error (n=3-6). 
EPA group 
Compared with the vehicle, EPA increased TNF-α secretion at 100 and 200 µM (p = 
0.024 for both) and 15-HEPA also increased TNF-α levels at 50 µM (p = 0.036) and 
100 µM (p = 0.024) (Figure 6.9A). However, 5,15-diHEPA did not impact the 
secretion of TNF-α at any dose, and 8,15-diHEPA only reduced TNF-α secretion 
significantly at the highest dose of 200 µM (p = 0.048) (Figure 6.9B). These results 
suggest that both EPA and 15-HEPA have pro-inflammatory properties whilst 8,15-









































































































Figure 6.9: TNF-α levels in C8-B4 treated cells with A) EPA and 15-HEPA in comparison with 
vehicle, B) 5,15-diHEPA and 8,15-diHEPA compared to vehicle, C) 15-HEPA in comparison with 
EPA, D) 5,15-diHEPA and 8,15-diHEPA compared to 15-HEPA at different doses of 50, 100 and 
200 µM. **: p < 0.01, *: p < 0.05, no indicator: not significant. Average results presented and error 
bars indicate + one standard error (n=3-6). 
Within the EPA group, 15-HEPA seems to have higher pro-inflammatory activity 
than EPA by increasing TNF-α secretion at concentrations of 50 and 100 µM (p = 
0.016 and p = 0.009 respectively) when comparing these two compounds (Figure 
6.9C). Both 5,15-diHEPA and 8,15-diHEPA were found to significantly decrease 
TNF-α levels at all doses compared to 15-HEPA (0.001 < p < 0.01), indicating the 
two di-hydroxy compounds are more anti-inflammatory than the pro-inflammatory 
mono-hydroxy EPA (Figure 6.9D). The results suggest that adding one hydroxy 
group makes EPA more pro-inflammatory, whilst adding another hydroxy group 













































































































In comparison with the vehicle, only 7,17-diDPAn-6 reduced TNF-α level 
significantly at 50 and 200 µM doses (p = 0.024 for both), indicating that it is anti-
inflammatory (Figures 6.10A and B). When compared to DPAn-6, 17-HDPAn-6 was 
found to decrease TNF-α secretion at a dose of 200 µM (p = 0.009) (Figure 6.10C). 
When compared to 17-HDPAn-6, 7,17-diHDPAn-6 reduced TNF-α levels at a 
concentration of 200 µM (p = 0.026), whereas 10,17-diHDPAn-6 tended not to 
decrease TNF-α secretion as much as 17-HDPA did (Figure 6.10D). The results 
indicate that adding hydroxy groups on DPAn-6 to form 17-HDPAn-6 and 7,17-
diHDPAn-6 increased the anti-inflammatory properties. However, adding a second 




Figure 6.10: TNF-α levels in C8-B4 treated cells with A) DPAn-6 and 17-HDPAn-6 in comparison 
with vehicle, B) 7,17-diHDPAn-6 and 10,17-diHDPAn-6 compared to vehicle, C) 17-HDPAn-6 
compared to DPAn-6, D) 7,17-diHDPAn-6 and 10,17-diHDPAn-6 compared to 17-HDPAn-6 at 
different doses of 50, 100 and 200 µM. **: p < 0.01, *: p < 0.05, no indicator: not significant. Average 









































































































During the assays, cells were observed for any changes after treatment with the 
PUFAs and analogues. At 200 µM EPA altered cell shapes were observed and dead 
cells were found after treatment with 200 µM DPAn-6, so these two PUFAs 
appeared to be toxic at this dose. For both THP-1 and C8-B4 cell line assays, the 
anti-inflammatory activity of the PUFAs and resolvin analogues in each group are 
summarised based on structure-activity relationship in Table 6.4.  
Table 6.4: Anti-inflammatory activity of each PUFA group (IL-1β level in THP-1 treated cells, 
TNF-α in THP-1 and C8-B4 treated cells). PUFA: PUFA versus vehicle, Mono-hydroxy compound: 
mono-hydroxy PUFA versus PUFA, Di-hydroxy isomer 1: di-hydroxy PUFA with 10 carbons 
between two hydroxy groups versus mono-hydroxy PUFA and Di-hydroxy isomer 2: di-hydroxy 
PUFA with 7 carbons between two hydroxy groups versus mono-hydroxy PUFA. ↑: increase of anti-
inflammatory activity, ↓: decrease of anti-inflammatory activity and ‘-‘: no change in anti-
inflammatory activity. ( ): tending to increase or decrease anti-inflammatory activity (not significant).  























































































DHA ↑ - (↑) ↑ ↑ - ↓ ↓ ↑ ↓ ↓ ↑ 
DPAn
-3 
↑ - (↑) ↑ ↑ ↑ ↓ ↓ ↓ ↓ ↓ ↑ 
EPA ↑ - ↓ ↑ ↑ ↓ ↓ - ↑ ↓ - ↑ 
DPAn
-6 
↑ - - - ↑ ↑ - - ↑ (↓) ↓ (↓) 
ETE ↑ - - ↑ - (↑) (↑) ↑ (↑) (↓) - - 
 
PUFAs were compared to the vehicle. Mono-hydroxy PUFAs were compared to the 
corresponding PUFA. Both di-hydroxy products were compared with the 
corresponding mono-hydroxy PUFA. Changes in anti-inflammatory activity between 
the chemical structures of PUFAs, mono-hydroxy and di-hydroxy PUFA compounds 
are discussed in detail in the discussion section below. The potential structure-
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activity relationships were identified through the comparison across different groups, 
cell lines and anti-inflammatory assays. 
4. Discussion 
Cell viability of human monocytic cells (THP-1) 
The cell viability assays showed that all of the precursor PUFAs, and most of the 
mono- and di-hydroxy resolvin analogues had no adverse effect on cell function. 
However, one mono-hydroxy compound (17-HDHA) and three di-hydroxy 
compounds (7,17-diHDHA, 7,17-diHDPAn-6 and 5,15-diHETE) showed some 
impacts on cell viability, but the results were inconclusive as the results between the 
three sets of cell viability assays were inconsistent. 17-HDHA and 5,15-diHETE 
showed an adverse effect in two of the cell viability assays, whereas 7,17-diHDHA 
and 7,17-diHDPAn-6 showed an adverse effect on only one cell viability assay. 
Previous studies have assessed the effects of several PUFAs, SPMs and analogues on 
cell viability using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium 
bromide (MTT) assay, which is similar to the alamar blue assay but uses a different 
reagent [281-283]. Hamid and co-workers reported that the alamar blue assay (the 
method used in this study), was found to be more sensitive in detecting cytotoxic 
effects of most tested drug compounds (117 drugs) than the MTT assay [284].  
PUFAs are a part of the normal human diet, so it is expected that they would not 
show any effect on cell viability at the tested concentration of 50 µg/mL 
(approximately 150 µM). Some previous studies with THP-1 cell lines also showed 
that DHA and EPA did not affect cell viability in the concentration range of 6.25 – 
100 µM [282] or at concentrations of 10, 50 and 75 µM [283]. However, the possible 
impact on cell viability of the four resolvin analogues listed above was unexpected, 
as SPMs are endogenously synthesised from PUFAs in the body and typically show 
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anti-inflammatory and pro-resolving activity. Various SPMs and analogues such as 
Resolvin E1, Resolvin D1 and Maresin R1 have not shown cytotoxicity or impacted 
viability of various cell lines [82, 281, 285, 286]. Due to the potential bioactivity of 
these compounds, a number of studies have focused on using PUFAs and SPMs to 
reduce cytotoxicity of toxic agents on normal cells or to induce cytotoxicity in 
tumour cells [287-290]. For example, Resolvin D1 showed no cytotoxicity on human 
gingival fibroblasts (HGFs), and it decreased the cytotoxicity of ethanol on HGFs 
and inhibited the cytotoxic effects of bacteria such as Porphyromonas gingivalis on 
HGFs [288]. DHA and 17-hydroperoxy DHA were found to induce higher 
cytotoxicity than 17-HDHA in human neuroblastoma cells (tumorigenic neural cells) 
[287].  
The possible impact on cell viability from the compounds must be considered when 
interpreting the results of the anti-inflammatory assays, as a decrease in IL-1β and 
TNF-α secretion may be due to an increase in the number of dead cells rather than 
from actual anti-inflammatory activity. This is because a decrease in the number of 
living cells or an impact on cell function, could cause a decrease in IL-1β and TNF-α 
levels. The two di-hydroxy compounds (8,15-diHEPA and 8,15-HETE) showed an 
increase in the number of living cells in the alamar blue OD assay, suggesting these 
compounds have a positive impact on cell growth. Cell proliferation assays of the 
two molecules would be necessary in future work. However, there are also other 
possibilities for this finding; these two compounds may increase enzyme activity in 
viable cells inducing the redox reaction of the indicator dye (resazurin) or the dye 
may be contaminated with the reduced compound (resorufin), resulting in an increase 
of the alamar blue OD value but not directly due to cell growth. Furthermore, 7,17-
diHDHA and 7,17-diHDPAn-6 may inhibit the enzyme activity causing the decrease 
only in alamar blue OD value but not in the cell count assay. As for the alamar blue 
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assay, measurement with absorbance seemed to be more sensitive to detect adverse 
effects on cell function than with fluorescence. There was quite high variability in 
the alamar blue OD results for some of the mono-hydroxy compounds (17-HDHA_1, 
17-HDPAn-3 and 17-HDPAn-6). The alamar blue assay is sensitive to a range of 
experimental conditions such as temperature, pH, light, cell density, incubation time 
and microbial contamination [291], and therefore this may contribute to high 
variation in these results.  
Anti-inflammatory activity 
Human monocytic cells (THP-1)  
Almost all PUFAs and resolvin analogues tested, demonstrated potential anti-
inflammatory activity through a reduction in IL-1β secretion. Although the assay 
results showed variation in the extent of the reduction for each compound across 
duplicate assays, only 10,17-diHDPAn-3 failed to show a statistically significant 
reduction in one of the two assays. The results for TNF-α were more selective with 
only seven of the twenty tested compounds showing a reduction in TNF-α secretion. 
All five mono-hydroxy compounds showed anti-inflammatory activity, as well as 
two di-hydroxy compounds (7,17-diHDPAn-6 and 5,15-diHETE). None of the 
PUFAs showed a reduction in TNF-α secretion. However, the results for two of the 
mono-hydroxy compounds (15-HETE and 15-HEPA) were not replicated across the 
two assays. Furthermore, the effect observed for 5,15-diHETE in reducing TNF-α 
(and IL-1β) secretion could also have been caused by the reduction in cell numbers 
and the impact on cell function seen for this compound and may not be related to 
anti-inflammatory activity. In this cell line, the anti-inflammatory activity of all five 
mono-hydroxy compounds was preserved in both IL-1β and TNF-α assays, whereas 
all five PUFAs and almost di-hydroxy compounds only showed anti-inflammatory 
activity in the IL-1β assay. 
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Two preparations of 17-HDHA were used in the THP-1 cell assays (labelled 17-
HDHA_1 and 17-HDHA_2). As can be seen from the results, the responses from 
these two compounds were not the same despite being chemically identical; 17-
HDHA_1 caused a much greater reduction in TNF-α secretion than 17-HDHA_2 
(although the difference from the control was not statistically significant). The reason 
for this is unclear, however, 17-HDHA_1 was prepared using commercial soybean 
LOX-1 approximately 10 months before 17-HDHA_2 was prepared from soybean 
flour LOX. Unlike the 17-HDHA prepared from soybean flour LOX, the 17-HDHA 
prepared from commercial soybean LOX-1 did not require purification by HPLC 
after synthesis and extraction. Whilst the major component in both preparations (17-
HDHA, purity >99%) was the same, it is possible that one of the differences (storage 
time, enzyme used in synthesis, or purification method), has resulted in differences in 
trace impurities between the two preparations (although this was not observed in the 
HPLC results), which has affected the assay results. Long term storage of PUFAs 
and resolvin analogues may affect their impacts on cell viability and/or their 
bioactivity, so further investigation would be beneficial. 
Mouse brain cells (C8-B4) and comparison with human monocytic cells (THP-1) 
Unlike in the inflammatory assays employing THP-1 cells, where all PUFAs showed 
a reduction in IL-1β but not TNF-α secretion, different levels of inflammatory 
activities (anti-inflammatory, pro-inflammatory and neutral) for PUFAs were 
observed in TNF-α secretion for C8-B4 cells. DHA tended to have anti-inflammatory 
activity, showing a reduction in TNF-α levels at all doses but failed to have 
significantly statistical results. DPAn-3 only tended to have anti-inflammatory 
activity at the highest dose of 200 µM, whereas EPA unexpectedly showed pro-
inflammatory activity at high concentrations. ETE and DPAn-6 did not show any 
inflammatory activity.  
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DHA and EPA have received more interest in investigating anti-inflammatory 
activity compared to other PUFAs in the literature. Many previous studies with THP-
1 cells have demonstrated the anti-inflammatory activity of DHA and EPA through 
the decrease of a range of cytokines including TNF-α, IL-1β, IL-6 and MCP-1 [282, 
283, 292]. Moreover, in LPS stimulated human peripheral blood mononuclear cells, 
DHA, EPA and DPAn-6 were shown to decrease TNF-α and IL-1β production, 
whereas ETE did not affect the concentration of these two cytokines [293]. However, 
in this work, DHA, EPA and other PUFAs (ETE, DPAn-3 and DPAn-6) were found 
to reduce IL-1β levels but not TNF-α levels in LPS treated THP-1 cells. In part 
agreement with these findings, Mullen and colleagues found that DHA reduced IL-
1β levels significantly but did not affect TNF-α secretion in LPS-treated THP-1 cells, 
however, EPA was found to significantly decrease both IL-1β and TNF-α levels 
[292]. In a previous study, DPAn-3, EPA and DHA showed anti-inflammatory 
activity in significantly reducing another cytokine IL-6 secretion in LPS-stimulated 
RAW264.7 cells [294]. For the LPS treated C8-B4 cells in this study, DHA and 
DPAn-3 showed some anti-inflammatory activity in agreement with the studies 
mentioned above, but in contrast to those studies, EPA showed pro-inflammatory 
activity and DPAn-6 showed no activity. In agreement with a study by Nauroth et al. 
[293], ETE did not show anti-inflammatory behaviour in LPS treated C8-B4 cells. 
The anti-inflammatory activity of PUFAs may vary depending on cell lines and 
cytokines tested.  
As for the mono-hydroxy PUFA compounds, almost all showed potential anti-
inflammatory activity in decreasing TNF-α levels, which is similar to the results 
from the treated THP-1 cells. 17-HDPAn-3 and 17-HDPAn-6 showed a trend of 
decreasing TNF-α levels in the concentration range 50 – 200 µM, demonstrating a 
dose-dependent response. However, only 17-HDPAn-3 gave statistically significant 
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results (at all doses). These results matched with the anti-inflammatory activities 
observed in LPS-stimulated THP-1 monocytes, which showed a reduction of IL-1β 
and TNF-α levels, giving a strong indication of anti-inflammatory activity. As an 
exception, 15-HEPA showed potential pro-inflammatory activity, increasing TNF-α 
levels at low doses, which was not observed in THP-1 monocyte assays.  
In support of the current work where all mono-hydroxy compounds tested showed 
anti-inflammatory activity through a reduction in both IL-1β and TNF-α secretion in 
the THP-1 cell line, 17-HDHA was previously found to significantly decrease TNF-α 
levels both in vitro and in vivo in a number of studies [67, 270, 295]. Other studies 
have also found that 17-HDHA, 17-HDPAn-6, 15-HEPA and 15-HETE have anti-
inflammatory activity in vitro and in vivo. In a study by Chiu and colleagues, both 
17-HDHA and 17-HDPAn-6 were found to decrease mRNA expression of TNF-α 
and iNOS in cell line RAW264.7 [270]. Dangi et al. showed that 17-HDHA and 17-
HDPAn-6 had anti-inflammatory activity through a reduction of the leukocyte count 
in exudates in vivo, however, 17-HDHA did not show a statistically significant 
reduction [67]. 17-HDHA, 15-HEPA and 15-HETE in vitro were shown to have an 
inhibitory effect on 5-LOX activity, which can decrease the synthesis of the pro-
inflammatory lipid mediator, LTB4 [261, 262]. 15-HETE can also activate a receptor 
to induce anti-inflammatory activity for neuroprotection in ischemic rat brain [275]. 
These studies also agree with the current results, where 17-HDPAn-6 showed anti-
inflammatory activity in treated C8-B4 cells, but not the pro-inflammatory activity 
displayed by 15-HEPA or the inactivity of 17-HDHA and 15-HETE.  
In C8-B4 treated cells, seven of ten di-hydroxy PUFAs had potential anti-
inflammatory activity, showing a reduction of TNF-α secretion. Five compounds 
(7,17-diHDHA, 10,17-diHDHA, 7,17-diHDPAn-6, 10,17-diHDPAn-3 and 5,15-
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HETE) showed a reduction of TNF-α secretion at all doses, whereas 7,17-diHDPAn-
3 and 8,15-diHEPA only decreased TNF-α levels at the highest dose of 200 µM. 
Among these seven compounds, only 5,15-diHETE and 7,17-diHDPAn-3 failed to 
show statistically significant results. The reduction in TNF-α secretion by 10,17-
diHDHA and 10,17-diHDPAn-3 were statistically significant at high doses of 100 
and 200 µM, whereas the 7,17-diHDHA and 7,17-diHDPAn-6 reduction of TNF-α 
secretion was statistically significant at random doses of 50 and 200 µM. 7,17-
diHDPAn-6 and 5,15-diHETE were also found to show promising anti-inflammatory 
activity in THP-1 treated cells in both IL-1β and TNF-α assays, providing a strong 
indication that these two compounds have anti-inflammatory activity. The other five 
compounds (7,17-diHDHA, 10,17-diHDHA, 7,17-diHDPAn-3, 10,17-diHDPAn-3 
and 8,15-diHEPA) also showed activity in the IL-1β assay in treated THP-1 cells, but 
not in the TNF-α assay, so the results are less conclusive in showing anti-
inflammatory activity. 
RvD5DHA, PDXDHA, PDXDPAn-6 and RvD5DPAn-3, members of SPM superfamily, have 
anti-inflammatory and pro-resolving activities with confirmed activity [54, 67, 264-
268, 270, 274, 296]. A study in vitro on tert-butyl hydroperoxide-stimulated human 
retinal pigment epithelium cells for the prevention and treatment of age-related 
macular degeneration found that PDXDHA reduced TNF-α secretion significantly 
[264]. Similarly, several in vivo studies showed that PDXDHA inhibited production of 
inflammatory cytokines such as TNF-α and IL-1β in a range of disease models [265-
268]. RvD5DHA was found to have anti-inflammatory activity in reducing 
neutrophilic inflammation [274] and through increasing bacterial clearance and 
survival in a murine peritonitis model [296]. Both RvD5DHA and PDXDHA were also 
demonstrated to possess a significant inhibitory effect on mammalian 5-LOX activity 
in vitro [54]. PDXDPAn-6 was found to significantly decrease the leukocyte count in 
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exudates in vivo [67] and decrease mRNA expression of TNF-α and iNOS in vitro 
[270]. 
These results agree with the current work in the THP-1 cell line where RvD5DHA, 
PDXDHA and PDXDPAn-6 showed a reduction in IL-1β secretion, but differ in that they 
did not reduce TNF-α levels in this study. In contrast, PDXDPAn-6 did not show anti-
inflammatory activity in the TNF-α assay in treated C8-B4 cells. Gobbetti et al. 
found that RvD5DPAn-3 did not decrease TNF-α and only partly reduced IL-1β 
production in vivo [75]. These results agree with the current findings in treated THP-
1 cells, except that in this study, the compound showed a significant reduction in IL-
1β secretion. However, RvD5DPAn-3 showed anti-inflammatory activity through a 
reduction of TNF-α secretion at the highest dose (200 µM) in treated C8-B4 cells. No 
work on inflammatory assays involving cytokine secretion has been done on the 
other analogues of resolvin D5 and protectin DX except those discussed above. 
Previous studies showed that di-hydroxy PUFAs containing conjugated trienes with 
E,Z,E geometry, called poxytrins, such as PDXDHA, 8,15-diHETE and 9,16-
dihydroxy linolenic acid had anti-inflammatory activity through their anti-
aggregatory action, whereas compounds with all trans or E,E,Z conjugated trienes 
had no activity [297, 298]. However, the results in this work were mixed with 
conjugated triene molecules only sometimes showing inhibition of cytokine secretion 
across the three inflammatory assays. This activity was observed strongly for 10,17-
diHDHA, 10,17-diHDPAn-3 and 8,15-diHEPA in two assays, whereas 10,17-
diHDPAn-6 and 8,15-diHETE showed activity in only one assay.  
Some of the tested compounds (17-HDPAn-3, 10,17-diHDHA, 10,17-diHDPAn-3 
and 7,17-diHDPAn-6) were observed to decrease TNF-α secretion at all doses in a 
dose-dependent manner although several compounds only showed statistically 
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significant results at some doses. These compounds displayed stronger evidence of 
anti-inflammatory activity compared to the others, so 17-series resolvin analogues 
especially from DPAn-3 precursors are possibly more powerful anti-inflammatory 
than 15-series resolvin analogues. Moreover, some compounds (DHA, DPAn-3, 17-
HDPAn-3, 17-HDPAn-6, 7,17-diHDPAn-6 and 5,15-diHETE) showed potential anti-
inflammatory activity in multiple assays (at least two), again providing a strong 
indication of anti-inflammatory activity. Overall, among the 20 compounds tested in 
this work 17-HDPAn-3 and 7,17-diHDPAn-6 have been strongly shown to be anti-
inflammatory molecules.  
PDX is an isomer of PD1. Both are derived from DHA and their chemical structures 
differ only in the stereochemistry of the hydroxy group at C10 and the double bond 
geometry of the conjugated triene (mentioned in Chapter 2) [74]. PD1 has been 
reported to be more active than PDX in the resolution of inflammation through 
inhibition of PMN infiltration in vivo [272]. Therefore, this could support why PDX 
compounds derived from various PUFAs had less bioactivity and did not show 
consistent anti-inflammatory activity across assays.  
Structure-activity relationship 
In THP-1 treated cells (Table 6.4), all PUFAs showed higher anti-inflammatory 
activity than the vehicle in reducing IL-1β secretion but not TNF-α secretion. The 
high degree of variation between three replicate TNF-α assays for PUFAs may have 
affected these results, as overall, no change in TNF-α secretion was observed when 
the results from the three assays were combined. From the THP-1 IL-1β assay, the 
PUFAs in order of decreasing bioactivity are DHA > EPA, DPAn-3 and DPAn-6 > 
ETE. For the C8-B4 treated cells, anti-inflammatory activity of PUFAs was observed 
in the following order from high to low activity compared to vehicle: DHA and 
DPAn-3 (anti-inflammatory) > ETE and DPAn-6 (no activity) > EPA (pro-
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inflammatory). DPAn-3 tended to have higher anti-inflammatory activity than DHA 
in the C8-B4 cell line, whereas DHA had higher anti-inflammatory activity than 
DPAn-3 in the THP-1 cell line. DHA was found to have higher anti-inflammatory 
activity than EPA consistently in both cell lines. Similarly, Nauroth and co-workers 
also found that DHA had higher anti-inflammatory activity than EPA in inhibiting 
inflammatory cytokines, IL-1β and TNF-α, in human peripheral blood mononuclear 
cells stimulated by LPS [293].  
Other studies also showed that DHA had higher ability than EPA to suppress IL-1β 
and IL-6 secretion in LPS-stimulated THP-1 cells [282, 283, 292], and IL-6 secretion 
in LPS-activated RAW264.7 cells [294]. Moreover, DPAn-6 had higher anti-
inflammatory activity than DHA in the same study by Nauroth and co-workers [293]. 
In contrast, DPAn-6 was found to have lower anti-inflammatory activity than DHA 
in THP-1 cells and showed no anti-inflammatory activity in the C8-B4 cell line in the 
current study. This is in agreement with the probable involvement of DPAn-6, an 
omega-6 PUFA and metabolite of ETE in the omega-6 pathway, in pro-inflammatory 
lipid mediator pathways [293]. In a similar manner, ETE showed no activity and 
EPA had pro-inflammatory activity in C8-B4 cell line as they are also known 
precursors of pro-inflammatory lipid mediators. 
Most mono-hydroxy PUFAs showed an increase in anti-inflammatory activity 
through decreases in both IL-1β and TNF-α secretion, compared to their 
corresponding PUFAs in both THP-1 and C8-B4 cell lines (Table 6.4). Similarly, 
Tsunomori et al. reported that 15-hydroperoxy EPA was much more efficient than 
EPA in inhibiting platelet aggregation by reducing the formation of aggregation 
markers such as 12-HETE and thrombotic B2 in vitro [299]. As for di-hydroxy 
PUFAs (Table 6.4), only 5,15-diHETE had higher anti-inflammatory than 15-HETE, 
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measured with both the IL-1β and TNF-α secretion assays in the THP-1 cell line, 
whereas other di-hydroxy PUFAs decreased or did not affect anti-inflammatory 
properties compared to their corresponding mono-hydroxy PUFAs. In agreement 
with this work, 10,17-diHDPAn-6 was also previously found to have less anti-
inflammatory activity compared to 17-HDPAn-6 in vitro and in vivo [67, 270]. In 
contrast with the results of the THP-1 cell line, most of the di-hydroxy PUFA 
products tested with the C8-B4 cell line showed an increase in anti-inflammatory 
activity compared to their corresponding mono-hydroxy PUFAs except for 8,15-
diHETE, 7,17-diHDPAn-3 and 10,17-diHDPAn-6. However, there was a consistent 
increase in anti-inflammatory activity for 5,15-diHETE compared to 15-HETE for 
both THP-1 and C8-B4 cell lines. This strongly suggests that 5,15-diHETE had 
higher anti-inflammatory activity than 15-HETE, and di-hydroxy PUFAs with 
double conjugated dienes may have enhanced activity compared to the corresponding 
mono-hydroxy PUFAs, and more activity than di-hydroxy PUFAs with a conjugated 
triene. 
The mechanism of the anti-inflammatory and pro-resolving activity of PUFAs and 
SPMs analogues has been partially elucidated as involving the regulation of 
cytokines by ligand-receptors and polarisation of different macrophage phenotypes. 
Several SPMs are known to have anti-inflammatory activity due to their mechanisms 
of acting as ligands (agonists and antagonists) binding to select surface receptors to 
induce specific actions of anti-inflammatory and/or pro-resolving activity. For 
example, RvE1 and RvD1 have functions as antagonists for the LTB4 receptor to 
inhibit LTB4 production, and RvD1, RvD3 and RvD5 can act as an agonist of the 
human GPR32 receptor to stimulate macrophage phagocytosis  [10, 187, 300].  
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There are two macrophage phenotypes (M1 and M2), which have different functions 
in inflammation. The M1 phenotype is known to produce pro-inflammatory 
cytokines such as TNF-α and IL-1β, reactive oxygen and nitrogen species, when cells 
are stimulated with inflammatory stimuli such as LPS. In contrast, the M2 phenotype 
produces anti-inflammatory cytokines and SPMs, and has scavenging and protective 
activity [10, 301]. Several SPMs and analogues such as RvD1 and MaR1 precursor 
(13S,14S-epoxy-DHA) have been shown to shift the macrophage phenotype from M1 
to M2 in vitro and in vivo to express their anti-inflammatory and pro-resolving 
activities, in a few studies [302, 303]. 17-HDHA, 17-HDPAn-6 and 10,17-diHDPAn-
6 in particular, were found to activate the anti-inflammatory and pro-resolving M2 
polarised macrophages, with a reduction of TNF-α and iNOS gene expression, and 
an increase of IL-1 receptor antagonist, scavenger receptor expression and 
phagocytosis activity in vitro. 10,17-diHDPAn-6 appeared to have lower activity 
than 17-HDPAn-6 [270].  
As for the TNF-α assay in the C8-B4 cell line, it is interesting to note that the di-
hydroxy PUFA compounds having double bond systems with symmetrical structures 
(Figure 6.12) were consistently more anti-inflammatory than their corresponding 
mono-hydroxy PUFAs. These symmetrical structures are found in the compounds 
5,15-diHETE (Figure 6.12A), 8,15-diHEPA and 10,17-diHDPAn-3 (Figure 6.12B), 
7,17-diHDHA (Figure 6.12C). These structures could potentially be applied to the 
design of novel anti-inflammatory SPMs with high bioactivities. The other di-
hydroxy compounds without symmetrical double bond systems did not always show 
higher anti-inflammatory activity compared to their corresponding mono-hydroxy 
PUFAs. They showed either lower anti-inflammatory activity or no change in 
activity. However, the mechanism through which the symmetrical structures would 






Figure 6.12: Three different symmetrical structures (A, B, C) found in resolvin and protectin 
analogues. 
5. Conclusion 
In this chapter, most PUFAs and resolvin analogues have shown potential anti-
inflammatory properties in vitro by reducing IL-1β and TNF-α secretion in two 
different cell types, human monocytic cells (THP-1) and mouse brain cells (C8-B4). 
However, compounds derived from precursors of ETE, DPAn-6 and EPA, which are 
known to be involved in pro-inflammatory pathways, showed either no activity or 
pro-inflammatory activity in some cases. The anti-inflammatory properties of PUFAs 
can be adjusted by chemical modifications by adding hydroxy groups and forming 
conjugated double bond systems. The formation of mono-hydroxy PUFAs almost 
universally enhanced the anti-inflammatory activity compared to the parent PUFAs 
across different cytokine assays and cell lines. The effects of adding a second 
hydroxy group were more varied, only sometimes improving the anti-inflammatory 






This work demonstrated that almost all resolvin and protectin analogues synthesised 
from PUFAs using a crude enzyme from soybean flour have potential anti-
inflammatory activity similar to endogenous SPMs. These novel resolvin D5 and 
protectin DX analogues (di-hydroxy PUFAs) and their precursors (mono-hydroxy 
PUFAs), may be useful anti-inflammatory compounds in the treatment and 
prevention of inflammatory disorders. This work also reinforces the idea that the 
anti-inflammatory activity of PUFAs at least partially arises from their conversion 















GENERAL CONCLUSIONS AND FUTURE WORK 
 
It has been demonstrated in this project that SBF can be used directly without any 
complex purification as a natural and inexpensive source of lipoxygenase enzymes to 
produce a variety of potentially bioactive resolvin and protectin analogues from a 
range of substrates. SBF is more versatile than 15-sLOX-1 in efficiently oxygenating 
both FFAs and various esterified FAs (TL, DHA TAG, tuna oil and anchovy oil). 
LOX sourced from SBF can be used as an effective enzyme preparation compared to 
the purified and commercially available 15-sLOX-1 in producing bioactive resolvin 
and protectin analogues. The sfLOX can catalyse twice the amount of substrate and 
give a greater total product yield. The sfLOX-catalysed reaction yield with DHA or 
TL is high (approximately 60% or greater), and the products suggest a highly regio- 
and stereo-specific reaction. Other esterified FAs (DHA TAG, tuna oil and anchovy 
oil) are also good substrates for sfLOX with small amounts of substrate remaining at 
the end of the respective reactions. 
Importantly, most PUFAs and the resolvin and protectin analogues synthesised from 
sfLOX have been confirmed to have positive bioactivity in anti-inflammatory assays 
of IL-1β and/or TNF-α in two different cell lines in vitro, as was expected. Structure-
activity relationships of these compounds associating the number of hydroxy groups 
and conjugated double bond systems with their activities have been identified and 
discussed. The anti-inflammatory properties of PUFAs were improved in many cases 
by adding a hydroxy group and forming a conjugated diene, whereas adding a second 
hydroxy group and forming either a conjugated triene or two conjugated dienes 
showed varied effects on their bioactivities.  
For future work, DHA and EPA-enriched TAGs containing mono-hydroxy PUFAs (a 
hydroperoxy group and two conjugated double bonds), synthesised from reactions 
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with sfLOX and fish oil, would be promising to test for anti-inflammatory activity. It 
would be useful to identify the stereo-specificity of the sfLOX-catalysed tuna oil 
reaction products before assessing their biological activity.  
There is potential to use the approach outlined in Chapter 5 for the separation of 
biologically-important PUFA-containing TAGs from complex natural lipid mixtures 
in industrial applications. After dioxygenation, hydroperoxylated PUFA-containing 
TAGs could be easily separated from the lipid mixture based on differences in 
polarity, and then used in pharmaceuticals and nutraceuticals, while the remaining 
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